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There are strong epidemiological associations between high serum uric acid
concentrations and increased cardiovascular risk. However, it is unclear if uric acid is
an independent causal risk factor, serves a protective role due to its antioxidant
properties, or simply acts as a passive marker of risk through association with other
factors. The distinction is important because, if acting as a causal risk factor,
treatment to lower uric acid concentrations might reduce cardiovascular risk.
Aims
To study the cardiovascular effects of raising and lowering circulating uric acid
concentrations, so as to identify potential mechanisms by which uric acid could
impair cardiovascular function or, as an antioxidant, serve a protective role.
Methods
I developed a technique of uric acid administration that allowed the effects of raised
concentrations to be examined in vivo. The potential impact on serum antioxidant
capacity, plasma viscosity, platelet aggregability, systemic haemodynamics,
baroreflex sensitivity, large arterial stiffness, and endothelial function were studied in
healthy subjects. The effects of high uric acid concentrations were studied in a model
of acute exercise-induced oxidative stress, and in regular smokers and patients with
type 1 diabetes who are ordinarily exposed to chronic oxidative stress. The effects of
lowering uric acid, by means of urate oxidase, were studied in patients with type 2
diabetes to explore whether this might improve vascular function in these patients.
Results
Raising and lowering uric acid concentrations had no effect on vascular function in
healthy subjects. Uric acid administration significantly increased serum antioxidant
capacity, reduced oxidative stress during acute aerobic exercise, and improved
endothelium-dependent vascular responses in regular smokers and patients with type
1 diabetes. Lowering uric acid concentrations did not influence vascular function in
healthy subjects or patients with type 2 diabetes.
Conclusions
High uric acid concentrations did not impair vascular function, at least in the acute
situation, and appear to preserve vascular function by protecting against oxidative
stress in smokers and patients with type 1 diabetes. These findings do not support a
causal link between high serum uric acid concentrations and increased cardiovascular
risk. Further research is required to define the mechanisms by which high uric acid
concentrations ameliorate endothelial dysfunction, and to examine whether these
properties have therapeutic potential in diseases characterised by oxidative stress.
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Atherosclerosis is the primary cause of cardiovascular disease, and manifests as
coronary heart disease, cerebrovascular disease and peripheral arterial disease. At
present, cardiovascular disease is the leading cause of death and disability in
developed nations, and poses an enormous worldwide public health problem. The
global prevalence of atherosclerotic disease is increasing rapidly, and is expected to
become the leading cause of death worldwide by 2020 [1], Current approaches to
cardiovascular disease prevention centre on identification and amelioration of major
risk factors for atherosclerosis.
1.1.1 Major Cardiovascular Risk Factors
Major risk factors for cardiovascular disease were originally identified in an
unselected population enrolled in the Framingham Heart Study. Namely, high total
serum cholesterol and low-density lipoprotein cholesterol concentrations, low serum
high-density lipoprotein cholesterol concentrations, high blood pressure, regular
cigarette smoking, and advancing age [2], Diabetes mellitus, obesity and family
history of premature atherosclerotic disease are also considered major risk factors in
their own right [3,4]. Numerous studies have shown that risk factor modification,
including smoking cessation, lowering blood pressure in patients with hypertension
and cholesterol reduction in patients with hypercholesterolaemia, significantly
reduces the incidence of cardiovascular events and lowers overall mortality.
Ten-year coronary heart disease risk can be estimated on the basis of risk observed in
the untreated Framingham study population. Such risk calculations usually take
account of age, gender, blood pressure, total serum cholesterol or total: HDL
cholesterol ratio, the presence or absence of diabetes, and smoking status. Large
studies have confirmed that these factors account for more than 80% of the risk of
premature coronary artery disease [5, 6], Several emerging risk factors have been
identified, which bear close associations with cardiovascular disease risk and or the
mechanisms involved in the development and promotion of atherosclerosis. These
are distinguished from established major risk factors because an independent causal
role in cardiovascular disease has not been fully established, and potential clinical
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benefits associated with amelioration of these factors has not been demonstrated [7],
Identification of novel risk factors is an important step towards evolving new
strategies to prevent or delay the progression of atherosclerosis and thereby reducing
cardiovascular risk.
Table 1. Established and emerging cardiovascular risk factors
Major Cardiovascular Risk Factors
Modifiable Life Habit Non-modifiable
Elevated total cholesterol Obesity Advanced age
Elevated LDL cholesterol Physical inactivity Male sex
Low HDL cholesterol High saturated fat Family history
Diabetes mellitus intake
Regular smoking
Emerging and Potential Cardiovascular Risk Factors
Inflammatory markers Thrombotic factors Platelet factors
C-reactive protein Fibrinogen Platelet aggregation
Interleukins (eg. IL-6) PAI-1 Platelet size and volume
Vascular and cell tPA
adhesion molecules D-dimer
Leukocyte count Fibrinopeptide A
Lipid-related factors Other factors
Triglycerides Metabolic syndrome Homocysteine
Oxidised LDL Large arterial stiffness ACE genotype




In healthy adults, the endothelium is a non-thrombogenic and non-adhesive
monocellular layer that covers around 400 m2, and weighs approximately 1.5 kg and
contains an estimated 1.2 trillion cells [8]. The endothelium serves to maintain blood
vessel integrity in vivo, and acts as a selectively permeable barrier to regulate the
passage of macromolecules between the circulation and local tissues. In addition to
its structural role as a barrier and transporter, the endothelium is physiologically
active and plays a key role in regulating cardiovascular function through the
generation and release of a number of paracrine factors.
Table 2. Factors synthesised and released by the endothelium
Vasodilators Nitric oxide
Prostacyclin





Pro-thrombotic factors Tissue factor
Platelet activating factor
von Willebrand factor
Anti-thrombotic factors Tissue factor pathway inhibitor
Fibrinolysis promoters Tissue plasminogen activator
Fibrinolysis inhibitors Plasminogen activator inhibitor-1
Leukocyte adhesion molecules Intracellular adhesion molecule-1
Vascular cell adhesion molecule-1
Selectins





In 1980, Furchgott and Zawadzki observed that vasodilator responses to
acetylcholine in isolated aortic rings were dependent on the presence of an intact
endothelium [9], The endothelium was found to release a potent vasodilator in
response to acetylcholine, which was originally coined 'endothelium derived
relaxing factor' (EDRF), and subsequently characterised as nitric oxide. To date,
nitric oxide remains the most extensively studied aspect of endothelial biology. It is
formed during a stereo-specific reaction that converts L-arginine to L-citrulline under
the control of nitric oxide synthase. Three isoforms of nitric oxide synthase have
been characterised: endothelial (eNOS), neuronal (nNOS) and an inducible isoform
localised predominantly within inflammatory cells (iNOS). Endothelial nitric oxide
synthase is a dimer consisting of two inactive identical monomers, and believed to be
principally localised adjacent to the plasmalemmal calveolae, bound to calveolin.
The enzyme is inactive in this complexed state, but dissociates in the presence of
calcium to become active within the endothelial cell cytoplasm [10]. Hormones and
autocrine factors, including acetylcholine, and mechanical factors that stimulate
endothelial nitric oxide synthase do so through receptor-mediated increases in
intracellular calcium concentrations. Constitutive endothelial nitric oxide synthesis is
thought to be evoked by normal calcium concentrations within endothelial cells.
Nitric oxide is a free radical that is rapidly scavenged, for example by haem moieties,
so that its effects are observed close to its site of production. It diffuses to the
abluminal environment and causes cyclic GMP-mediated decreases in smooth
muscle calcium concentration, thereby mediating vascular relaxation. In addition,
endothelium-derived nitric oxide inhibits leukocyte adhesion, reduces platelet
aggregability and inhibits hypertrophy of underlying vascular smooth muscle. The
vasodilating effects of nitric oxide have been demonstrated in epicardial and
resistance vessels under normal resting conditions [11]. Nitric oxide has been shown
to play a key physiological role in cardiovascular regulation by influencing the
contractile state of resistance vessels that determine basal blood flow. Intra-brachial
administration of the L-arginine analogue L-NMMA, which inhibits endothelial
nitric oxide synthase, is associated with around a 30-40% reduction of resting
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forearm blood flow in healthy subjects [12]. Similarly, systemic administration of L-
NMMA causes a significant increase in systemic vascular resistance and blood
pressure in healthy individuals [13].
1.2.2 Assessment of Endothelial Function
The extent to which regional blood flow is diminished in vivo by local administration
of nitric oxide synthase inhibitors, such as L-NMMA, is a measure of the extent to
which constitutive nitric oxide bioavailability contributes to vascular tone. In states
characterised by impaired endothelial function, basal nitric oxide bioavailability is
diminished and, therefore, the response to L-NMMA administration is attenuated.
Responsiveness of the endothelium to a variety of endothelium-dependent
mechanical and pharmacological stimuli can also be examined in vivo by measuring
regional blood flow, using venous occlusion plethysmography, or assessing the
extent of arterial vasodilatation by ultrasonography or angiography.
The forearm vascular bed provides an important model for studying endothelial
function in vivo because it is readily accessible to minimally-invasive arterial drug
administration, and the responses to endothelium-dependent vasoactive substances
correlate well with those observed in the coronary circulation [14, 15]. Endothelial
function can be determined by measuring the forearm blood flow responses to intra-
brachial administration of, for example, acetylcholine. In health, the normal response
to acetylcholine administration is vasodilatation and increased blood flow, mediated
by the relaxant effects of endothelium-derived nitric oxide on underlying smooth
muscle. However, in the presence of severe endothelial dysfunction this response is
attenuated, and paradoxical vasoconstriction may be observed due to an unopposed
direct effect of acetylcholine on vascular smooth muscle. Concomitant
administration of L-NMMA blunts the vasodilator response to acetylcholine
confirming that the latter is, at least in part, dependent on endothelium-derived nitric
oxide [12]. Administration of endothelium-independent nitric oxide-mediated
vasodilator substances, for example sodium nitroprusside, allows assessment of the
underlying vascular responsiveness to nitric oxide stimulation. Measurement of
blood flow responses to both endothelium-dependent and endothelium-independent
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vasodilators takes account of nitric oxide responsiveness, and allows more informed
interpretation of endothelial function.
1.2.3 Endothelial Dysfunction
Endothelial dysfunction is associated with impaired nitric oxide bioavailability, and
is thought to play an important early role in the development of atherosclerosis. This
hypothesis is underpinned by animal models, which have shown that chronic nitric
oxide synthase inhibition causes accelerated progression of atherosclerosis and,
conversely, that L-arginine supplementation to enhance vascular nitric oxide
bioavailability delays development of atherosclerosis [16]. A murine knock-out
model has demonstrated that the absence of endothelial nitric oxide synthase
expression causes development of atherosclerotic lesions, which are not
characteristically seen in the wild type strain [17].
Endothelial dysfunction, characterised by impaired blood flow responses to
endothelium-dependent vasodilators, has been identified in patients with any one of a
number ofmajor cardiovascular risk factors, including advanced age [18, 19],
hypertension [20-22], hypercholesterolaemia [23, 24], cigarette smoking, [25-27],
type 1 diabetes [28-30] and type 2 diabetes [31, 32], Furthermore, the presence of
multiple cardiovascular risk factors exerts an additive effect on endothelial
dysfunction [24, 33, 34], Risk factor modification, including cholesterol lowering,
smoking cessation, exercise and oestrogen replacement, result in short-term
improvements in endothelial function, and are accompanied by long-term
improvements in cardiovascular risk reduction. Risk factor modification allows rapid
restoration of endothelial function, even in the presence of established atherosclerosis
[35], suggesting that vascular nitric oxide bioavailability plays a dynamic role in
influencing the development and propagation of atherosclerosis in humans.
1.2.4 Endothelial function as a predictor of clinical outcome
A plausible temporal relationship between the presence of cardiovascular risk
factors, endothelial dysfunction and subsequent development of atherosclerosis has
been established in laboratory and animal models. The association between risk
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factor amelioration and restoration of endothelial function, even in the setting of
established atherosclerosis, has stimulated interest in the potential predictive value of
endothelial function in a clinical setting. Recently, a number of studies have found
that endothelial function carries independent prognostic information in high-risk
patient groups, including patients with mild coronary artery disease [36], established
coronary artery disease [37], hypertension [38, 39] and peripheral arterial disease
[40], These studies have shown that impaired endothelial function is predictive of
increased cardiovascular morbidity and worsened clinical outcome, consistent with
animal model data. Therefore, endothelial function has become increasingly accepted
as a surrogate marker of future cardiovascular risk. Measurement of endothelial
function has become established as an important research tool used to exploring the
mechanism involved in development and progression of atherosclerosis, and the
potential effects of novel therapeutic agents.
1.3 Large Arterial Compliance
Disruption of endothelium-dependent nitric oxide bioavailability also manifests as
reduced large artery compliance [41]. In health, large arterial compliance reduces
peak central blood pressure during systole and enhances blood pressure during
diastole, thereby minimising the variation between systolic and diastolic blood
pressures. Loss of large arterial compliance, so called arterial stiffening, is a
characteristic finding in the presence of any one of a number of cardiovascular risk
factors, for example diabetes mellitus [42] or hypercholesterolaemia [43]. This is
thought due to loss of nitric oxide bioavailability, rather than structural factors alone,
and is mimicked in vivo by nitric oxide synthase inhibition. Large arterial stiffening
is associated with a widened pulse pressure and increased central systolic BP, which
is augmented by early pressure waveform reflection from the peripheral arterial tree
[43], This results in increased cardiac work during systole, and reduced coronary
blood flow during diastole. There has been increasing interest in the potential
mechanisms that promote large arterial stiffness, because the haemodynamic
consequences might contribute to increased cardiovascular risk. Recent studies have
emphasised the importance of pulse pressure as a more powerful cardiovascular risk
predictor than either systolic or diastolic blood pressure alone [45],
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1.3.1 Pulse waveform analysis
Pulse wave analysis is an established non-invasive method that allows large artery
stiffness to be quantified in vivo [46], Examination of the radial artery pulse
waveform by applanation tonometry allows a corresponding aortic pressure
waveform to be constructed, using a validated general transfer function [47],
Increased large arterial stiffness causes more rapid waveform propagation, such that
reflected waves summate with central pressure waveforms earlier in cardiac cycle,
enhancing systolic rather than diastolic pressure. Augmentation index is a measure of
the extent to which central blood pressure is augmented during systole by pressure
waveforms reflected from the peripheries. Large arterial stiffening is associated with
higher pulse waveform velocity and increased augmentation index [48].
Augmentation index is also influenced by the proximity of the effective site of
waveform reflection, which is the hypothetical point in the peripheral vasculature
from which collective pressure waveforms appear to be reflected towards the aorta. It
is governed by structural factors, such as arterial branching points, and sites of
significant impedance mismatch. Increased systemic vascular resistance causes
impedance mismatch to occur more proximally, at interfaces between conduit and
resistance vessels. Therefore, systemic vascular resistance is a potential confounding
factor that can influence augmentation index independently [49], Notwithstanding,
augmentation index has been shown to provide a reproducible and reliable measure
of large artery stiffness in vivo [50-52],
1.3.2 Baroreflex Receptor Sensitivity
The arterial baroreceptor reflex is a key component of the autonomic nervous system,
which is normally responsible for regulation of heart rate and central blood pressure.
The baroreceptors are stretch-receptive peripheral nerve endings embedded in the
adventitia of large arteries, principally located in the carotid sinuses and aortic arch.
Action potentials propagate centrally via carotid sinus nerves and the aortic depressor
nerve, and synapse with central neurons in the nucleus tractus solitarius of the
medulla. These in turn synapse with efferent neurons, which provide
parasympathetic and sympathetic innervation of the cardiovascular system.
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The viscous and elastic properties of the aorta and carotid arteries are key factors that
determine strain on the baroreceptor endings during changes in blood pressure. The
baroreceptor reflex is impaired in patients with hypertension and established
atherosclerosis, and structural vascular changes resulting in loss of arterial
compliance have been considered the predominant mechanisms responsible.
Recently, a number of factors have been shown to impair sensitivity and activation of
baroreceptors, irrespective of vascular structural abnormalities. These include
oxidative stress and free radicals, factors released from activated platelets, and
impaired endothelium-dependent prostacyclin and nitric oxide bioavailability [53].
Endothelial dysfunction is capable of impairing baroreceptor activity by effects on
humoral factors that directly influence receptor activity, and through loss of large
arterial compliance. Therefore, measurement ofbaroreceptor reflex sensitivity
provides an additional means of examining the interaction between endothelial
function and large arterial function in vivo. Impairment of the baroreceptor reflex
mechanism is a recognised finding in patients who have sustained a recent
myocardial infarction, and is independently predictive of increased mortality [54],
Conventionally, the baroreceptor reflex has been determined by observing heart rate
responses to systemically administered pressor and depressor agents, for example
phenylephrine and sodium nitroprusside respectively, and is characterised by the
slope of the relationship between change in heart rate and change in blood pressure.
However, these manoeuvres examine baroreflex activity during extremes of blood
pressure change that may not be physiologically relevant. Furthermore, this method
is confounded by direct effects administered drugs might have on baroreceptor
function, irrespective of the blood pressure changes they evoke. A more recent
approach has been to examine spontaneous baroreflex activity, evident in the patterns
of heart rate and blood pressure change encountered under physiological conditions.
Sequences of parallel increases or decreases in pulse interval and blood pressure are
representative of spontaneous baroreceptor reflex activity, and the slope of the
relationship encountered across a number of such sequences has been used to provide
a quantitative measurement. This technique, so-called sequence analysis of
baroreflex sensitivity, has been shown to be reproducible and reliable in subjects at
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rest, and during stimuli known to affect neural control of the cardiovascular system
[55], Similarly, analysis of the relationship between pulse interval and blood pressure
variability, using frequency domain rather than time domain analyses, has been
established as a reliable means of determining spontaneous baroreceptor reflex
sensitivity, so-called spectral analysis [56], Both sequence and spectral analysis
methods allow baroreflex sensitivity to be determined without the need for
exogenous drug administration, and across a more physiological range of blood
pressure changes than evoked by pharmacological stimulation.
1.4 Tissue plasminogen activator
Considerable attention has been devoted to the impact of endothelial dysfunction on
nitric oxide-mediated vascular function. However, there is increasing recognition of
the consequences of endothelial dysfunction on other important aspects
cardiovascular regulation, including impairment of tissue plasminogen activator
activity. Tissue plasminogen activator plays an important physiological role in
fibrinolysis by enabling the actions of plasmin. Reduced tissue plasminogen activator
concentrations, as a consequence of endothelial dysfunction, confer a pro-thrombotic
effect that is believed to enhance the progression of early thrombus formation and
atherosclerosis, and contributes to arterial occlusion in acute coronary syndromes
[57], Tissue plasminogen activator concentrations can be measured in forearm
venous effluent blood, and the response to intra-brachial administration of specific
endothelium-dependent stimuli, for example bradykinin or substance P, can be
determined [58, 59], Administration to localised vascular beds is preferred because it
avoids adrenergic activation and central haemodynamic responses evoked by
systemic administration of bradykinin, which can independently stimulate tissue
plasminogen activator release [60], Previous studies have found that tissue
plasminogen activator release is attenuated in regular smokers, and this is proposed
as an important mechanism underlying the increased risk of coronary thrombosis in
this group [61, 62], Furthermore, reduced tissue plasminogen activator
concentrations are associated with increased risk in patients with established left
ventricular hypertrophy [63], and contribute to ventricular remodelling and
congestive heart failure after acute myocardial infarction [64], Blockade of the renin-
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angiotensin-aldosterone by angiotensin-converting enzyme inhibitor treatment
increases endothelium-dependent tissue plasminogen activator release, suggesting a
possible mechanism by which this class of drugs might lower cardiovascular risk.
Tissue plasminogen activator release is an agonist-specific endothelium-dependent
response. Muscarinic agonists do not appear to evoke a tissue plasminogen activator
response, while the response to substance P is mediated, at least in part, through
stimulated nitric oxide production [65]. Bradykinin-mediated endothelial tissue
plasminogen activator release appears to be independent of nitric oxide, which might
offer advantages to the use of bradykinin as a preferred agonist [59],
1.5 Oxidative stress and cardiovascular dysfunction
1.5.1 Oxidants
An oxidant is any substance capable of removing outer shell electrons from adjacent
molecules and, in human biology, free radicals are regarded as the most potent. By
definition, free radicals are capable of existing with one or more unpaired electron in
their outer shell, and are inherently unstable and highly reactive. Oxygen derived
free radicals are of greatest biological significance, including superoxide (02'-) and
the hydroxyl radical (OH ), and normally arise as a consequence of inefficient
oxidative metabolism. Molecules subjected to oxidation by free radicals will be left
with an unpaired outer shell electron, having become free radicals themselves, and
may be capable of propagating further oxidation. In this manner, oxidants can cause
severe disruption of cellular function [66],
In the cardiovascular system, lipoproteins are particularly vulnerable to attack, and
polyunsaturated fatty acids are susceptible to oxidation at the sites of unsaturated
carbon double bonds. Lipoprotein oxidation results in peroxyl radical formation,
which in turn reacts with fatty acids to generate lipid peroxides, which are capable of
propagating redox chain reactions, and which decompose to form toxic secondary
products that directly damage local tissues. Measurement of intermediate and
secondary lipid peroxidation products, for example isoprostane and malondialdehyde




A number of important physiological antioxidant systems oppose the effects of free
radicals and oxidants on target substrates. Those capable of sequestering transition
metal ions, which in free form catalyse formation of hydroxyl radicals, can be
considered as preventative antioxidants and include the copper-binding protein
caeruloplasmin, the iron-binding protein transferrin, and albumin. Enzymatic
antioxidants catalyse the breakdown of oxidants within cells, such as superoxide
dismutase, catalase and glutathione peroxidase. Non-enzymatic, or 'scavenging',
antioxidants are consumed during quenching of free radicals and oxidants, thus
preventing organ damage. These sacrificial antioxidants can conveniently be
considered as water-soluble or lipid-soluble agents, partly reflecting the respective
degree to which each is active in aqueous or lipid-rich compartments. The principal
aqueous antioxidants are vitamin C (ascorbic acid) and uric acid, while bilirubin and
thiol-containing molecules appear to make a comparatively small contribution [69].
Vitamin C is the most potent electron donor among scavenging antioxidants, and is
widely distributed intracellularly and extracellularly, and can be regenerated from its
oxidised form, dehydroascorbate. Uric acid is also widely distributed in tissues and
extracellular fluid. Circulating uric acid concentrations are significantly higher than
those of vitamin C and, therefore, it provides the most abundant source of free
radical scavenging activity in human serum.
Vitamin E refers to the tocotrienol group of lipophillic antioxidants, of which a-
tocopherol is the most potent. Vitamin E defences can rapidly become depleted, and
regeneration requires transfer of electrons from vitamin C at the interface between
lipid and aqueous compartments. Carotenoids, including beta-carotene, circulate in
lipoproteins and provide a comparatively small contribution to antioxidant activity in
man. Ubiquinol-10 (reduced co-enzyme Q10) is present in small quantities and may
have an important role in regeneration of active vitamin E.
1.5.3 Oxidative stress
Oxidative stress is a term used to describe an unfavourable imbalance between
potentially harmful oxidants and protective antioxidants. Oxidative stress is a
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characteristic finding in the presence ofmajor cardiovascular risk factors, including
regular smoking, diabetes mellitus, hypertension and hypercholesterolaemia.
Oxidative stress in these situations appears to be primarily due to increased oxidant
exposure. The presence ofmultiple risk factors causes a synergistic increase in both
oxidant activity [70] and markers of oxidative vascular damage [71]. Regular
smokers and patients with type 1 diabetes characteristically have low serum
concentrations of ascorbic acid and uric acid [72, 73], It is unclear to what extent
these changes might contribute as a cause of oxidative stress, or whether lower
concentrations simply reflect increased consumption in the presence of high oxidant
activity. In either case, it is likely that the consequent reduction in antioxidant
defences might increase susceptibility to oxidative damage given that both regular
smokers and patients with type 1 diabetes are characteristically exposed to excess
vascular free radical activity.
1.5.3.1 Isoprostanes
Until recently, the lack of an adequate biological marker of oxidative stress in vivo
has limited studies of the efficacy of antioxidant supplementation. A number of
oxidative reaction products have been explored, including lipid hydroperoxides,
malonyl dialdehyde, and prostaglandin F2-like substances, so called F2-isoprostanes.
F2-isoprostanes are a family of compounds formed by non-enzymatic oxidative
modification of arachadonic acid, and result from free radical attack of phospholipids
in cell membranes or circulating low-density lipoproteins. They are formed in situ in
the cell membrane, from which they are cleaved by phospholipase, and circulate in a
free form or as a phospholipid-bound ester, in a bound: free ratio of approximately 1:
2 [68], Of the F2-isoprostanes, 8-Ao-PGF2a (iPF2a-HI) has been shown capable of
exerting a number of biological effects, such as smooth muscle contraction,
vasoconstriction, and increased platelet aggregability. However, the relevance of
these effects remains uncertain because they are caused by significantly higher 8-iso-
PGF2a concentrations than typically found in human plasma. Concentrations of 8-
Ao-PGF2a are stable in isolated body fluids, and quantification in plasma or urine
provides a marker of free radical generation in vivo. Its concentrations in biological
fluids are increased in the presence of major cardiovascular risk factors characterised
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by oxidative stress, for example hypercholesterolemia, cigarette smoking, and
diabetes mellitus. Elevated 8-wo-PGF2a concentrations in these conditions support
the hypothesis that oxidative modification is an important early step in the
development of atherosclerosis. Circulating 8-wo-PGF2a concentrations provide a
non-invasive quantitative measure of lipid peroxidation, and represent a major
advance in assessment of vascular oxidative stress in vivo.
1.5.4 Oxidative stress and endothelial dysfunction
Endothelial cell injury may be a consequence of direct free radical damage, or the
result of interactions with toxic secondary products of lipid peroxidation, including
oxidised low density lipoprotein. Loss of endothelial integrity is associated with
diminished local nitric oxide bioavailability, which predisposes to platelet adherence
and release of chemotactic agents. Low density lipoprotein is capable of traversing
dysfunctional endothelium, so that cholesterol and cholesterol esters accumulate in
the sub-endothelial site. In the presence of oxidative stress, sub-endothelial low
density lipoprotein becomes oxidised and acts as a potent chemo-attractant stimulus
for macrophage migration and smooth muscle proliferation. Oxidised low density
lipoprotein is highly toxic to the endothelium, and thus propagates endothelial
dysfunction and accumulation of sub-endothelial low density lipoprotein [74],
Macrophages ingest native low density lipoprotein cholesterol via a receptor-
mediated pathway, whereas the oxidised form is ingested by a separate scavenger
pathway that is not subject to negative feedback down-regulation. The latter pathway
results in formation of cholesterol-saturated macrophages, or foam cells, a
characteristic pathological finding in atherosclerotic plaques.
Ordinarily, nitric oxide is subjected to rapid inactivation, and its effects are short¬
lived and localised to its site of production. Oxidative stress creates an environment
conducive to abnormally rapid degradation of nitric oxide, which is accelerated, for
example, by oxidised low density lipoprotein [75]. Therefore, oxidative stress is
capable of reducing vascular nitric oxide bioavailability through both impaired
endothelial production and enhanced oxidative degradation. Increased free radical
activity, in the bloodstream or arterial intima, appears to contribute to endothelial
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dysfunction, which has stimulated interest in factors capable of reducing oxidative
stress, and influencing susceptibility of low density lipoprotein to oxidation.
1.6 Platelet aggregability
Platelets serve an important physiological role by preserving vascular integrity in the
absence of injury, and protecting against spontaneous haemorrhage. However,
platelet adhesion and mural thrombosis are ubiquitous in the initiation and
propagation of atherosclerotic plaques. Platelets are capable of adherence to
dysfunctional endothelium and exposed sub-endothelial collagen and macrophages.
When activated, they degranulate and release thrombin, cytokines and growth factors
that stimulate further platelet adhesion and platelet-platelet interactions, migration of
monocytes, proliferation of underlying vascular smooth-muscle cells, and release of
pro-coagulant factors [76], Activated platelets provide a source of free arachadonic
acid, which is metabolised to prostaglandins, for example thromboxane A(2), and
leukotrienes. Thomboxane A(2) is a potent vasoconstricting and platelet-aggregating
substance, while leukotrienes stimulate and amplify local inflammatory responses.
Thereby, platelet activation at sites of endothelial damage is believed to play a
prominent role in atherogenesis. Studies of induced thrombocytopenia in animal
models demonstrate that the absence of platelet activation prevents the development
of atherosclerosis [77], Platelet activation is also a key event initiating event in acute
coronary syndromes, whereby platelet activation at the site of coronary plaque
rupture promotes additional platelet recruitment and accumulation into an expanding
arterial wall thrombus. Platelet or coagulation protein abnormalities have been
observed in two-thirds ofpatients presenting with coronary thrombotic events [78],
1.7 Plasma Viscosity
There has been growing interest in the link between mechanical forces within blood
vessels, so-call shear stresses, and the development of atherosclerosis. The
development of atherosclerotic plaques is accelerated at sites of low shear stress,
typically at arterial bifurcation sites, or where longitudinal forces are diminished by,
for example, flow eddies. Shear stress is the energy transferred to the vessel wall due
to interaction with fluid in motion, and has been identified as an important stimulus
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of endothelium-dependent nitric oxide liberation [79, 80], Therefore, local nitric
oxide bioavailability is reduced under conditions of low vascular shear stress, for
example immediately downstream from arterial bifurcation points, and this might in
part explain the predisposition to atherogenesis at these sites. It is believed that there
is a physiological range of shear stresses, within which diminished shear stress
amplifies the risk of atherogenesis, while excess shear stress causes increased vessel
wall tension and can stimulate vascular smooth muscle hypertrophy [81].
Three key determinants of shear stress are: cardiac output, vessel geometry (calibre
and length), and blood viscosity. Blood viscosity is a measure of the inherent
resistance of the blood to changes in flow. Increased viscosity increases drag and
enhances the tendency for eddies and low vascular shear stresses, alongside
increasing cardiac burden to maintain cardiac output. Blood is a non-Newtonian fluid
and, thereby, it will change viscosity dependent on the speed with which it flows.
Viscosity at high flow speeds is similar to water, whereas at low flow speeds, for
example during diastole, its viscosity increases three to five fold. The key
determinants of blood viscosity are plasma viscosity, haematocrit and erythrocyte
deformability, fibrin content and, to a lesser extent leukocyte and platelet
concentrations. In healthy subjects, plasma viscosity makes the greatest contribution
to changes in blood viscosity, given that the other haematological indices are
comparatively static. Plasma viscosity is primarily determined by an inverse
relationship with temperature, and plasma protein constituents of which large,
asymmetric proteins in high concentrations have greatest influence (fibrinogen >
immunoglobulins > albumin). Across British populations, plasma viscosity ranges
1.15 - 1.50 mPa.s at 37°C, and there is a close relationship with the risks of ischaemic
heart disease [82, 83] and peripheral vascular disease [84], Plasma viscosity is
increased in the presence of any one of a number of major cardiovascular risk
factors, including advancing age, male sex, regular smoking, hypertension and
hypercholesterolaemia. The effects of these individual risk factors on viscosity is
additive, and it has been proposed that changes in blood rheology might offer a
potential mechanism by which major cardiovascular risk factors additively increase
the risk of arterial disease and atherothrombosis [85], A causal role is supported by
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studies that have identified a relationship between hyperviscosity and increased risk
of left ventricular hypertrophy in patients with hypertension [86], and worsened
ischaemia in patients with peripheral vascular disease [87]. After myocardial
infarction, high plasma viscosity is a strong predictor of 6 month and 2 year mortality
[88], A further study showed that each 0.01 mPa.s increase in plasma viscosity is
associated with a 4% increase in coronary heart disease risk [89], and another found
that plasma viscosity is strongly associated with the incidence of cardiac events, even




2.1 Physiochemical and Biochemical Properties
Uric acid (2,6,8-trihydroxypurine) can exist in free acid form as a stable, colourless,
odourless, off-white powder. Uric acid comprises a five member imidazole ring
fused with a six member imidazole ring, and both synthetic and extracted
preparations are available with greater than 99% purity determined by high
performance liquid-phase chromatography. It is a weak acid that can be ionised at
positions 9 and 3, with pKa dissociation constants of 5.57 and 10.30 respectively
[91], and confers a modest pH buffering effect in solution. It is comparatively inert,
and does not act as a reducing agent under physiological conditions. At pH values
greater than 5.57, uric acid exists predominantly in ionised form, as the urate ion,
which is more soluble than its free acid. For example, in human serum at pH 7.4,
approximately 98% of uric acid exists as monosodium urate, whereas in bodily fluids
such as urine with pH less than 5.57, uric acid is the predominant form [92]. This has
implications for formation of uric acid-containing crystals in urine in preference to
other bodily fluids (discussed further in Chapter 3.5.2).
For the purposes of this thesis, the term uric acid will be used interchangeably
throughout to describe either the free or ionised forms, unless otherwise specified.
Uric acid (free form) Monosodium urate (salt)
Figure 1. Structural formula of free uric acid and its monosodium salt.
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2.2 Uric acid in human biology
2.2.1 Purine metabolism
Nucleic acids derived from dietary sources and endogenous cell turnover comprise
purine bases, adenine and guanine, and pyrimidine bases, cytosine, thymine and
uracil. In humans, both a de novo and a salvage pathway exist for purine
biosynthesis, and the liver is the main site of de novo purine formation [93], Certain
cells have limited capacity to generate purines, for example neurons, and in some
cells the de novo pathway may be completely absent, for example erythrocytes.
Therefore, the salvage pathway is of physiological relevance, and the nucleotide
breakdown products hypoxanthine and guanine are converted to guanosine
monophosphate or inosine monophosphate by the action of the enzyme
hypoxanthine-guanine phosphoribosyltransferase. Purines participating in the salvage
pathway decrease de novo synthesis, to some extent, through the negative feedback
effects of adenosine monophosphate and guanosine monophosphate on enzyme
activity [94], Purines obtained from dietary sources do not appear to be salvaged but
are metabolised by the enzyme xanthine dehydrogenase to uric acid, the ultimate
product of purine metabolism in man. The enzyme xanthine dehydrogenase can be
converted to xanthine oxidase, an alternative means of purine catabolism to uric acid
in humans (discussed further in Chapter 3.2.4). Although purine nucleotides are
broken down by all cells, uric acid is only formed in those cells and tissues capable
of expressing xanthine dehydrogenase, primarily the liver, small intestine and
skeletal muscle.
The rate of uric acid production arising from endogenous purine metabolism in
healthy adults is around 400 mg daily, and dietary purine sources contribute to
formation of around 300 mg additional uric acid each day [95],
2.2.2 Elimination of uric acid
Approximately 5% of blood uric acid is bound to plasma proteins, and generally
regarded as being of little clinical significance [96], Renal handling of uric acid is
complex and involves four sequential processes; glomerular filtration of virtually all
of the uric acid entering the glomerulus, reabsorption of 98-100% of filtered uric acid
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in the proximal convoluted tubule, secretion of uric acid into the lumen of the distal
portion of the proximal convoluted tubule, and further reabsorption from the distal
convoluted tubule [97, 98], Urate reabsorption is indirectly coupled to sodium
transport by an electoneutral anion exchanger. Anions, such as chloride and organic
acid anions, first enter the proximal tubular cell through sodium-dependent co-
transport and move back into the tubular lumen in exchange for uric acid [99]. Urate
secretion into the tubule is thought to occur through a voltage-sensitive ATP-
dependent transporter mechanism located in the tubular luminal membrane [100],
The net urinary excretion of uric acid is around 6-12% of the amount filtered [97],
2.2.3 Serum uric acid concentrations
Serum uric acid concentration in any individual is determined by the extent of dietary
purine ingestion, the rate of endogenous cell turnover and nucleic acid liberation, and
the efficiency of renal clearance. Across unselected populations, serum uric acid
concentrations observe a Gaussian distribution [101, 102], Much of the variability
results from factors that increase uric acid production (such as high purine or protein
diets, alcohol consumption, conditions associated with high cell turnover, or
enzymatic defects in purine metabolism) or factors that influence clearance, and
renal function in particular [103], Concentrations are elevated on the first day after
birth but drop to a low level in the succeeding days and remain low until
approximately the 10th year [104], Serum uric acid concentrations achieve adult
values with the beginning of puberty and a typical 95% normal reference range is
120-420 pmol/1 in men and 120-360 p.mol/1 in women [104], Exposure to lower uric
acid concentrations in women appears due, at least in part, to the effect of oestrogen
on renal uric acid clearance [105], Both supplemental oestrogen therapy and
oestrogen replacement therapy cause enhanced uric acid clearance, and reduce serum
concentrations. Consistent with these observations, serum uric acid concentrations
increase in post-menopausal females, and the differences between men and women
decrease with advancing age [106]. Hyperuricaemia is arbitrarily defined by a serum
or plasma uric acid concentration of greater than 420 pmol in men or greater than
360 pmol/1 in women. Asymptomatic hyperuricaemia is frequently detected by
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biochemical screening, and few of such individuals ever develop clinical disorders
thought directly attributable to raised uric acid concentrations (see Chapter 3.5).
Uric acid has limited solubility in aqueous media and human bodily fluids. The
maximal achievable concentration ofuric acid in water is around 380 mmol/1 at
37°C, and plasma becomes saturated at uric acid concentrations beyond 405 pmol/1
[107, 108], At higher concentrations, plasma is supersaturated with regards to uric
acid, and potential exists for precipitation ofuric acid crystals, particularly at
concentrations greater than 650 pmol/1 [109], In the uncommon setting of acute
tumour lysis syndrome, serum uric acid concentrations ofmore than 1200 pmol/l
have been described [110]. The solubility of uric acid increases as sodium
concentration decreases and body temperature increases [109], A number of drugs
are known to influence serum uric acid concentrations [111, 112].
Table 3. Drugs known to influence serum uric acid concentrations.
Increased uric acid concentrations Decreased uric acid concentrations
Thiazide diuretics Probenecid, sulphinpyrazone
High dose loop diuretics Allopurinol, oxypurinol
Salicylates (low dose) Ascorbic acid
Nicotinic acid Calcitonin




Ethambutol Salicylates (> 2 g/day)
Pyrazinamide ACE inhibitors
Vitamin B12 Losartan
Radiographic contrast agents Verapamil
2.2.3.1 Circadian variation in serum uric acid concentrations
Circadian variations in cell turnover, metabolism and renal function have long been
recognised. These factors can influence circulating uric acid concentrations and,
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therefore, circadian patterns of uric acid clearance and serum concentrations have
been observed. For example, uric acid clearance has been studied in healthy people
during a twenty-four hour period of recumbent rest, under conditions of adequate
hydration. The lowest values were observed at night, the steepest rise in uric acid
clearance occurred between 7 and 10 am, and there was around a two-fold difference
between highest and lowest clearance throughout the study period [113]. Similar
circadian patterns of serum uric acid concentrations have been observed in
ambulatory healthy individuals, where highest concentrations are observed during
wakeful hours, and lowest concentrations during and after sleep [114]. Hour-by-hour
variations in serum uric acid concentrations are likely to reflect not only patterns of
clearance, but also the effects of dietary intake and exercise. Lactate, produced
during ambulation and moderately intense exercise inhibits tubular secretion of uric
acid so that serum concentrations increase [115].
2.2.4 Intracellular uric acid concentrations
In healthy individuals, the normal total body pool of exchangeable uric acid is
estimated at around 1.2 g in men and 0.6 g in women, and is subject to much greater
variation between individuals than that reflected by serum measurements [116].
Transport ofuric acid across cell membranes into endothelial cells depends on an
active carrier-mediated mechanism transport, and intracellular concentrations are
lower than those in the circulation. Furthermore, active cellular efflux, assisted by the
negative membrane potential and lower cellular pH, serve to maintain lower
intracellular uric acid concentrations [117]. Therefore, high circulating uric acid
concentrations may not necessarily be accompanied by correspondingly high
concentrations within tissues. The lack of close correlation between circulating uric
acid concentrations and those found in other fluids and tissues is an important
confounding factor that explains the poor correlation between serum concentrations
and the risk of crystal arthropathy (discussed in Chapter 3.5.1).
2.3 Antioxidant properties
Uric acid is known to possess antioxidant properties, and is believed to be one of the
most abundant sources of antioxidant activity in human plasma. It is capable of
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scavenging powerful free radicals including superoxide, hydroxyl radical, and singlet
oxygen, and can chelate transition metals, which promote free radical liberation. Its
antioxidant properties have been identified both in vitro and ex vivo. The importance
of uric acid as a physiological antioxidant has been underpinned by studies that
demonstrate it contributes more than two-thirds of all free radical scavenging
capacity of human serum [73, 118].
2.3.1 Uric acid and lipid peroxidation
In addition to its role as a free radical scavenger, uric acid is known to interact
directly with peroxynitrite, which may have additional effects on human
cardiovascular redox conditions. Peroxynitrite is a powerful radical that is capable of
damaging phospholipid components of endothelial cell membranes. Lipoproteins are
particularly vulnerable to attack by free radicals at sites of polyunsaturated fatty acid
carbon double bonds, and the interaction with peroxynitrite in the presence of oxygen
causes rapid formation of peroxyl radicals. In turn, these react with fatty acids to
generate lipid peroxides, which are unstable radicals capable of propagating redox
chain reactions. The interaction of lipid peroxides and cellular components, so called
lipid peroxidation, results in formation of a number of toxic secondary oxidation
products, which can cause further direct tissue damage. Their quantification in bodily
fluids, for example plasma or urinary isoprostane concentrations, is indicative of the
extent of local lipid peroxidation and provides a biological marker of oxidant activity
in vivo [119].
Uric acid is particularly effective in quenching hydroxyl, superoxide and
peroxynitrite radicals, and may serve a protective physiological role by preventing
lipid peroxidation [120], Uric acid concentrations have been found to increase during
acute oxidative stress and ischaemia in a number of organs and vascular beds. The
consequent increase in antioxidant defences conferred by high uric acid
concentrations has been proposed as a compensatory mechanism that protects against
increased free radical activity [121], Animal models have shown that, for example,
transient middle cerebral artery occlusion causes a significant increase in cerebral
uric acid concentrations, which can remain elevated for several days after the
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primary ischaemic insult [122], Physiological concentrations of uric acid protect
hippocampal neurons in vitro against excitotoxic and metabolic injury during acute
ischaemia. Raising circulating uric concentrations in vivo, by means of direct
administration, reduced infarct volume and improved functional outcome in a rat
model of acute ischaemic stroke [123]. This suggests that high concentrations of uric
acid protect against oxidative tissue damage during acute neuronal ischaemia.
2.3.2 Uric acid and peroxynitrite
Nitric oxide is normally subjected to rapid degradation, which is increased in the
presence of excess peroxynitrite. Peroxynitrite is a potent oxidant that is capable of
causing endothelial injury by direct interaction, so that in the setting of oxidative
stress, the increased peroxynitrite concentrations might be an important mechanism
underlying endothelial dysfunction. Uric acid, as a powerful antioxidant, is capable
of quenching peroxynitrite activity. Animal models of cardiac reperfusion injury and
cerebral ischaemia have shown that uric acid protects against peroxynitrite-mediated
protein nitration, thereby conserving tissue viability [124], Furthermore, uric acid has
been found to react with peroxynitrite to form a stable nitric oxide donor [125] and,
therefore, high uric acid concentrations might conserve nitric oxide dependent
vascular function in the setting of oxidative stress.
2.3.3 Uric acid and superoxide dismutase
Superoxide dismutase normally acts to convert superoxide free radicals to less potent
hydrogen peroxide radicals, thereby preventing superoxide-mediated nitric oxide
degradation. As a consequence, superoxide dismutase is critical in maintaining
endothelial and vascular integrity. Furthermore, superoxide dismutase is itself
degraded by hydrogen peroxide [126], Uric acid is capable of preventing hydrogen
peroxide-mediated degradation of superoxide dismutase, accompanied by the
formation of an intermediary urate radical [126], While potentially a pro-oxidant, the
urate radical is itself significantly less active than classical oxidants, and is rapidly
regenerated back to uric acid in the presence of ascorbic acid [126], In this manner,
uric acid appears to serve a role in preserving superoxide dismutase activity, and
attenuating hydrogen peroxide activity.
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2.4 Evolutionary aspects of uric acid metabolism
Uric acid is metabolised to allantoin by urate oxidase in virtually all other
mammalian species apart from humans and higher apes. In hominoids, the gene
encoding urate oxidase has been identified on chromosome lp22, but is not
expressed due to two non-sense mutations at codon positions 33 and 187, and an
aberrant splice site [128, 129], As a consequence, circulating uric acid concentrations
are significantly higher in hominoids than most other species. The pattern of genetic
mutations that prevent expression ofurate oxidase, and other uric acid-degrading
enzymes (allantoinase, allantoinicase, ureidoglycolate lyase and urease), has
suggested that loss of urate oxidase has arisen through selective pressure [130], This
has generated speculation over the potential evolutionary benefits that may be
conferred to hominoids by high serum uric acid concentrations. For example, it has
been suggested that the antioxidant properties of uric acid might serve to defend
against the oxidants, to which exposure cumulatively increases with longevity [131].
A positive correlation has been observed between mean serum uric acid
concentrations and life span across a wide range ofmammalian species [132],
The time frame of the urate oxidase gene mutations is estimated to have occurred
between 8 and 24 million years ago, in the Miocene era. During this early
evolutionary period, the hominoid diet is likely to have consisted primarily of fruit
and vegetables, providing a daily sodium intake of less than 700 mg (1.9 g sodium
chloride). Coupled with arid climatic conditions prevailing at that time, early
hominoids are likely to have had greater dependence on salt-retaining mechanisms
for blood pressure homeostasis, such as the renin-angiotensin-aldosterone system.
Animal models have shown that in the setting of a low salt diet, uric acid causes
increased blood pressure by enhancing sodium sensitivity and activation of the renin-
angiotensin-aldosterone system [133]. Uric acid causes morphological renal vascular
changes so that increased salt sensitivity persists, even after restoration of normal
uric acid concentrations [134], The effect of high circulating uric acid concentrations
on salt sensitivity has not been studied in humans. It is tempting to speculate that
higher concentrations might have provided an evolutionary advantage to early
hominoids, by means of conserving blood pressure in the setting of low salt intake,
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whereas. However, it is possible that this effect might be unfavourable in the
presence of an adequate or high salt intake.
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Chapter 3.
Uric acid and cardiovascular disease
3.1 Epidemiological associations with cardiovascular risk
Observational studies show that serum uric acid concentrations are higher in patients
with established coronary heart disease compared to healthy controls [135].
Furthermore, strong epidemiological links between elevated serum uric acid
concentration and increased cardiovascular risk have been recognised for many years
[101, 136]. However, hyperuricaemia is associated with a number of confounding
factors, many ofwhich recognised as independent cardiovascular risk factors [137-
142],









High C-reactive protein concentrations
These confounding factors cause difficulty interpreting relationships between serum
uric acid concentration and cardiovascular risk in epidemiological studies. Many
authorities have attempted to address the issue of confounding factors by the use of
multivariate analyses. However, these do not fully exclude the possibility of residual
confounding within such closely associated variables. Epidemiological studies in
both unselected populations and high risk patient groups and have given conflicting
results (see Tables 5 and 6). It appears that epidemiological data alone will not have
sufficient power to discriminate whether high serum uric acid concentrations are
independently related to increased cardiovascular risk, or indirectly linked through
associations with other established risk factors.
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Table 5. Epidemiological associations between serum uric acid concentrations
and cardiovascular risk in unselected populations.






Framingham 1985 [144] 5209 26 Y N
1987 [145] 5127 30 Y Women
1999 [146] 6763 17.3 Women N
Honolulu Heart 1975 [147] 8006 2 Y Y
Study (men) 1995 [148] 2710 20 Y Y
1996 [149] 6411* 21 Y Y
Chicago Heart 1979 [150] 24997 5 Y Y
Assoc. (women) 1989 [151] 6797 11.5 Y Y
NHANES I 1995 [152] 5421 13.5 Y Women
2000 [153] 5926 16.4 Y Y
ARIC study 2000 [154] 13504 8 Women N
British Regional 1997 [155] 7688 16.8 Y N
Heart Study men
Social Institution 1982 [156] 6355 5 Y N
of Finland
Gothenburg" 1988 [157] 1462
women
12 Y Y
MONICA 1999 [158] 1044 8 Y Y
**
project men
Evans County 1973 [159] 2212 - Y N
***
Study
NHANES III"* 1999 [160] 16025 - Y Y
'alcohol abstainers, **all-cause mortality, '''prevalence
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Table 6. Epidemiological associations between serum uric acid concentrations
and cardiovascular risk in high risk groups.
Study Year Ref. Number Duration Univariate Independent
(y) correlation correlation
Elderly Patients:
CASTEL study* 1993 [161] 318
(> 80 y)
7 Y Y
McArthur 2001 [162] 870 7 N N
Studies (>65 y)
Patients with hypertension:
HDFPC research 1985 [163] 10940 5 Y Y
group 1987 [164] 3693" 5 Y Women
Work site study 1999 [165] 7978 6.6 Y Y
PIUMA study 2000 [166] 1720 4 Y Y
European 1991 [167] 822 3 Y N
Working Party
SHEP study 2001 [168] 4327 5 Y Y
Syst-China 2001 [169] 1873 3 Y Y
Syst-Eur 2002 [170] 4522 2 N N
Patients with established coronary artery disease:
Coronary Drug 1976 [171] 2789 3 Y N
Project
Atherogene 2002 [172] 1017 2.2 Y Y
Study
French Canadian 1973 [173] 1002 - N N
_ „ ***
Study
Spokane study"* 2001 [142] 277 - Y Women
Patients with type 2 diabetes:
Lehto et al. 1998 [174] 1017 7 Y Y
'all-cause mortality, "thiazide treated subgroup, "'coronary artery disease severity
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3.2 Associations between uric acid and cardiovascular risk
3.2.1 Uric acid and renal function
Renal clearance is the major route of uric acid elimination, and renal impairment is
characteristically associated with increased serum uric acid concentrations.
Furthermore, low renal blood flow stimulates tubular reabsorption of uric acid [141],
Around 25% to 40% of patients with a clinical history of gout have impaired renal
function, with evidence of histologic injury in the majority [175], Typically, the renal
lesions seen in patients with gout consist of variable degrees of arteriolosclerosis,
glomerulosclerosis, and interstitial fibrosis, often with focal deposition of urate
crystals in the outer medulla. Many authorities have ascribed the renal injury to
coexistent hypertension or aging-associated renal disease [176]. However, these
factors alone might not entirely account for all of the renal injury observed [177],
Lowering serum uric acid concentrations in patients with a clinical history of gout
has been found to improve renal function in some studies [178, 179], but not all
[180],
A number of clinical studies have shown that high serum uric acid concentrations are
an important risk marker for renal impairment across unselected adult populations
[176, 181]. High uric acid concentrations appear to contribute to progression of renal
impairment, as found in one study [182], but this has been refuted by the results of
another study [183]. In patients with IgA nephropathy, uric acid concentrations have
been shown to be an independent predictor of deteriorating renal function [184, 185].
In patients with type 2 diabetes, hyperuricaemia confers a significantly greater risk of
developing renal impairment [186], However, in patients with accelerated
hypertension, a close correlation has been found between baseline serum uric acid
and creatinine concentrations, but high uric acid measurements did not predict
subsequent decline in renal function [187],
On the basis of existing literature, it is unclear whether the known association
between serum uric acid concentrations and renal impairment can be fully explained
by reduced clearance alone. During exposure to extreme high serum uric acid values,
for example those encountered in the comparatively rare setting of acute tumour lysis
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syndrome, there is grossly increased uric acid excretion that may be accompanied by
tubular and ureteric crystal formation (see Section 3.5.2). It is not known whether
chronic exposure to high circulating concentrations are causally associated with renal
injury in wider populations.
3.2.2 Uric acid and hypertension
Oxonic acid inhibits urate oxidase activity and thereby increases serum uric acid
concentrations in animal models of hyperuricaemia. Dietary supplementation with
2% oxonic acid in rats has been shown to significantly increase blood pressure from
125 ± 15 to 143 ± 13 mmHg (mean ± SEM) at 4 weeks, and a close correlation was
found between the resultant uric acid concentration and rise in blood pressure [133],
The effect persisted until death or euthanasia at 7 weeks, and was prevented by
concurrent administration of allopurinol and a uricosuric agent [133]. A
characteristic form ofmicroscopic kidney injury and increased renin concentrations
were noted, suggest a possible renal mechanism for the observed increase in blood
pressure. Oxonic acid supplementation to Sprague-Dawley rats fed a low salt diet
caused high blood pressure at 5 weeks, 143 ± 4 versus 126 ± 2 mmHg (mean ± SEM)
in controls [188], Histology and immunostaining showed pre-glomerular arteriolar
hypertrophy, suggesting a renal mechanism. Blood pressure elevation and renal
damage were prevented by allopurinol administration [188], Findings from these
animal models have tempted speculation that high serum uric acid concentrations
might play a causal role in the development of hypertension in humans.
Renal function is a major determinant of serum urate concentration, and around one
quarter of hypertensive patients have co-existent hyperuricaemia due to impaired
renal uric acid clearance [189].
Asymptomatic hyperuricaemia has been found to predict future development of
hypertension in unselected populations [190-194],
The US National Health and Nutrition Survey (NHANES) III showed that age-
adjusted rates ofmyocardial infarction and stroke are higher across increasing serum
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uric acid quartiles in male and female hypertensive patients [160], In essential
hypertension, high serum uric acid concentrations are associated with significantly
increased cardiovascular risk, independent of renal function and other confounding
factors. During a mean 6.6-year follow-up, the proportional hazard ratio associated
with one standard deviation increase in serum uric acid concentration (29.2 pmol/l)
was 1.22 (95% confidence interval 1.11 - 1.35), and higher than that found for
comparable increases in blood glucose, cholesterol or systolic blood pressure [165],
Similarly, a significant association has been found between serum uric acid
concentrations and cardiovascular and total mortality in patients with isolated
systolic hypertension, after adjusting for renal function [169], An association
between serum uric acid concentration and pulse pressure has been identified in
unselected populations, suggesting a possible mechanistic link between
hyperuricaemia and isolated systolic hypertension [195],
Thiazide diuretics confer unequivocal benefits in patients with hypertension, and
cause a significant reduction in cardiovascular and all-cause mortality [196],
Persistence of the relationship between elevated serum uric acid concentration and
increased cardiovascular risk among thiazide treated patients has prompted
speculation that uric acid elevation may attenuate some of their potential benefits
[197], An association has been found between high serum uric acid concentration
and poorer response to anti-hypertensive therapy [198]. Despite this, a large recent
clinical trial has reported that thiazide treatment reduces cardiovascular risk to a
similar or greater extent than other anti-hypertensive agents associated with
comparable reductions in blood pressure [199]. Interestingly, these findings have
prompted speculation that the increase in serum uric acid concentrations associated
with thiazide diuretics might be a mechanism by which treatment reduces
cardiovascular risk [200], although this hypothesis has not been examined directly.
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3.2.3 Uric acid and insulin resistance
Serum uric acid concentrations are closely associated with serum triglyceride and
cholesterol concentrations, blood glucose, fasting and post-carbohydrate plasma
insulin concentrations, waist-hip ratio and body mass index [101, 137-140]. Uric acid
measurements are higher in subjects with impaired glucose tolerance than healthy
subjects, and independently associated with components of the metabolic syndrome.
Uric acid values are more closely associated with body mass index, blood pressure
and glycaemia after oral glucose administration, than insulin sensitivity per se [201].
Among apparently healthy people, high serum uric acid concentrations have been
found to predict weight gain, [193], impaired glucose tolerance and type 2 diabetes
[192], Elevated serum uric acid concentrations predict the subsequent development
of diabetes mellitus, even in the presence of normal creatinine clearance and plasma
glucose concentrations [202],
Insulin has a physiological renal tubular effect that reduces sodium and uric acid
clearance [203], Insulin resistance and type 2 diabetes are characterised by impaired
insulin-mediated glucose metabolism in peripheral tissues, whereas renal sensitivity
to insulin persists [203, 204], This suggests that high serum uric acid concentrations
might be secondary to hyperinsulinaemia, which is a characteristic finding in insulin
resistance syndromes and type 2 diabetes. Insulin resistance is an independent
predictor of coronary heart disease and stroke in apparently healthy adults [205],
Therefore, a non-causal relationship between high serum uric acid concentrations and
cardiovascular risk might be explained by its role as an early marker of peripheral
insulin resistance.
In patients with established type 2 diabetes, high serum uric acid concentrations
predict stroke risk, independent of other identifiable risk factors [174], as described
also in unselected patient populations [206]. Paradoxically, high serum uric acid
concentrations in the setting of acute ischaemic stroke are associated with better
clinical outcome [207]. This raises the possibility that uric acid, through a number of
potential mechanisms, might play distinct roles in the development of atherosclerosis
and its late ischaemic disease manifestations.
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3.2.4 Uric acid and xanthine oxidase
The xanthine oxidoreductase gene encodes xanthine dehydrogenase, a 150 kDa
protein. Xanthine dehydrogenase is constitutively expressed and catalyses the
metabolism of hypoxanthine and xanthine to uric acid. Xanthine dehydrogenase
requires NAD+ as an electron acceptor, thereby generating a stable reaction product,
NADH. However, in the setting of oxidative stress, xanthine dehydrogenase is
converted to xanthine oxidase by thiol oxidation of sulphhydryl residues, or
irreversible proteolytic cleavage [208]. Unlike xanthine dehydrogenase, xanthine
oxidase is unable to utilise NAD+ as an electron acceptor and, instead, reduces
molecular oxygen to the highly reactive superoxide radical [209], Xanthine oxidase-
derived reactive oxygen species have been implicated in a number of pathologies,
including myocardial ischaemia, cerebral ischaemia and tissue reperfusion injury.
Under conditions of tissue ischaemia, local uric acid concentrations become
significantly increased [210]. This is thought to result from enhanced availability of
purine substrate, due to increased local formation and release of adenosine [211],
alongside up-regulation of xanthine oxidase activity [212], For example, cardiac
ischaemia caused by transient coronary artery occlusion is associated with acute
increases in local uric acid concentrations [213]. Tourniquet-induced lower limb
exsanguination causes a 5-fold increase in systemic vascular xanthine oxidase
activity during reperfusion, and serum uric acid concentrations become significantly
elevated for at least 2 hours [214],
To date, no specific xanthine oxidase inhibitor is available. Allopurinol, and its
active metabolite oxypurinol have been widely used in a therapeutic setting, and in
clinical research as a means of inhibiting xanthine oxidase. However, both
compounds bind at a common molybdenopterin cofactor site so as to inhibit the
activity of both xanthine dehydrogenase and xanthine oxidase. Inhibition of xanthine
oxidase reduces formation of superoxide radicals, and has been shown to reduce
oxidative stress in situations where activity of this enzyme is significantly increased,
for example congestive heart failure [215], However, inhibition of both xanthine
dehydrogenase and xanthine oxidase causes a significant reduction in uric acid
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concentrations. Uric acid has been shown to protect against free radical mediated
injury in the setting of ischaemia. Loss of antioxidant capacity, as a consequence of
allopurinol-mediated reduction in uric acid concentrations exacerbates oxidative
stress in certain situations [216, 217], Therefore, effects of allopurinol and
oxypurinol on vascular redox state and oxidative stress are likely to depend on the
extent to which xanthine oxidase is active. High serum uric acid concentrations
appear to offer an important marker of enhanced vascular xanthine oxidase activity,
associated with sub-clinical tissue ischaemia. This is consistent with an inverse
relation between serum uric acid concentrations and lower limb blood flow found in
patients with chronic heart failure. This mechanism offers a potential explanation for
a non-causal association between high serum uric acid concentrations and conditions
associated with increased cardiovascular risk.
Endothelial cells of microvascular origin are rich in xanthine dehydrogenase, and
uric acid predominates as the final product of local purine metabolism. Conversely,
xanthine dehydrogenase is relatively lacking in endothelial cells associated with
medium and large arteries, and hypoxanthine is the predominant final product of
purine metabolism [218]. This interesting observation suggests that the comparative
lack of uric acid availability within large vessel walls, and resulting loss of
antioxidant defences might contribute to the preponderance of atherosclerosis
development at these sites, although this remains unproven.
3.2.4.1 Xanthine oxidase and cardiovascular risk
Vascular xanthine oxidase activity is significantly up-regulated in both experimental
and human congestive heart failure [219, 220]. Serum uric acid concentration is a
particularly powerful marker of increased cardiovascular risk in such patients, and
the relative risk ratios associated with concentrations 400-600, 600-800 and >800
pmol/1 are 1.8, 6.3 and 18.5 respectively, compared to those < 400 pmol/l [221], Uric
acid remains an important prognostic indicator, even when the potential confounding
effects of renal function and diuretic use are taken into consideration [222],
Allopurinol has been found to significantly improve serum antioxidant capacity and
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endothelial function in patients with chronic heart failure [215, 223], underpinning
the importance of excess xanthine oxidase activity in this group.
Excess xanthine oxidase activity also appears to play a significant role in mediating
oxidative stress in patients with diabetes mellitus, and administration of allopurinol
affords protection against free radical mediated vascular injury in this patient group
[224], Furthermore, allopurinol has been shown to allow restoration of endothelial
function in patients with type 2 diabetes mellitus, associated with increased serum
antioxidant capacity [225], The contribution of increased xanthine oxidase activity to
vascular dysfunction is less certain in the presence of other major cardiovascular risk
factors. In patients with hypertension and hypercholesterolaemia, there is clear
evidence that excess superoxide participates in vascular dysfunction [226]. Animal
and human studies are inconsistent with regard to xanthine oxidase as an important
source of superoxide radicals [227-229], whereas NAD(P)H oxidase or endothelial
nitric oxide synthase may be more important sources in these patients [230],
3.2.5 Uric acid and alcohol intake
A significant j-curve relationship has been identified between alcohol intake and
serum uric acid concentrations [231], and a similar relationship has been shown
between alcohol ingestion and cardiovascular risk [232], These findings indicate that
alcohol intake is an important confounding factor in examining relationships between
serum uric acid concentrations and cardiovascular risk. Alcohol ingestion can cause
with increased serum uric acid concentrations through a number ofmechanisms: (1)
high purine content of some alcoholic beverages, (2) increased adenine nucleotide
turnover [233], and (3) raised lactate concentrations that decrease renal tubular
secretion of uric acid by competing for the organic anion transporter [115]. Despite
alcohol intake being an important confounding factor, an independent relationship
between serum uric acid concentration and cardiovascular risk has been shown in
middle-aged alcohol-abstinent men included in the Honolulu Heart Study [147].
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3.3 Potential pathophysiological links between uric acid and
cardiovascular risk
3.3.1 Pro-oxidant effects of uric acid
Despite its widely acknowledged antioxidant properties, like other antioxidants uric
acid may exert pro-oxidant effects under certain circumstances. For example, uric
acid has been found to promote oxidation of low density lipoprotein in vitro [234,
235], Oxidation of low density lipoprotein is believed to be an important step in the
development and progression of atherosclerosis, and high uric acid concentrations
might significantly impair vascular function if such a mechanism operates in vivo. Its
pro-oxidant properties have been found to be inhibited by vitamin C [236],
underpinning the importance of functional interactions between various aqueous anti¬
oxidants.
3.3.2 Uric acid and vascular inflammation
Uric acid is able to traverse dysfunctional endothelial cells, and accumulate in
crystals nested within developing atherosclerotic plaques [237], Monosodium urate
crystals have been shown to stimulate granulocyte adherence to the endothelium, and
liberation of peroxide and superoxide free radicals [238, 239], Therefore, uric acid
appears capable of promoting atherosclerosis progression by accumulating at sites of
endothelial dysfunction, stimulating leukocyte activation and propagating endothelial
dysfunction. It is likely that in the presence of endothelial dysfunction, high serum
uric acid concentrations will confer a greater predisposition for sub-endothelial uric
acid accumulation. Qualitative and quantitative analyses of the protein adsorptive
properties ofmonosodium urate monohydrate crystals have shown that they
preferentially adsorb immunoglobulin G from normal human serum, to which it
binds with high affinity [240], This property suggests a means of Fc receptor
mediated sub-endothelial phagocytosis, which might further promote localised
vascular inflammation.
Uric acid has been shown to exert a dose-dependent mitogenic effect on rat aortic
vascular smooth muscle in vitro [241], Half-maximal induction of vascular smooth
muscle DNA synthesis occurred at 150 prnol/1 and maximal effects at 250 pmol/1.
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While both concentrations are considerably in excess of serum concentrations
normally found in the rat, they are similar to those to which humans are ordinarily
exposed (95% reference range 120 - 420 pmol/1). The mitogenic effect was specific
for vascular smooth muscle, not observed in response to other purine metabolites or
aqueous antioxidants [241], This observation indicates that uric acid is capable of
exerting a direct effect on vascular smooth muscle, and suggests a further possible
mechanism by which sub-endothelial uric acid crystal accumulation might contribute
to the progression of atherosclerosis.
A consistent relationship has been noted between elevated serum uric acid
concentration and circulating inflammatory markers in animal models and humans
[242-244],
3.3.3 Uric acid and enhanced platelet aggregability
For more than forty years, enhanced platelet aggregability has been proposed as a
potential biological mechanism of increased cardiovascular risk in the setting of high
serum uric acid concentrations [171, 245, 246]. Monosodium urate crystals have
been found to promote the release of platelet components in vitro [247].
Furthermore, the observation of high serum uric acid concentrations in patients with
thromboangitis obliterans lent support to the possibility that uric acid might influence
platelet activation in vivo [248]. Patients with a clinical history of gout have been
shown to exhibit characteristic abnormalities of platelet morphology, which are
restored by treatment with allopurinol [249], Furthermore, treatment with
sulphinpyrazone, a uricosuric agent, has been shown to reduce platelet aggregability
and improve clinical outcome in patients who had suffered a recent myocardial
infarction [250], However, interpretation of these studies is difficult because both
allopurinol and sulphinpyrazone are highly protein-bound, and capable of reducing
platelet aggregability independent of effects on serum uric acid concentration.
Tranylcypromine (a prostacyclin synthetase inhibitor) catalyses ADP-induced
platelet aggregation. However, tolerance to this effect develops rapidly due to
inactivation of cyclooxygenase free radicals [251], Uric acid has been shown to
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prevent tolerance and prolong platelet activation, which was thought due to its
antioxidant properties [251]. High uric acid concentrations might be capable of
promoting platelet aggregation if a similar mechanism were operating in vivo,
although this has not yet been demonstrated.
Rats treated with dietary oxonic acid supplementation, to increase serum uric acid
concentrations have been shown to exhibit increased ADP-induced and thrombin-
induced platelet aggregation, which is restored after normalisation of uric acid
concentrations [252],
A study in 12 patients with a clinical history of gout found normal platelet
aggregation and adhesion, which were not influenced by the uric acid level [253].
However, this study is likely to be confounded by wide variability in the baseline
characteristics of this group. In another clinical study, ADP, adrenaline and collagen
mediated platelet aggregation were studied in 5 healthy subjects. Treatment with
ribonucleic acid 3 g/day and allopurinol, to raise and lower serum uric acid
concentrations respectively, had no effect on platelet aggregability [254], although
the evoked changes in serum uric acid concentrations were comparatively small.
Halofenate has lipid-lowering and uric acid-lowering properties in vivo.
Administration of halofenate to 14 patients with type IV hyperlipoproteinemia and
hyperuricaemia had no effects on platelet aggregability or blood coagulability [255],
suggesting that lowering serum uric acid concentrations did not influence platelet
function. However, because the intervention altered both lipid and uric acid
concentrations, it is difficult to draw conclusions about the possible independent
effects of each.
At present, the relationship between serum uric acid concentration and platelet
aggregability is well understood. An association has been recognised between high
serum uric acid concentrations and increased platelet aggregation, and a number of
potential biological mechanisms have been proposed on the basis of laboratory and
animal data. Clinical studies have been unable to identify a clear link between uric
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acid and platelet function, however, these have involved small subject numbers and
been limited by a number of potential confounding factors.
3.3.4 Uric acid and plasma viscosity
A recent study in men with borderline and established hypertension found that serum
uric acid concentration tended to correlate with whole blood viscosity at low and
high shear rates in both groups, but these findings were not statistically significant
[256]. The potential mechanisms by which uric acid might influence plasma
viscosity are unclear. Previous studies have demonstrated an inverse relationship
between insulin resistance and increased blood viscosity [257, 258], and an
association has been found between serum triglyceride concentrations and plasma
viscosity in adults attending a cardiovascular prevention clinic [259]. Therefore, a
relationship between high uric acid concentrations and increased viscosity might be
explained by its confounding association with plasma triglycerides. The direct impact
of high serum uric acid concentrations on plasma viscosity is not known, and its
potential contribution to increased viscosity in insulin resistance syndromes has not
previously been examined.
3.2.5 Uric acid and salt sensitivity
In certain people, exposure to high dietary sodium causes a significant increase in
systemic blood pressure, for example more than a 10-20 mmHg increase in systolic
blood pressure. Such individuals are described as having 'salt sensitivity', which may
predispose to the development of hypertension. Animal models have demonstrated
that high serum uric acid concentrations increase sodium sensitivity and activate the
renin angiotensin aldosterone system, thereby increasing blood pressure (discussed in
Section 2.4). If a similar mechanism operates in humans, then high serum uric acid
concentrations might predispose to hypertension by increasing salt sensitivity in the
context of a high dietary salt intake. One previous study showed that salt-sensitive
individuals, defined by blood pressure response to dietary salt loading, had higher
serum uric acid concentrations than healthy counterparts [260], The relationship
between hyperuricaemia and salt sensitivity offers a plausible mechanism to explain
the observed associations between raised serum uric acid concentrations and high
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blood pressure and cardiovascular risk. Clinical studies are required to identify
whether such a mechanism operates in people.
3.4 Causal versus non-causal association with cardiovascular risk
The key criteria for causality proposed by Bradford Hill are valuable in assessing the
significance of epidemiological observations [261],
Table 7. Bradford Hill criteria applied to the relationship between serum uric
acid concentrations and cardiovascular risk.









Most epidemiological studies show cardiovascular hazard
ratio < 2 between lowest and highest categories
Appears to be present in most studies, but often negated by
consideration of confounding factors
Consistent association with risk in many studies,
particularly for women and less so for men
Existing findings are non-specific due to associations
between uric acid and a variety of confounders
Reasonable temporal relationship, and high concentrations
predict future events in a number of subject groups
A number of potential mechanisms proposed, but none
proven to be relevant
On the basis of these criteria, a causal relationship between uric acid and
cardiovascular disease appears possible, albeit somewhat weak. In order to address
the role of uric acid as a potential causal risk factor, basic clinical research needs to
identify possible biological mechanisms by which high concentrations might impair
vascular function. This thesis specifically examines the effects of raising or lowering
serum uric acid concentrations on mechanisms linked to atherosclerosis development
such as endothelial function, large arterial stiffness, baroreflex sensitivity and
circulating antioxidant activity, in order to establish biologically plausible
mechanistic links. Additional longitudinal studies are needed to address the impact of
manipulating serum uric acid concentrations on long-term cardiovascular risk.
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3.5 Uric acid and other diseases
3.5.1 Acute Gout
Gout is a clinical disorder characterised by acute joint inflammation, usually at a
single medium to large joint. It is predominantly an inflammatory disorder, and
appears to be triggered by acute changes in the composition of pre-formed uric acid
crystals. The precise mechanisms involved are unclear, but certain factors appear
capable of inducing instability within uric acid crystals, which triggers an ensuing
localised inflammatory cascade. Physiochemical instability of uric acid crystals can
result from local changes such as reduced temperature, increased or decreased local
pH, increased calcium concentrations, and increases or decreases in circulating uric
acid concentration.
In the setting of eating a purine-free diet, the total body pool of exchangeable uric
acid is estimated at 1.2 g in men and 0.6 g in women. By contrast, patients prone to
acute gout or uric acid deposition in soft tissues appear to have substantially
increased total body urate reservoirs, up to 18-30 g [116]. It is unclear why certain
individuals might accumulate abnormally high amounts of uric acid, thereby
predisposing to gout. Uric acid crystals accumulate throughout life and, given that
the existence of formed uric acid crystals is a prerequisite for developing acute gout,
it is unsurprising that its occurrence is rare in youth and becomes more prevalent
with advancing age.
Serum uric acid concentrations are a comparatively unreliable indicator of the risk of
developing acute gout. For example, in individuals with severe chronic
hyperuricaemia and serum uric acid concentrations exceeding 540 pmol/1, the annual
incidence of gouty arthritis is less than 5% [262], By contrast, the vast majority of
patients who develop acute gout have serum uric acid concentrations within the
normal reference range. Most authorities advocate that the risks of developing acute
gout are more closely related to high total body uric acid content and chronic uric
acid accumulation, rather than to short term increases in serum concentrations.
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3.5.2 Uric acid nephropathy
Hyperuricaemic nephropathy can be considered as two distinct entities. Firstly,
'classical' chronic uric acid nephropathy is associated with high serum uric acid
concentrations and clinical history of gout. The condition is characterised by
precipitation of uric acid microcrystals within the renal interstitium, which evokes a
localised inflammatory response. A peripheral rim of leukocytes and fibrosis
surrounds a central monosodium urate crystal, which gives the hallmark histological
appearance of a renal tophus, and is often accompanied by decreased glomerular
filtration rate. In an analysis ofmore than 11000 autopsy cases, chronic
hyperuricaemic nephropathy was identified in only 0.3% of cases, which is
substantially fewer than predicted on the basis of the prevalence of hyperuricaemia
[263]. Furthermore, renal impairment can be attributed to alternative causes in the
vast majority of such cases [263, 264], The presence of renal tophi is not dependent
on high urinary uric acid concentrations [263]. Currently, the relationship between
chronic hyperuricaemia and renal impairment remains poorly understood, and it
remains uncertain if chronic renal impairment precedes the formation of renal tophi
or vice versa.
By way of contrast, acute uric acid nephropathy is associated with sudden, and often
striking increases in serum uric acid concentration. These patients may be younger,
and there is rarely any clinical history of gout. The majority of cases of acute uric
acid nephropathy occur in patients with underlying haematological malignancy, or
those receiving cytotoxic treatment, due to rapid cell turnover and overwhelming
urate production [264, 265], There is gross hyperuricosuria, associated with uric acid
precipitation in tubules and collecting ducts, which can result in obstructive
nephropathy and acute renal impairment [110, 266], With appropriate prophylactic
measures and treatment, including intravenous hydration and uric acid lowering




4.1 Uric acid as an independent cardiovascular risk factor
A key hypothesis underpinning the early studies outlined in this thesis was that uric
acid might be an independent cardiovascular risk factor, in view of the established
associations between high serum concentrations, vascular dysfunction and increased
cardiovascular risk. An extension of this hypothesis was that elevated serum uric acid
concentrations might mediate increased risk through mechanisms common to other
established independent cardiovascular risk factors.
The aim of the initial studies was to develop a suitable vehicle for localised and
systemic administration of uric acid, so as to allow the effects of high serum
concentrations to be examined. The effects of raising serum uric acid concentrations
on endothelial function, endogenous fibrinolysis, large arterial compliance and
baroreceptor reflex sensitivity in vivo, and plasma viscosity and platelet aggregability
ex vivo, were examined in healthy subjects free ofmajor cardiovascular risk factors.
4.2 Uric acid as an antioxidant
The existing evidence that uric acid exhibits free radical scavenging effects prompted
further consideration of the potential importance of its antioxidant properties. In
contrast to the rationale underlying the initial series of clinical studies, a secondary
hypothesis was that uric acid might serve a protective role, as an antioxidant, and
protect against vascular dysfunction in the setting of oxidative stress.
A series of experiments was designed to examine the impact of high uric acid
concentrations on serum antioxidant capacity, and the consequent effects on vascular
function in the setting of acute oxidative stress, evoked by aerobic physical exercise,
and chronic oxidative stress, as found in regular smokers and patients with type 1
diabetes.
4.3 Uric acid as an independent risk factor in type-2 diabetes
An additional hypothesis was that high uric acid concentrations might make a
specific contribution to cardiovascular risk in patients with type 2 diabetes, based on
particularly strong associations between type 2 diabetes, hyperuricaemia and
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endothelial dysfunction. An extension of this hypothesis was that lowering serum
uric acid concentrations might improve vascular function in this patient group.
An additional series of clinical studies was designed to evaluate the effects of
systemic urate oxidase administration, as a means of lowering serum uric acid







For all studies described in this thesis, the relevant protocols were submitted to the
Lothian Health Board local research ethics committee, Research and Development
department of the Lothian University Hospitals NHS Trust, and Health and Safety
department of the University of Edinburgh for consideration. Studies were
undertaken only after appropriate approval had been granted. The University of
Edinburgh provided compensation arrangements where appropriate, and all studies
were conducted in accordance with the appropriate Standard Operating Procedures in
place within the Clinical Research Centre of the University of Edinburgh. In all
cases, studies were performed in accordance with Good Clinical Practice, and in
keeping with the principles outlined in the Declaration of Helsinki.
5.1.2 Subject recruitment
In all cases, subjects were provided with written 'Patient Information Sheets' as
approved by the local research ethics committee, and given at least 24 h to consider
these before deciding whether to participate. Subjects were recruited to participate in
the study only if they were willing to provide informed consent, documented in
writing, and if all inclusion criteria were met and there was no exclusion criterion.
5.1.2.1 Healthy subjects
Healthy volunteer subjects were recruited from a community database of healthy
volunteers held in the Clinical Research Centre of the University of Edinburgh.
Inclusion criteria were men or women, aged 18 to 45 y. Exclusion criteria were
elevated blood pressure (> 160/100 mmHg), clinical history of joint, kidney or
cardiovascular disease, taking any prescribed medication, taking any over the counter
medications in the previous week, regular tobacco use, serum creatinine >110
pmol/1, or serum uric acid > 420 prnol/1. For female subjects, an additional exclusion
criterion was pregnancy. A human chorionic gonadotrophin (hCG)-based urinary
pregnancy test was performed in all female subjects apart from those who had
undergone previous hysterectomy or sterilisation more than 2 years before.
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5.1.2.2 Regular smokers
Apparently healthy tobacco users were recruited from a community database held in
the Clinical Research Centre of the University of Edinburgh. Inclusion criteria and
exclusion criteria were identical to those of the healthy subject group, except for the
following additional criteria. Inclusion criterion: smoking at least 10 cigarettes per
day every day for at least 6 months. Exclusion criterion: unwilling or unable to
abstain from smoking during the clinical observation phase of the study within the
Clinical Research Centre.
5.1.2.3 Patients with type 1 diabetes mellitus
Patients with type 1 diabetes were identified from the outpatient diabetes clinic at the
Western General Hospital. Subjects were provided with study documentation at the
time of attendance at the clinic, which they could take away and consider. Inclusion
and exclusion criteria were identical to those of the healthy subject group, except that
the use of insulin was permitted. Patients with type 1 diabetes who required any other
medications were excluded from participation, as for healthy subjects.
5.1.2.4 Patients with type 2 diabetes mellitus
Patients with type 2 diabetes were identified from the outpatient diabetes clinics at
the Western General Hospital and Eastern General Hospitals. Subjects were provided
with study documentation at the time of attendance at the clinic, which they could
take away and consider. Inclusion and exclusion criteria were identical to those of
the healthy subject group, except that the use of insulin and/or oral anti-
hyperglycaemic medications were permitted. Patients with type 2 diabetes who
required any other medications were excluded from participation, as for healthy
subjects.
5.2 Drug preparation and administration
All drugs and solutions were stored in accordance with the manufacturers
recommendations, and prepared on the day of administration using aseptic
techniques and in accordance to local Standard Operating Procedures.
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5.2.1 Uric acid and lithium carbonate
Uric acid and lithium carbonate were supplied in powder form with purity >99.99%
(Ultrapure preparations, Sigma Chemical Company, Poole, UK). Each was
reconstituted in sterile dextrose solution (Baxter Healthcare, Norfolk, UK), and
filtered (0.22 prn Millex, Millipore, Molsheim, France) prior to administration to
remove potential pyrogens. Laboratory analyses of filtered 4% dextrose vehicle/0.1%
lithium carbonate containing uric acid was performed prior to administration to
ensure that filtration had not lessened the quantities of uric acid in solution.
Table 8. Laboratory confirmation of lithium and uric acid concentrations in aqueous
solutions used for study administration
Vehicle Assumed lithium concentrations:
Li2C03 (mmol/1) (F.W. = 73.89 g) 13.5
Free Li (mmol/1) 27.1
Actual measured lithium concentration:
Lithium assay (mmol/1) 27.5
Uric acid Assumed uric acid concentrations:
Uric acid (mg/ml) 0.5 1.0 2.0 4.0
Uric acid (mmol/1) (F.W. = 168.1 g) 3.0 5.9 11.9 23.8
Actual measured uric acid concentrations:
Uric acid assay (mmol/1) 3.0 5.7 16.2 27.2
5.2.2 Urate oxidase
As discussed in 2.4, urate oxidase is an enzyme that catalyses the metabolism of uric
acid to more soluble waste products that are cleared by renal elimination. A
pharmaceutical-grade preparation (Fasturec®, Sanofi-Synthelabo Pharmaceutical,
Paris, France) was administered parenterally to lower circulating uric acid
concentrations. Urate oxidase was supplied in anhydrous form, in 1.5 mg vials, and
reconstituted in 5 ml sterile saline immediately prior to study administration.
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5.2.3 Acetylcholine, sodium nitroprusside, bradykinin, L-NMMA
Acetylcholine (CIBAVision-Ophthalmics, Southampton, UK) and sodium
nitroprusside (David Bull Laboratories, Warwick, UK) were supplied as
pharmaceutical grade preparations. L-NG-monomethylarginine and bradykinin (both
Calbiochem-Novobiochem, Nottingham, UK) were supplied as synthetic compounds
with greater than 99.99% purity determined by HPLC. All vasoactive drugs were
diluted to the required concentrations in 0.9% sterile saline (Baxter Healthcare,
Norfolk, UK) immediately before each study.
5.2.4 Other reagents
Lidocaine was used for local anaesthesia during venous and arterial cannulation
procedures (1% Xylocaine®, AstraZeneca, Luton, UK).
5.3 Haemodynamic measurements
5.3.1 Heart rate and blood pressure
Heart rate and brachial blood pressure measurements were recorded in the dominant
arm using a validated oscillometric device (HEM-705CP, Omron, Japan) [267].
5.3.2 Cardiac index and systemic vascular resistance index
Cardiac output was assessed non-invasively using transthoracic bioimpedance
(NCCOM3-R7, BoMed, CA, USA) [268], and expressed as cardiac index (CI) to take
account of inter-individual differences in body habitus that influence cardiac output.
Cardiac index (l.min"Im"2)= cardiac output -r body surface area. Systemic vascular
resistance index was calculated as mean arterial pressure divided by cardiac index.
Where available, integrated mean arterial pressure was used in this calculation; in
other cases, mean arterial pressure was calculated as diastolic pressure + l/3(systolic-
diastolic pressure).
5.4 Venous occlusion plethysmography
5.4.1 Blood flow measurement
Blood flow was measured in both forearms by venous occlusion plethysmography, as
previously described [269, 270], Forearm measurements were recorded using
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mercury-in-silastic strain gauges connected to a microcomputer, and recorded using
Chart® software (ADInstruments, Hastings, UK). Cuffs placed across both wrists
were inflated to 200 mmHg during measurement, to exclude the hand circulation,
and cuffs placed across the upper arms were inflated intermittently to 40 mmHg to
occlude venous return from the forearm without impeding arterial inflow.
5.4.2 Brachial artery cannulation
The brachial artery of the non-dominant arm was cannulated using a 27-standard
wire gauge steel needle (Cooper's Needle Works Ltd., Birmingham, UK) under local
anesthesia, using an aseptic technique (Figure 2). Vasoactive drugs were
administered via a 16-gauge epidural catheter (Portex Ltd., Kent, UK) connected to
an IVAC PI 000 syringe pump (Alaris Medical Ltd., Hampshire, UK). The rate of
infusion was kept constant at 1 ml/min in all cases.
5.4.3 Determination of endothelial function
Intra-brachial saline was administered for at least 20 min to allow establishment of
baseline blood flow. This was followed by administration of acetylcholine 7.5, 15
and 30 pg/min, sodium nitroprusside 2, 4 and 8 pg/min, and L-NMMA 2 and 4
mmol/min. The order of acetylcholine and sodium nitroprusside infusion was
randomised between subjects, and constant between study visits. Drug infusions
were separated by at least 20 min administration of saline to allow restoration of
basal blood flow, and infused for 6 min at each dose. Measurements were taken
during the last 3 min of each 6 min intra-brachial infusion, and the last five
recordings averaged to determine flow in each arm. The ratio of blood flow in the
infused versus non-infused limbs was considered, to account for any systemic
effects, and responses to each vasoactive drug were expressed as a percentage change
from baseline blood flow immediately preceding drug administration [269],
50
Figure 2. Brachial artery cannula insertion. (A) the course of the brachial artery
is identified by palpation. (B) insertion of the 27-Gauge steel needle attached to a
Portex catheter. (C) the needle is advanced carefully, observing for pulsatile blood




5.5 Pulse waveform analysis
The dominant radial artery pulse waveform was assessed using applanation
tonometry (SPC-301 micromanometer, Millar Instruments, USA), and a
corresponding aortic pressure waveform was generated by PWA software
(Sphygmocor, PWV, Australia) (Figure 3). Augmentation index is a validated
measure of large arterial stiffness, calculated as the difference between the first and
second central systolic blood pressure peaks, expressed as a percentage of pulse
pressure [271], Measurements were recorded in triplicate at each time-point, and the
mean value used for data analysis.
Figure 3. Pulse waveform analysis using non-invasive applanation tonometry at
the dominant radial artery site.
5.6 Baroreflex Sensitivity
Non-occlusive systolic blood pressure was measured continuously using a Portapres
device (TNO, Amsterdam, Netherlands) with the photoplethysmographic cuff placed
over the middle phalynx of the middle finger of the dominant hand. Continuous
electrocardiogram signals were recorded simultaneously (Figure 4). Signals from
both devices were recorded over a 15 min period, and analyzed offline using Chart
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HRV software (ADInstruments, Hastings, UK). Baroreflex sensitivity was
determined by two independent methods. Fast Fourier transformation of blood
pressure and pulse interval data gave the total spectral power of the variability of
each, and the formula (powerep / powerPi)/2 gave spontaneous baroreflex sensitivity
by spectral analysis (BRSspec). Parallel increases or decreases in blood pressure and
pulse interval are representative of spontaneous baroreflex activity. Sequences of
parallel increases or decreases over two or more consecutive beats were analysed,
and the resulting slope (Apulse interval / Ablood pressure) was used to represent
baroreflex sensitivity by sequence analysis (BRSseq).
The prognostic importance of baroreflex sensitivity had been ascertained by
techniques that employed pharmacological manipulation ofblood pressure [54].
Spectral analysis and sequence analysis techniques to measure spontaneous
baroreceptor activity have been introduced more recently, and their relationship to
clinical outcome is less well established. Despite this, spontaneous baroreflex
sensitivity measurements by both methods have gained increasing acceptance. They
are reproducible, and sensitive to orthostatic manoeuvres to activate or suppress
baroreceptor activity [55, 56].
Figure 4. Spontaneous baroreflex sensitivity was determined by analysis of
simultaneous ECG and systolic BP signals. Non-invasive continuous BP signals were
generated using a Portapres device, which incorporated a non-occlusive




Serum uric acid concentrations were determined from 5 ml venous blood samples
collected in serum gel tube (Sarstedt Ltd., Leicester, UK). Assays were performed in
the Clinical Biochemistry department of the Western General Hospital, within 24 h
of sample collection, using a colorimetric dry-slide method (Vitros, Ortho-Clinical
Diagnostics, Amersham, UK). The standard reference range for this assay was 120-
420 pmol/1, and intra-assay precision was 1.8%.
5.7.2 Antioxidant capacity
5.7.2.1 Enhanced chemiluminescence assay
Enhanced chemiluminescence (ECL) is based on the emission of light that occurs
when luminol is oxidised by hydrogen peroxide, catalysed by horseradish
peroxidase, and enhanced by phenol. Light emission is dependent on continuous
production of free radicals, and is extinguished by biological fluids for a lag period
that is proportional to their antioxidant content [272, 273]. A luminometer (Model
1251; BioOrbit, Turku, Finland) was used to establish the duration of the lag period
caused by addition of serum. This was calibrated against a standard curve generated
by addition of 0.16, 0.32, 0.48, and 0.64 pM Trolox, a water-soluble tocopherol
analogue (6-hydroxy-2,5,8-tetramethylchroman-2-carboxylic acid, Sigma, Dorset,
UK), and serum antioxidant capacity was expressed as pM of Trolox equivalents.
5.7.2.2 'Total Antioxidant Status' assay
The Total Antioxidant Status (TAS) assay (Randox Laboratories, Crumlin, UK) is
based on the activity of the free radical ferrylmyoglobin, which is formed by
oxidation ofmetmyoglobin by hydrogen peroxide. Ferrylmyoglobin interacts with
the chromogen ABTS (2,2'-amino-di-[3-ethylbenzthiazole sulfonate]) to form a blue-
green chromophore radical (ABTS-), which has maximal absorbance at 417, 645,
734, and 815 nm. Addition of serum causes a reduction in ABTS- radical activity that
is proportional to its antioxidant content [274, 275]. ABTS- absorbance was
determined at 600 nm using a Cobas Fara (Roche Diagnostics, East Sussex, UK), and
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measurements were calibrated against a Trolox standard curve. Serum antioxidant
capacity was expressed as pM Trolox equivalents.
5.7.3 8-isoprostaglandin F2a
Solid-phase extraction was performed using an Isosolute C18(EC) 100 mg/ 3 ml
silica sorbent column (International Sorbent Technology, Mid Glamorgan, UK), and
8-wo-PGF2a was eluted with ethylacetate: methanol (99: 1) buffer. Assays were
performed on undiluted samples and after 1: 2 dilution with buffer, and each
concentration was assayed in duplicate. 8-Ao-PGF2a concentrations were measured
using an enzyme-linked immunosorbent assay (EIA) (Cayman Chemical Co., Ann
Arbor, USA). The assay is based on competition between 8-Ao-PGF2a and
acetylcholinesterase-8-Ao-PGF2a conjugate for limited amounts of 8-Ao-PGF2a-
specific rabbit immunoglobulin-G bound to 96-well plates. Ellman's reagent contains
an acetylcholinesterase substrate, which formed a distinctive yellow reaction product
whose absorbance was detected at 412 nm using a Vmax kinetic microplate
spectrophotometer (Molecular Devices Ltd., Winnersh, UK). The extent of
absorbance is proportional to the amount of conjugate in each well, which is
inversely proportional to free 8-Ao-PGF2a concentrations during incubation [276],
Mean values were expressed as a percentage ofmaximal binding absorbance, and 8-
Ao-PGF2a content was determined by comparison to absorbance of standard
isoprostane concentrations (3.9, 7.8, 15.6, 31.3, 62.5, 125, 250 and 500 pg/ml). The
standard reference range was 4.6 - 65.9 pg/ml, and intra-assay precision was 6.0%.
5.7.4 Lithium
Serum lithium concentrations were determined by a standard reference laboratory
method, using an automated colorimetric assay (Vitros dry slide, Johnson & Johnson,
CA, USA).
5.7.5 Tissue plasminogen activator
Tissue plasminogen activator antigen concentrations were determined using a two-
site enzyme-linked immunosorbent assay and photometric measurement (Coaliza
tPA and Coaset tPA, Chromogenix) [58], Each sample was measured in duplicate,
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and the mean value used for data analysis. Samples were encoded with a unique
identifier so that the person performing the measurements was blinded to subject,
time-point, drug and forearm from which the sample had been obtained.
5.7.6 Plasma viscosity
Plasma viscosity was determined at 37°C using a Beckman-Coulter Viscometer II
(Beckman Coulter U.K. Limited, High Wycombe, UK), 0.5 ml sample volume, 0.38
x 200 mm capillary and 2.5 PSI (17.24 kPa) measuring pressure. Reproducibility
with this method was good across a range of values; ± 0.03 mPa.s between 1.00 -
2.00 mPa.s, and ± 0.05 mPa.s between 2.01 - 5.00 mPa.s.
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Chapter 6.
Development of Vehicle for Uric Acid Administration
6.1 Uric acid dissolution
6.1.1 Introduction
Uric acid is sparingly soluble in conventional aqueous media, for example 0.9%
saline or 5% dextrose solutions. Therefore, a suitable vehicle was required so as to
allow administration of sufficient quantities of uric acid to cause a significant
increase in serum uric acid concentration after local and systemic administration.
Uric acid has been found to be highly soluble in strong alkaline solutions, for
example 0.1% sodium hydroxide, but these are too toxic to consider for human
administration. Uric acid solubility depends heavily on pH. For example, saturating
concentrations are 350-890 pmol/1 at pH 5.0, but 9400-12000 prnol/1 at pH 7.0 [92],
Other factors may improve uric acid solubility in vivo, including low sodium
concentrations, the presence of urea, proteins and mucopolysaccharides.
Historical references describe high solubility of uric acid in lithium carbonate-based
media and several authorities, including James Parkinson advocated their use as
elixirs to prevent and treat gouty arthritis [277], Uric acid has been given by systemic
administration to dogs to explore its pharmacokinetics [278], and two previous
reports describe systemic administration of uric acid to small numbers of patients
with hypouricaemia, using an aqueous lithium carbonate vehicle [279, 280],
6.1.2 Aims
To explore the dissolution characteristics of uric acid in lithium carbonate and
sodium hydrogen carbonate solutions.
6.1.3 Materials and methods
Lithium carbonate (FW 73.89, approximately 99%) and uric acid (FW 168.1,
minimum 99%) were supplied as Ultrapure® preparations from Sigma-Aldrich Co.
Ltd., Gillingham, Dorset, UK. Sodium hydrogen carbonate (FW 84.01, minimum
99.5%) was supplied from BDH Laboratory Supplies, Poole, Dorset, UK. Studies
were performed using a flat-based 100 ml Pyrex conical flask and 2 cm magnetic
stirrer (Fisher Scientific Ltd., Loughborough, Leicestershire, UK). Incremental
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amounts of carbonate salt were added to 50 ml 4% dextrose (10 ml double distilled
water and 40 ml sterile 5% dextrose solution) until saturation.
Uric acid was added to a lithium carbonate and sodium hydrogen carbonate
solutions, in progressively decreasing increments until saturation. The pH of the
solutions was measured using a standard pH-meter, calibrated using pH8 buffer, and
recorded at intervals throughout the study.
6.1.4 Results
Table 9. pH of aqueous lithium carbonate
U2C03 Distilled 5% dextrose Li2C03 Li2C03 PH
(g) water (ml) (ml) (g/1) (mmol/1)
0.02 10 40 0.4 5.42 10.1
0.04 10 40 0.8 10.83 10.3
0.06 10 40 1.2 16.25 10.4
0.08 10 40 1.6 21.66 10.4
0.10 10 40 2.0 27.08 10.5
Table 10. pH of aqueous sodium hydrogen carbonate
NaHC03 Distilled 5% dextrose NaHC03 NaHC03 PH
(g) water (ml) (ml) (g/1) (mmol/1)
0.03 10 40 0.6 7.1 7.8
0.15 10 40 3.0 35.7 8.3
0.3 10 40 6.0 71.4 8.4
0.6 10 40 12.0 142.8 8.7
0.63 10 40 12.6 150.0 8.7
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Table 11. Uric acid solubility in aqueous lithium carbonate
LhCOs 80: 10 Li2C03 Saturation Uric acid Uric acid PH
(g) dextrose: (g/1) point: uric (mg/ml) (mmol/1)
water (ml) acid (mg)
0.02 50 0.4 125.0 2.5 14.9 9.4
0.04 50 0.8 225.0 4.0 23.8 9.3
0.06 50 1.2 250.0 5.0 29.7 9.0
0.08 50 1.6 275.0 5.5 32.7 8.9
0.10 50 2.0 250.0 5.0 29.7 8.9
Table 12. Uric acid solubility in aqueous sodium hydrogen carbonate
NaHCOs 80: 10 NaHCOs Saturation Uric acid Uric acid PH
(g) dextrose: (g/1) point: uric (mg/ml) (mmol/1)
water (ml) acid (mg)
0.03 50 0.6 <12.5 - - 7.8
0.15 50 3.0 12.5 0.25 1.5 8.3
0.3 50 6.0 100.0 2.0 11.9 8.4
0.6 50 12.0 150.0 3.0 17.8 8.7
0.63 50 12.6 180.0 3.6 21.4 8.3
6.1.5 Discussion
Uric acid solubility was carbonate concentration and pH dependent. Higher
concentrations of could be dissolved in lithium carbonate solution, to a maximum
concentration of 5 mg/ml. As a safety precaution, to avoid precipitation, 4mg/ml was
selected as the maximum concentration to be prepared for human administration in
4% dextrose/0.1% lithium carbonate solution.
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6.2 Effect of uric acid solution on blood pH
6.2.1 Introduction
4% dextrose/0.1% lithium carbonate vehicle was found to have pH 10.4, partially
buffered by the addition of uric acid (Section 6.1). The possibility of an effect on
local pH in vivo might render the vehicle solution hazardous and non-viable for
human administration due, for example, to peripheral vein irritation. Furthermore,
changes in local serum pH in vivo might result in difficulty interpreting any
haemodynamic responses to uric acid.
6.2.2 Aims
To examine the effects of 4% dextrose/0.1% lithium carbonate vehicle on ex vivo
serum pH, in concentrations up to and exceeding those likely to be achieved in vivo.
6.2.3 Methods
A healthy male subject rested supine for 10 min, and 20 ml venous blood sample was
drawn from a large antecubital fossa vein using an 18 G needle and aseptic
technique. 5 ml whole blood was immediately added to each of 4 tubes containing
potassium EDTA solution and 0, 0.1, 1.0 and 2.0 ml of 0.8% lithium carbonate
solution, and gently mixed. After centrifugation at 1000 g for 20 minutes at 4°C,
serum was separated and pH measured in triplicate.
6.2.4 Results
Table 13. Effect of 4% dextrose/0.1% lithium carbonate vehicle on plasma pH.
Vehicle Blood Relative pH 1 pH 1 pHl Mean pH S.D.
(ml) (ml) concentration
0 5 - 7.5 7.5 7.6 7.53 0.06
0.1 5 1 in 50 7.5 7.6 7.6 7.57 0.05
1 5 1 in 5 7.6 7.7 7.7 7.67 0.06
2 5 1 in 2.5 7.7 7.6 7.63 0.06
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6.2.5 Discussion
There is no clinically significant change in plasma pH following addition of 0.1ml,
1.0ml or 2.0ml of vehicle solution to 5ml of blood. In our forearm blood flow studies
vehicle will be infused at a maximum of 1 ml/min to the brachial artery, and forearm
blood flow is estimated at 50 ml/min. The volumes of vehicle solution were chosen
to represent the effect of dilution where forearm blood flow is 50, 5 and 2.5 ml/min,
so as to overestimate potential effects on pH.
The present findings indicated that, even if forearm blood flow is substantially less
than anticipated, administration of vehicle solution will not significantly alter local
plasma pH. Potential effects are likely to be minimised further in vivo due to the
extensive buffering capacity of human blood and tissues.
Nonetheless, these studies do not fully exclude the possibility that intra-brachial or
intravenous administration of vehicle, or uric acid in vehicle, might exert some effect
on local or circulating acid-base balance. Therefore, the designs of subsequent
clinical studies incorporated safety laboratory measurements that included serum
bicarbonate concentrations, to determine whether administrations might have any
effect on serum pH.
Furthermore, it was not possible to exclude the possibility that lithium might exert a
confounding effect on vascular function in vivo. Therefore, serum lithium
concentrations were closely examined in earlier studies involving systemic uric acid
administration and, in later studies, a saline control arm was used in addition to
vehicle alone to examine for possible confounding effects.
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Chapter 7.
Intra-brachial Administration of Uric Acid in Healthy Subjects
7.1 Introduction
Uric acid could be dissolved in 4% dextrose/0.1% lithium carbonate vehicle solution
(see Chapter 6). The following study was designed so that the potential effects of
high local uric acid concentrations on vascular tone and blood flow could be
examined in the forearm vascular bed, by means of direct intra-brachial
administration of uric acid. Resting vascular tone is determined only in part by native
endothelial function and is comparatively insensitive to the potential effects of high
uric acid concentrations on endothelial function. Therefore, endothelial function was
assessed directly by intra-brachial administration of acetylcholine, sodium
nitroprusside and L-NMMA during co-administration of uric acid, or vehicle as
control. The purpose of this study was to examine whether high uric acid
concentrations might impair endothelial function in the forearm vascular bed, as has
previously been shown with acute exposure to a number of established major
cardiovascular risk factors [281, 282],
7.2 Methods
Six healthy men were recruited to a two-way randomised placebo controlled study.
Subjects underwent insertion of a brachial artery needle, followed by intra-arterial
saline administration for 20 min to allow baseline blood flow to be established. This
was followed by infusion of 0, 0.5, 1.0, 2.0, 4.0 mg/min uric acid in 4%
dextrose/0.1% lithium carbonate vehicle for 6 min at each dose, and 12 min at the
maximum dose. Forearm blood flow was assessed at baseline, and during infusion of
each concentration using venous occlusion plethysmography. Heart rate and blood
pressure were recorded at baseline and during each infusion.
The rate of uric acid administration was selected on the basis ofmaximum solubility
of 4 mg/ml in vehicle solution, and estimated resting forearm blood flow of 50
ml/min. The a priori study assumption was that delivery of uric acid 0.5, 1.0, 2.0 and
4.0 mg/min would cause an increase in local uric acid concentrations of 58, 117, 235
and 467 pmol/1 respectively.
62
In a separate study, 10 healthy men were recruited to a two-way randomised placebo
controlled study. Subjects underwent intra-arterial administration of saline for 30
min, to establish baseline blood flow, followed by ACh 7.5, 15 and 30 mmol/min,
SNP 2, 4 and 8 mmol/min, and L-NMMA 2 and 4 pmol/min, where the order of
infusion of ACh and SNP was randomised between subjects. Drug infusions were
separated by 20 min saline to allow restoration of basal blood flow, and infused for 6
min at each dose. Uric acid 2.0 mg/min in 4% dextrose/0.1% lithium carbonate
vehicle, or vehicle alone, were co-infused locally. 5 ml effluent venous blood was
collected from each forearm during infusion, for uric acid measurement.
7.3 Results
Table 14. Baseline characteristics of study population. NM = not measured
Characteristic Mean ± SEM Mean ± SEM
Number/ male 6/6 10/10
Age (y) 29 ±4 23 ± 1
Systolic BP (mmHg) 118 ± 8 110 ± 4
Diastolic BP (mmFIg) 72 ±7 68 ±5
Heart rate (bpm) 62 ±4 59 ±2
Creatinine (pmol/1) NM 84 ±4
Glucose (mmol/1) NM 4.6 ±0.2
Cholesterol (mmol/1) NM 4.1 ±0.2
Body mass index (kg/m2) NM 23 ± 1
Uric acid (pmol/l) NM 258 ± 13
7.3.1 Resting forearm blood flow
Neither vehicle nor uric acid administration had any effect on basal forearm blood
flow (Figure 5). No effects on heart rate or systemic blood pressure were observed.
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Figure 5. Mean ± SEM forearm blood flow, as infused: non-infused forearm
ratio expressed as % change from baseline, during intra-brachial
administration of uric acid 0-4 mg/min in vehicle (n = 6).
7.3.2 Venous effluent uric acid concentrations
Mean ± SEM venous effluent uric acid concentrations in the infused and non-infused
forearms were 384 ± 7 and 280 ± 1 p.mol/1 during uric acid 2.0 mg/min
administration (p < 0.001), and 290 ± 4 and 283 ± 1 p.mol/1 during vehicle
administration respectively. This represented increases of 33 ± 3% and -1 ± 0% from
baseline concentrations in the infusion arm, during uric acid 2.0 mg/min and vehicle
administration respectively (p < 0.001).
7.3.3 Endothelial function
Dose-dependent changes in forearm blood flow were observed during administration
of acetylcholine, sodium nitroprusside and L-NMMA (Figure 6). Uric acid
administration did not have an effect on the responses to any vasoactive drugs (p =
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Figure 6: Forearm blood flow responses to acetylcholine 7.5-30 pg/min, sodium
nitroprusside 2-8 pg/min and L-NMMA 2-4 pmol/min, as % change
from baseline infused: non-infused forearm ratio, during local co¬
administration of 2 mg/min uric acid or vehicle (n = 10).
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7.4 Discussion
Neither vehicle alone, nor uric acid in vehicle solution had any effect on basal
forearm blood flow. This suggests that short-lived localised hyperuricemia does not
have any direct effect on resting vascular tone in the forearm.
The dose-dependent responses to intra-brachial administration of vasoactive drugs
was as expected in a healthy, young population who were free of any major
cardiovascular risk factors. Lack of effect of uric acid co-administration on forearm
blood flow responses to acetylcholine, sodium nitroprusside and L-NMMA suggests
that high local uric acid concentrations do not influence endothelium-dependent and
endothelium-independent nitric oxide-mediated responses, nor basal nitric oxide
bioavailability. This suggests that high uric acid concentrations, at least in the acute
setting, do not impair endothelial function in healthy subjects in whom oxidative
stresses are low [69],
The rise in local uric acid concentrations associated with intra-brachial
administration at 2.0 mg/min, although significant, was less than had been
anticipated. This may reflect significantly higher basal forearm blood flow than had
been allowed for using a prior estimate of 50 ml/min. It is possible that active uptake
of uric acid by tissues might also account for lower venous concentrations than
expected, but the short-term nature of the intra-brachial administration used in this
study makes this a less plausible explanation. The modest increase evoked by local
uric acid administration is a potential limitation of the present study. Effects on
endothelial function might be more clearly observed if elevation to significantly
higher concentrations had been attained. Localised administration of uric acid is
unlikely to allow higher concentrations to achieved due to the limited solubility of
uric acid, and the need to constrain intra-brachial infusion rates at no more than 1
ml/min.
No adverse effects were observed, confirming the feasibility of uric acid
administration in a lithium carbonate based vehicle in a clinical research setting.
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Chapter 8.
Intravenous Administration of Uric Acid in Healthy Subjects
8.1 Introduction
The studies described in Chapters 7 illustrate the lack of effect of intra-brachial
administration ofuric acid on basal blood flow and endothelial function in the
forearm vascular bed. However, observations in the setting of localised uric acid
administration are hampered by a number of important limitations. In particular, the
technique allows only the effects of immediate or very short-term exposure to high
uric acid concentrations to be evaluated. Furthermore, the potential rise in serum uric
acid concentrations that can be achieved by this method is limited by constraints on
intra-brachial infusion rate. In order to overcome these limitations, the present study
was designed to examine the feasibility of raising systemic uric acid concentrations
by means of intravenous infusion.
A secondary aim of the study was to evaluate the impact of uric acid administration
on serum antioxidant capacity. Uric acid has potentially important antioxidant
properties in vitro, and a number of observational studies have shown a positive
correlation between uric acid concentrations and serum antioxidant capacity,
suggesting that it may contribute to antioxidant defences in vivo. However, the
potential for uric acid to behave as a pro-oxidant is also recognised (see Chapter
3.3.1). The effect of raising circulating uric acid concentrations on in vivo antioxidant
defences is uncertain. Vitamin C was chosen as an active comparator because its
effects have been more widely studied in vivo and ex vivo, and it too is an aqueous
antioxidant of similar molecular weight to uric acid. The biological relevance of the
antioxidant properties of vitamin C is better established. For example, vitamin C
concentrations are lower in regular smokers and patients with diabetes or
hypertension, and acute administration allows restoration of endothelial function in
these groups.
In designing this study, particular consideration was given to a number of important




8.2.1 Calculation of systemic uric acid dose
Intra-brachial administration of uric acid (total 237 mg) and vehicle caused mean ±
SEM systemic uric acid concentrations to increase by 62 ± 13 and -4 ± 3 p.mol/1
respectively (p < 0.001), described in Chapter 7. Volume of distribution for
administered uric acid was 22.6 ± 2.0 1, calculated using:
Volume of distribution = Administered dose -r- concentration achieved
The same equation was used to determine that administration of uric acid 0.988 g
would be required in order to achieve an increase of 260 pmol/1, representing an
approximate doubling from baseline serum concentrations. For convenience, a
systemic uric acid dose of 1000 mg uric acid was chosen. For the purpose of
systemic administration, this was dissolved in 500 ml 4% dextrose/0.1% lithium
carbonate as uric acid 2 mg/ml solution.
8.2.2 Safety considerations regarding lithium
Lithium is used in the treatment of bipolar affective disorder, and has a narrow
therapeutic range. Therapeutic drug monitoring is implemented in clinical practice,
so as to maintain serum lithium concentrations at 0.8-1.4 mmol/1. Toxic effects
become more likely beyond this range, and particularly at concentrations greater than
2.0 mmol/1, including drowsiness, confusion, arrhythmia and, in severe cases, coma.
Lithium is a simple cation that is widely distributed throughout bodily fluids and
tissues and, therefore, serum concentrations were expected to decay rapidly due to
extravascular distribution and renal elimination. Furthermore, the risks of lithium
toxicity for any given serum concentration are substantially lower in individuals not
previously exposed to lithium treatment because tissues are less likely to become
saturated.
A calculation was performed to predict the maximum lithium concentration that
might be attained after administration of 500 ml 4% dextrose/0.1% lithium carbonate
vehicle as a bolus infusion. Lithium could be expected to distribute widely amongst
the extravascular compartment. For safety reasons, the calculations considered the
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possibility that lithium would be distributed within total body water compartment,
extracellular fluid compartment and the intravascular space alone.
500 ml 0.1% lithium carbonate/4% dextrose
0.5 g Li2C03 = 6.767 mmol (F.W. = 73.89 g)
Containing 13.534 mmol free lithium
Assumed Volume of Compartment Max. lithium fmmol/D
Distribution
40 1 Total body fluid 0.338
15 1 Extracellular 0.902
81 Intravascular 1.692
Based on distribution confined solely to the intravascular fluid compartment, the
predicted maximum lithium concentration after bolus administration was marginally
higher than the upper limit of the normal therapeutic range. Based on the more
plausible situation that lithium would be more widely distributed, lower
concentrations might be anticipated. However, as a safety precaution, administration
of 500 ml 4% dextrose/0.1% lithium carbonate would be infused over 1 h rather than
by bolus administration. The duration of exposure to high serum lithium
concentrations was expected to be short, and vehicle administration was not expected
to pose any significant clinical risk.
8.2.3 Study Protocol
Ten healthy subjects participated in this study. An exclusion criterion of serum uric
acid concentration >300 mmol/1 was applied, in addition to inclusion and exclusion
criteria for healthy subjects outlined in Section 5.12. The study had a randomised
placebo controlled double blind three-way crossover design, and study days were
separated by at least 1 week. The study was conducted in a quiet, comfortable
environment, maintained at 24 to 26°, within the Clinical Research Centre.
Participants attended at 09:00 a.m. on each study day and were asked to avoid
alcohol, caffeine and purine rich foods for twenty-four hours before.
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An 18-G cannula was inserted into a large vein of each antecubital fossa using local
anaesthesia and aseptic technique. The cannula in the non-dominant forearm allowed
infusion over 1 h of 1000 mg uric acid (5952 pmol) in 500 ml 4% dextrose/0.1%
lithium carbonate vehicle, vehicle alone, or 1000 mg vitamin C (5682 pmol) in 500
ml 0.9% saline. 5 ml venous blood was drawn from the other cannula at baseline and
15 min intervals during infusion for measurement of uric acid and lithium
concentrations. An additional 5 ml sample was collected for serum antioxidant
capacity by chemiluminescence and 'Total Antioxidant Status' assays: samples were
allowed to clot, centrifuged at 1000 g for 10 minutes at 4°C, decanted immediately
and stored at -40°C before analyses. Additional blood samples at 15, 30, 60, 120, 300
and 1260 min after infusion allowed analysis of uric acid and lithium kinetics.
8.2.4 Kinetic analyses for uric acid and lithium
Standard linear and semi-logarithmic graphs representing serum lithium
concentration versus time were plotted. Curve fitting by non-linear regression
analyses was performed using Prism® software, version 3.0 for Windows (GraphPad
Software Incorporated, San Diego, USA) [11], F tests were used to compare best-fit
curves generated by one and two exponent analyses, for each subject, and statistical
significance was accepted at the 5% level.
8.3 Results
Table 15. Baseline characteristics of the study population at screening
Characteristic Mean ± SEM
Number/ male 10/5
Age (y) 26 ± 1
Height (m) 1.69 ±3
Weight (kg) 63 ±3
Systolic blood pressure (mmHg) 106 ±5
Diastolic blood pressure (mmHg) 69 ±3
Serum urate (pmol/1) 227 ±9
Serum cholesterol (mmol/1) 4.2 ±0.2
Serum creatinine (pmol/1) 74 ±4
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Table 16. Safety laboratory data, presented as mean ± SD values
Baseline Post-infusion + 1 h ±21 h
Urea (mmol/1) 4.5 ± 1.5 4.3 ± 1.5 3.8 ± 1.6 3.9 ±2.2
Creatinine (pmol/1) 76 ±20 72 ± 19 67 ±21 77 ±26
Sodium (mmol/1) 140 ± 1 138 ± 1 140 ± 1 142 ± 1
Potassium (mmol/1) 3.8 ±0.3 3.8 ±0.3 3.8 ±0.2 4.2 ± 0.2
Bicarbonate (mmol/1) 24 ±2 24 ±2 25 ±2 25 ±2
No adverse events were observed in any subject.
8.3.1 Uric acid pharmacokinetics
Mean ± SEM baseline serum uric acid concentration was 227 ± 9 pmol/1 (95%
reference range 120 to 420 pmol/1). Infusion of vehicle and uric acid caused serum
concentrations to increase by -4 ± 2 and 307 ± 29 pmol/1 respectively, to 220 ± 27
and 534 ± 29 pmol/1 respectively at 1 h (p < 0.001).
0 15 30 45 60
Time during infusion (min)
Figure 7. Mean ± SEM serum uric acid concentrations during intravenous
administration of uric acid 1000 mg in vehicle or vehicle alone over 60 min. p<0.001
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Figure 8. Mean ± SEM increment in serum uric acid concentration during systemic
administration over 1 h of uric acid 1000 mg in vehicle or vehicle alone. p<0.001 by
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Figure 9. Increment in serum uric acid concentration exhibited a two-component
decay, with mean elimination half-life of 10.8 h.
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8.3.2 Antioxidant capacity
Administration of vehicle alone did not have any significant effect on serum
antioxidant capacity, determined by either the chemiluminescence or 'Total
Antioxidant Capacity' assay.
Administration of uric acid and vitamin C caused serum antioxidant capacity (by
chemiluminescence) to increase by 139% and 20% from baseline respectively (p <
0.001 and p = 0.56 compared to vehicle). Administration of uric acid and vitamin C
caused serum antioxidant capacity (by 'Total Antioxidant Status' assay) to increase
by 23% and 7% from baseline respectively (p < 0.001 and p = 0.65 compared to
vehicle).
The increase in serum antioxidant capacity caused by uric acid was significantly
greater than that caused by vitamin C, as determined by chemiluminescence (p <
0.001) and 'Total Antioxidant Status' assay (p < 0.001).
Table 17. Mean ± SEM serum antioxidant capacity before and after
administration of uric acid 1000 mg, vitamin C 1000 mg or vehicle,
determined by two distinct antioxidant assays. *p < 0.05, **p < 0.001
compared to baseline; *p < 0.05, **p < 0.001 compared to vehicle.
Baseline Post-infusion Change
TAS Uric Acid 1235 ±50 1520 ±53** 284±17"
Vitamin C 1288 ±30 1379 ±34* 92 ±28*
Vehicle 1264 ±47 1278 ±43 14 ± 15
Chemiluminescence Uric acid 384 ±41 896 ±69** 448 ± 84"
Vitamin C 410 ±34 477 ±33* 68 ± 34*
Vehicle 411 ±35 401 ±43 -9 ±28
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60
Figure 10. Mean ± SEM increment in serum antioxidant capacity during systemic
administration over 1 h of uric acid 1000 mg, vitamin C 1000 mg or vehicle,
determined by (A) chemiluminescence and (B) 'Total Antioxidant Status' assay.
*p < 0.05, **p<0.001 between uric acid and vehicle, #p < 0.005, ##p < 0.001 between
uric acid and vitamin C by Students' two-tailed t test.
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8.3.3 Lithium pharmacokinetics
Lithium carbonate infusion led to a time-dependent increase in serum lithium
concentration, as shown in Figure 11. The mean ± SEM peak concentration
immediately after administration was 0.93 ± 0.05 mmol/1. This was followed by a
rapid decay that appeared consistent with a one or two-compartment model (Figure
12). The unweighted decay plot data were subjected to exponential and bi-
exponential analyses, and compared to determine the best fit. The F value was >1.0
in favour of a two-compartment model for data from each subject. The sum of
squares, as a measure of distribution around the residuals, for the one and two
compartment models were 1.313 x 10"3 and 7.37 x 10"6 respectively. F = 96.06 and p
= 0.01 for the averaged data. Non-linear bi-exponential regression analysis of
individual subject data found elimination half-life 7.8 ± 1.7 h, distribution phase half-
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Figure 11. Time-dependent increase in serum lithium concentrations during
administration of 500 ml 4% dextrose/0.1% lithium carbonate vehicle over 1 h in





















































Figure 12. Decay of lithium concentrations after the end of administration of 500 ml
4% dextrose/0.1% lithium carbonate vehicle as (A) individual data on linear scale,
and (B) mean data on logarithmic scale representing distribution and clearance
components by bi-exponential analysis.
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8.3.4 Systemic haemodynamic data
Systemic administration of uric acid was not associated with any significant
haemodynamic effects. Administration of vehicle alone caused a modest reduction in
cardiac output, which was not observed during administration of uric acid and
vitamin C. There was a non-significant trend towards increased systemic vascular
resistance and blood pressure from baseline across all three study groups.
Table 18. Mean ± SEM systemic haemodynamic variables before and immediately
after intravenous administration of vehicle, vitamin C 1000 mg or uric acid 1000 mg.
Vehicle Vitamin C Uric Acid
Heart rate Before 59 ±3 57 ±3 54 ±2
(bpm) After 55 ±2 58 ±3 61 ±4
Mean blood pressure Before 78 ±2 79 ±2 80 ±2
(mmHg) After 81 ±2 82 ±2 84 ± 1
Cardiac output Before 6.8 ±0.5 6.8 ±0.4 6.8 ±0.3
(1/min) After 6.1 ± 0.4* 6.5 ±0.4 6.8 ±0.4
Systemic vascular resistance Before 11.9 ± 0.9 12.0 ±0.8 12.1 ±0.6
(1/min per mmHg) After 13.7 ±0.9 13.2 ±0.8 12.7 ±0.8
8.4 Discussion
No adverse clinical, biochemical or haemodynamic effects were observed following
administration of uric acid 1000 mg. These observations suggest that high uric acid
concentrations do not, at least in an acute setting, increase systemic vascular
resistance or blood pressure.
Peak lithium concentrations obtained were within acceptable limits, and short-lived
due to rapid distribution to extra-vascular compartments and renal clearance. No
subject was exposed to lithium concentrations above the normal therapeutic range.
These observations confirmed the feasibility and tolerability of systemic
administration of uric acid in a lithium carbonate-based vehicle in a research setting.
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This study found that raising serum uric acid concentrations, by means of direct
administration, causes increased serum antioxidant capacity as determined by two
methodologically distinct assays. The lithium carbonate-based vehicle solution had
no direct effects on serum antioxidant capacity or uric acid concentration. These
findings lend support to the view that high serum uric acid concentrations confer
increased free radical scavenging capacity in vivo, and might be protective in the
setting of oxidative stress. Acute administration of other naturally occurring
antioxidants has previously been shown to confer a favourable effect on clinical
outcome by preventing oxidative and free radical mediated tissue damage, for
example in the setting of sepsis syndrome or after recent myocardial infarction [283,
284], Based on the observed elimination half-life of administered uric acid, the
conferred increase in antioxidant capacity is likely to persist for at least several hours
after a single intravenous administration. Furthermore, the magnitude of the
increased serum antioxidant capacity conferred by uric acid was substantially greater
than that associated with vitamin C. This suggests that uric acid administration might
be a more useful research tool for exploring the potential effects of aqueous
antioxidants on vascular function.
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Chapter 9.
Intravenous Administration of Uric Acid and
Vascular Function in Healthy Subjects
9.1 Introduction
Having established the feasibility of raising circulating uric acid concentrations by
means of direct systemic administration, the effects on endothelial function, large
arterial stiffness and baroreceptor reflex sensitivity were examined. The premise
underlying this study was that systemic administration of uric acid would allow
vascular function to be examined in the presence of significantly higher serum
concentrations than afforded by local uric acid administration. Furthermore, if high
uric acid concentrations are capable of impairing endothelial function, then this
might be more readily observed in the presence ofmore prolonged exposure after
systemic administration than during transient elevations of local concentrations
during intra-brachial uric acid administration.
Established major cardiovascular risk factors, such as regular smoking, diabetes
mellitus, hypercholesterolaemia and hypertension, impair nitric oxide-dependent
endothelial function. In vascular beds that contribute to systemic vascular resistance,
this is characterised by impaired blood flow responses to endothelium-dependent
vasodilators, while in large conduit arteries endothelial dysfunction manifests as
increased large arterial stiffening and impaired baroreflex sensitivity.
9.2 Methods
Ten healthy subjects were recruited to a two-way randomised placebo controlled
study of endothelial function. An 18-standard gauge venous cannula was inserted
into a suitable vein in each antecubital fossa, under local anaesthetic. Subjects
underwent systemic administration of uric acid 1000 mg in 4% dextrose/0.1%
lithium carbonate vehicle, or vehicle alone over 1 h via the cannula in the non-
dominant forearm. 5 ml venous blood was drawn from the non-infused forearm
cannula at baseline, at the end of the infusion, and 1 h after the end of the infusion
for measurement of serum uric acid concentration. Immediately after completion of
systemic infusion, endothelial function was studied using venous occlusion
plethysmography and intra-brachial administration of acetylcholine, sodium
nitroprusside and L-NMMA, as described in Chapter 5.
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In a separate study, 8 healthy men were recruited to a three-way randomised placebo
controlled study. An 18-standard gauge venous cannula was inserted into a suitable
vein in each antecubital fossa under local anaesthetic, and Portapres finger cuff and
BoMed electrodes applied. Subjects rested supine for 30 min, then underwent
systemic administration of 1000 mg uric acid in 500 ml 4% dextrose/0.1% lithium
carbonate vehicle, vehicle alone, or 0.9% saline over 1 h via the non-dominant
forearm cannula. Electrocardiogram and Portapres signals were recorded for
baroreflex sensitivity determination before and after systemic infusion, and blood
pressure, cardiac index and pulse wave analysis measurements were recorded at
baseline and 15 min intervals after commencement of the infusion. 5 ml venous
blood was drawn via the non-infused forearm cannula at baseline and immediately
after infusion for measurement of serum uric acid concentrations and safety
laboratory investigations.
9.3 Results
No adverse events occurred in any subject.
Table 19. Mean ± SEM baseline characteristics of the study population
Characteristic Endothelial Haemodynamic
function study study
Number/ male 10/6 8/8
Age (y) 24 ± 1 30 ±4
Systolic BP (mmHg) 107 ±6 108 ±3
Diastolic BP (mmHg) 71 ±4 72 ±3
Heart rate (bpm) 58 ±3 60 ±2
Body mass index (kg/m ) 22 ± 1 23 ±0
Creatinine (pmol/1) 84 ±6 86 ±3
Glucose (mmol/1) 4.8 ±0.1 4.7 ±0.3
Cholesterol (mmol/1) 4.1 ±0.2 4.8 ±0.2
Uric acid (p.mol/1) 252 ± 14 366 ± 12
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9.3.1 Serum uric acid concentrations
Table 20. Mean ± SEM serum uric acid concentrations before, immediately after, and
1 hour after infusion of uric acid 1000 mg in 500 ml vehicle or vehicle alone.
*p < 0.001 compared to baseline. *p < 0.001 compared to vehicle administration.
Endothelial Uric Acid Vehicle
function Values Change from Values Change from
study baseline baseline
Baseline 227 ± 24 - 224 ± 27 -
Post-infusion 534 ± 37* 307 ±29* 220 ± 27 -3.9 ±2.1
+ 1 h 452 ± 32* 225 ±21* 217 ±27 -9.7 ± 10.5
Table 21. Mean ± SEM serum uric acid concentrations before and after infusion of
uric acid 1000 mg, vehicle alone or saline. *p < 0.001 compared to baseline.
*p < 0.001 compared to saline administration.
Haemodynamics Uric acid Vehicle Saline
study
Baseline 370 ± 16 370 ± 17 336 ± 12
Post-infusion 627 ± 23** 361 ± 17 350 ± 19
9.3.2 Forearm blood flow responses
Intra-brachial administration of acetylcholine, sodium nitroprusside and L-NMMA
caused dose-dependent changes in forearm blood flow, as shown in Figure 13. Prior
systemic administration of uric acid did not significantly alter responses to the














































Figure 13. Forearm blood flow responses to acetylcholine 7.5-30 pg/min, sodium
nitroprusside 2-8 pg/min and L-NMMA 2-4 pmol/min, as % change
from baseline infused: non-infused forearm ratio, after systemic
administration ofuric acid 1000 mg or vehicle alone (n = 10).
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9.3.3 Haemodynamic variables
Baseline values for augmentation index, haemodynamic variables and baroreceptor
reflex sensitivity were similar between study arms. A non-significant trend was
observed towards increased systemic vascular resistance and blood pressure in all
three study arms. Uric acid elevation had no effect on any haemodynamic variables.
Table 22. Mean ± SEM central blood pressure, heart rate, augmentation index,
cardiac index, systemic vascular resistance index and baroreflex sensitivity, before
and after intravenous 0.9% saline, vehicle and uric acid 1000 mg over 1 h, and mean
and 95% confidence intervals for change from baseline (A) at lh.
Saline Vehicle Uric acid
Before After Before After Before After
SBP (mmHg) 96 ±3 97 ±3 93 ±2 97 ±5 96 ±4 100 ±4
DBP (mmHg) 61 ±2 65 ±2 63 ±3 68 ±3 62 ±4 71 ±3
HR (bpm) 55 ±3 53 ±3 57 ±4 58 ±3 58 ±3 59 ±2
AIx (%) -6.7 ±6.0 -3.1 ±6.1 -2.6 ±6.0 -1.1 ±6.1 -3.6 ±5.1 -6.1 ±6.2
CI (1/min/m2) 3.3 ±0.2 3.0 ±0.2 3.3 ±0.4 3.3 ±0.3 3.1 ±0.2 3.2 ±0.3
SVRI (au) 12.0 ±1.0 13.7 ±0.9 10.2 ± 1.5 11.7 ± 2.0 12.3 ± 1.0 13.0 ± 1.0
BRSseq 22.3 ± 4.7 21.2 ±4.0 19.7 ±4.9 22.8 ±5.0 21.8 ±4.4 20.3 ±4.4
BRSspec 24.3 ±5.8 19.4 ±3.4 22.2 ±6.6 26.8 ±6.4 23.4 ±5.0 21.7 ± 5.9
Saline Vehicle Uric acid
Mean A A 95% CI Mean A A 95% CI Mean A A 95% CI
SBP (mmHg) 1 -6-8 3 -3-9 3 -6 - 12
DBP (mmHg) 3 -2 - 8 1 -4-6 6 -2- 14
HR (bpm) -1 -5-7 -1 -6-4 0 -5 - 5
AIx (%) 3.5 -0.6-7.6 1.1 -2.7-4.9 2.4 -1.5-6.3
CI (1/min/m2) -0.1 -0.5-0.3 0.2 -0.2-0.6 0.0 -0.3-0.3
SVRI (au) 0.9 -0.3-2.1 1.2 -0.3-2.7 0.3 -0.8-1.4
BRSseq 0.5 -1.3-2.3 0.8 -0.6-2.2 -0.5 -1.7-0.7
BRSspec -1.6 -3.7-0.5 2.2 -0.2-4.6 -1.4 -7.1 -4.3
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9.3.4 Safety laboratory variables
Table 23. Biochemical variables measured immediately before and after systemic
administration of 0.9% saline, vehicle and uric acid 1000 mg, as mean ± SEM.
Saline Vehicle Uric acid
Before After Before After Before After
Sodium (mmol/1) 142 ±0 141 ±0 143 ± 1 140 ±0 143 ±0 140 ±0
Potassium (mmol/1) 4.0 ±0.1 4.3 ±0.1 4.0 ±0.1 4.2 ±0.2 4.0 ±0.1 4.1 ±0.1
Urea (mmol/1) 5.3 ±0.5 4.9 ±0.6 4.8 ±0.4 4.5 ±0.4 5.2 ±0.6 4.9 ±0.5
Creatinine (pmol/1) 86 ±4 84 ±4 88 ±3 87 ±3 85 ±4 85 ±4
Cholesterol (mmol/1) 4.5 ±0.4 4.1 ±0.4 4.2 ±0.4 3.9 ±0.4 4.6 ±0.4 4.2 ±0.4
Triglycerides (mmol/1) 1.0 ±0.2 0.9 ±0.1 1.1 ±0.3 1.0 ±0.2 1.1 ±0.1 1.0 ±0.1
Lithium (mmol/1) - 0.0 ±0.0 - 0.6 ±0.1 - 0.6 ± 0.1
9.4 Discussion
As anticipated, intravenous administration of uric acid caused a substantial increase
in circulating concentrations, which was of a similar magnitude to that observed in
earlier studies, and persisted throughout the period when endothelial function was
examined. Despite the substantial increase in circulating uric acid concentrations,
local forearm blood flow responses to intra-brachial acetylcholine, sodium
nitroprusside and L-NMMA were not altered. These findings indicate that high
systemic uric acid concentrations do not influence constitutive nitric oxide
bioavailability or stimulated endothelial function in the forearm vascular bed,
consistent with the observations in the setting of local hyperuricaemia.
These findings are unlike the effects of acute exposure to high levels of other major
cardiovascular risk factors, for example glucose, lipids, blood pressure and smoking,
which have all been found to impair endothelial function, at least temporarily [281,
282], This suggests that high uric acid concentrations do not mediate cardiovascular
risk through impaired endothelial function. If indeed they are causally related to
cardiovascular risk, then it appears likely that mechanisms other than impairment of
endothelial function may be important.
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Baseline haemodynamic measurements were consistent with values previously
reported in healthy young subjects free ofmajor cardiovascular risk factors. As
anticipated, intravenous administration of uric acid caused a significant increase in
circulating uric acid concentrations. High serum uric acid concentrations had no
effect on augmentation index or baroreflex sensitivity, the latter determined by two
methodologically discreet tests. These findings indicate that exposure to high
circulating concentrations of uric acid does not impair normal large arterial
compliance, at least in the acute setting. Similarly, no effect of hyperuricaemia was
observed on central systolic or diastolic blood pressure. These observations are
distinct from those reported in the presence of established major cardiovascular risk
factors. For example, patients with diabetes mellitus and hypercholesterolaemia have
higher augmentation index values than healthy people [42, 43], This finding is
indicative of increased large arterial stiffening, which might contribute to
cardiovascular risk due to the consequent increase in systolic and lowering of
diastolic central blood pressures [48],
Hyperuricemia co-exists with impaired large artery compliance in several disease
states characterized by reduced vascular nitric oxide bioavailability, for example type
2 diabetes mellitus [31]. The present findings suggest that this may be a passive
association, rather than caused by the presence of high serum uric acid
concentrations. Alternatively, the apparent association between type 2 diabetes and
large arterial stiffness might be accounted for by co-existent hypertension, and this
needs further exploration in future studies.
Previous reports of hyperuricaemia in animal models had suggested a possible causal
relationship between uric acid and elevated blood pressure, mediated through
increased systemic vascular resistance [133], The present findings did not support the
possibility that a similar mechanism is operating in humans. The lack of effect of
high serum uric acid concentrations on systemic vascular resistance and blood
pressure is consistent with the observations reported in Chapter 8. A limitation is that
the small number of subjects included, and the comparatively wide 95% confidence
intervals do not fully exclude the possibility of a small haemodynamic effect of acute
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hyperuricaemia. A further limitation of the present study design is that only the acute
haemodynamic responses to hyperuricaemia could be observed. Therefore, the
possibility that chronic exposure to high circulating uric acid concentrations might
increase systemic blood pressure cannot be refuted.
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Chapter 10.
Intravenous Administration of Uric Acid and
Platelet Aggregation, Plasma Viscosity,
and Tissue Plasminogen Activator
10.1 Introduction
Increased platelet aggregability has long been proposed as one plausible mechanism
by which high uric acid concentrations might predispose to increased cardiovascular
risk. A number of in vitro and observations in animal models have fuelled
speculation that such a mechanism might operate within the human cardiovascular
system, although a small number of exploratory clinical studies have yielded
conflicting reports, as discussed in Section 3.3. A limitation associated with the
direct addition of uric acid to whole blood in vitro is that hyperuricaemia might
mediate effects on platelet aggregation through the release of other tissue factors.
One of the major drawbacks to examining the effects of in vivo hyperuricaemia on
platelet aggregability has been the lack ofmeans to raise serum uric acid
concentrations sufficiently to address the hypothesis. Therefore, having established
the viability of uric acid administration as a means substantially raising serum
concentrations, the present study sought to evaluate the potential effects on platelet
aggregability.
Secondary study aims were to evaluate the effects of high serum uric acid
concentration on other potential mechanisms related to thrombosis, through which
uric acid might contribute to cardiovascular risk. Haemorheological measurements
have received comparatively little attention, but are closely related to the
development of atheroembolism, and are believed to contribute to cardiovascular risk
in the setting of any one of a number of established cardiovascular risk factors.
Additionally, endothelium-derived tissue plasminogen activator is believed to play
an important role in regulating thrombosis in vivo, and impaired tissue plasminogen
activator bioavailability appears to be an important mechanism underlying increased
thrombosis risk in regular smokers (plasma viscosity and tissue plasminogen
activator are discussed in greater depth in Chapter 1). A functional dichotomy is
recognised between endothelium-dependent nitric oxide-mediated vasodilatation and
endothelium-dependent tissue plasminogen activator release. For example,
acetylcholine stimulates endothelial release of nitric oxide, but not tissue
plasminogen activator, whereas bradykinin is a potent stimulus for endothelial tissue
plasminogen activator release and less so nitric oxide. Therefore, the apparent lack of
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effect of hyperuricaemia on endothelium-dependent nitric oxide bioavailability (as
discussed in earlier Chapters) does not exclude the possibility that high serum uric
acid concentrations might influence other aspects of endothelial function such as the
release of tissue plasminogen activator in response to bradykinin.
The potential effects of high serum uric acid concentrations on plasma viscosity and
tissue plasminogen activator have not been examined in previous studies.
10.2 Protocols
10.2.1 Plasma viscosity and platelet aggregation
Ten healthy men were recruited to a randomised double blind three-way crossover
study. An 18-gauge standard venous cannula was inserted into a large vein in each
antecubital fossa using local anaesthetic (1% lidocaine). Uric acid 1000 mg in 500 ml
vehicle, 500 ml vehicle alone, or 500 ml 0.9% saline was infused via the non-
dominant forearm cannula over 1 h. Venous blood was drawn via the non-infused
forearm cannula immediately before and after infusion: 5 ml was collected in a
serum gel tube (Sarstedt Ltd., Leicester, UK) for measurement of serum uric acid
concentration; 10 ml was collected into a Sarstedt tube containing potassium EDTA
for measurement of plasma viscosity; 30 ml was collected into evacuated tubes
containing trisodium citrate (0.8 ml/10 ml) for measurement of platelet aggregation.
Samples for platelet aggregation were processed and analysed immediately after
collection. Each was centrifuged at 120 g for 10 min, and platelet-rich plasma was
aspirated. The remaining sample was centrifuged at 800 g for 10 min, and platelet
poor plasma was aspirated. Platelet counts were obtained using a Beckman-Coulter
Act-8 Counter (Beckman-Coulter U.K. Limited, High Wycombe, England). Platelet-
rich plasma samples were diluted with platelet poor plasma to achieve a final
concentration of 200 x 109/1. Aggregation studies were performed using a standard
optical technique (Chronolog Ca560 aggregometer; Labmedics, Stockport, England),
and samples were pre-warmed to 37°C before analyses. The maximal aggregation
responses to ADP 0, 2, 4, 6, 8 and 10 pM obtained within 7 min were recorded and
expressed as a percentage of response to ADP 100 pM in each subject. Repeated-
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measures analysis of variance was used to identify differences in response between
uric acid, vehicle and saline.
10.2.2 Forearm blood flow responses and tissue plasminogen activator
Eight healthy men were recruited to a randomised double blind two-way crossover
study. An 18-standard gauge cannula was inserted into a suitable vein in each
antecubital fossa, and a 27-standard gauge needle inserted into the brachial artery of
the non-dominant arm using local anaesthesia and aseptic technique. Uric acid 1000
mg in 500 ml vehicle or 500 ml vehicle alone saline were infused intravenously, over
1 h, via the venous cannula in the non-dominant forearm.
A 5 ml venous blood sample was collected from the non-infused forearm cannula
before and after infusion for measurement of serum uric acid concentration.
Immediately after infusion, subjects underwent intra-brachial administration of
acetylcholine 7.5, 15 and 30 pg/min, sodium nitroprusside 2, 4 and 8 pg/min, and
bradykinin 30, 100 and 300 ng/min. Each drug dose was infused for 6 min, and the
rate of infusion was kept constant at 1 ml/min throughout. The order of intra-brachial
drug infusion was randomised between subjects, and saline was administered for at
least 20 min between drugs to allow restoration of basal blood flow. Blood flow was
measured in both forearms by venous occlusion plethysmography during the last 3
min of each dose. Immediately after infusion of each dose, a 6 ml venous blood
sample was drawn from infused and non-infused forearm cannulae into separate
collecting tubes containing acidified buffered sodium citrate 0.105 mmol/1 (Stabilyte,
Biopool, Umea, Sweden), centrifuged at 2000 g for 20 min at 4°C. Plasma was




Table 24. Baseline characteristics of the study populations as mean ± SEM.
Plasma viscosity & Forearm blood
Characteristic platelet aggregation flow and TPA
Number/ male 10/6 8/3
Age (years) 35 ±2 27 ± 1
Height (m) 1.74 ±0.02 1.74 ±0.01
Weight (kg) 74 ±4 70 ±2
Body mass index (kg/m2) 24.4 ±0.8 22.1 ±0.6
Heart rate (min"1) 71 ±3 61 ±2
Systolic blood pressure (mmHg) 123 ±3 111 ±3
Diastolic blood pressure (mmHg) 75 ±2 64 ±2
Serum creatinine (pmol/1) 77 ±5 66 ±5
Serum cholesterol (mmol/1) 4.6 ±0.3 4.2 ±0.3
Plasma glucose (mmol/1) 6.8 ± 1.4 5.8 ± 1.2
Serum urate (pmol/1) 307 ± 24 234 ± 19
Haematocrit (1/1) 0.42 ±0.01 -
Platelet count (xl09/l) 239 ± 14 -
10.3.1 Serum uric acid concentrations
Table 25. Mean ± SEM serum uric acid concentrations before and after systemic
administration of uric acid 1000 mg in vehicle, vehicle and 0.9% saline. *p < 0.001
compared to baseline.
Baseline Post-infusion
Plasma viscosity & platelet Uric acid 307 ± 27 585 ±28"
aggregation study Vehicle 308 ± 20 313 ± 19
Saline 306 ± 24 295 ± 23
Forearm blood flow and tissue Uric acid 233 ±17 528 ±26*
plasminogen activator study Vehicle 237 ± 20 224 ±15
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10.3.2 Plasma viscosity
Table 26. Mean ± SEM plasma viscosity measurements (mPa.s) before and after
administration of uric acid 1000 mg, vehicle and 0.9% saline.
Baseline Post-infusion
Saline 1.56 ±0.06 1.54 ±0.08
Vehicle 1.54 ±0.06 1.55 ±0.05
Uric acid 1.55 ±0.07 1.54 ±0.07
10.3.3 Platelet aggregation
Dose-dependent aggregation responses to ADP were observed in all subjects. The
dose-response relationship was not altered by prior administration of uric acid or
vehicle (p = 0.78 and p = 0.59 compared to saline administration).
Figure 14. Mean ± SEM aggregation responses to ADP after administration of uric
acid 1000 mg, vehicle and saline, as percentage of the response to 100 pM ADP.
10.3.4 Forearm blood flow responses
Intra-brachial administration of acetylcholine, sodium nitroprusside and bradykinin
caused dose-dependent blood flow increases in the infused forearm. Administration
of uric acid did not have a significant effect on the responses to any vasoactive drug
























































Figure 15. Forearm blood flow responses to intra-brachial acetylcholine (ACh) 7.5-
30 pg/min, sodium nitroprusside (SNP) 2-8 pg/min and bradykinin (BK) 30-300
ng/min after systemic administration of uric acid 1000 mg or vehicle.
10.3.5 Tissue plasminogen activator
Intra-brachial administration of bradykinin caused a dose-dependent increase in net
release of tissue plasminogen activator, whereas acetylcholine and sodium
nitroprusside had no effect. Systemic administration of uric acid did not alter tissue
plasminogen activator responses to bradykinin, acetylcholine or sodium
nitroprusside, as shown overleaf.
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Table 27. Mean ± SD net t-PA release during intra-brachial administration of
acetylcholine 7.5-30 pg/min, sodium nitroprusside 2-8 pg/min and bradykinin 30-
300 ng/min, after systemic administration of uric acid 1000 mg or vehicle. *p < 0.05,
* ♦ * * +
p < 0.01, p < 0.005 compared to baseline.
Net t-PA release (ng.lOOml^.miiT1)
Vehicle Uric acid
Baseline 0.51 ±0.11 0.19 ±0.23
ACh 7.5 pg/min -0.06 ±0.23 -0.06 ±0.24
ACh 15 pg/min 0.43 ± 0.29 2.10 ± 1.28
ACh 30 pg/min 0.71 ±0.33 1.61 ±0.62
Baseline -0.14 ±0.40 0.36 ±0.72
SNP 2 pg/min -0.16 ±0.27 -0.85 ±0.81
SNP 4 pg/min -0.18 ±0.37 1.50 ± 0.81
SNP 8 pg/min -0.55 ± 0.60 -0.43 ± 0.60
Baseline 0.78 ±0.39 -0.13 ±0.41
BK 30 ng/min 2.51 ±0.52* 1.65 ±0.43**
BK 100 ng/min
* * *
7.60 ±2.33 5.72 ± 1.62***
BK 300 ng/min 14.40 ±2.83*** 15.7 ±3.23***
10.4 Discussion
Haematocrit and platelet count values were normal in the study population. High uric
acid concentrations in vivo did not manifest any effects on platelet aggregation
determined using an ex vivo method. This suggests that the observed relationship
between hyperuricaemia and increased platelet aggregability is non-causal, and
might arise through associations with other factors. The present findings contrast
with previously reported effects of vitamin C, another aqueous antioxidant with
similar molecular weight to uric acid. Acute oral administration of vitamin C has
been shown to inhibit ex vivo platelet aggregation in healthy subjects [285], Given
that high serum uric acid concentrations confer powerful antioxidant properties
within human serum, the previously observed effects of vitamin C appear unlikely to
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be explained by its antioxidant properties alone, and other mechanisms may be
important.
High uric acid concentrations had no discernable effect on plasma viscosity and
endothelium-dependent release of tissue plasminogen activator. This suggests that
uric acid is unlikely to predispose to thrombosis through either mechanism. Increased
plasma viscosity has been established as an important risk factor in patients with
hypertension, peripheral vascular disease and ischaemic heart disease [86-88],
Previous studies have shown an association between high serum uric acid
concentrations and hypercoaguable states, and it remains possible that this




Intravenous Administration of Uric Acid and
Oxidative Stress During Acute Aerobic Exercise
11.1 Introduction
Moderately intense physical exercise increases oxygen utilisation, and causes excess
oxygen-derived free radical liberation through mitochondral lipid peroxidation,
neutrophil degranulation, and up-regulation of xanthine oxidase activity, which
liberates superoxide (02*). Intense physical exercise provides a model for studying
the effects of acute oxidative stress in vivo, and has been shown to increase
susceptibility of low-density lipoprotein to oxidation, and impair endothelial-
dependent vasodilatation in the forearm vascular bed [286, 287], Oxidative stress
during acute exercise is characterised by elevated circulating 8-A0-PGF201
concentrations, which has provided an opportunity to examine the effects of
antioxidant administration on free-radical activity in vivo [288], Supplementation
with vitamin C or E increases resistance to exercise-induced lipid peroxidation in
healthy individuals [289], However, beta-carotene does not reduce oxidative stress
during acute physical exercise [290], and combined administration of vitamin C and
N-acetyl-cysteine paradoxically increase 8-Ao-PGF2a concentrations after acute
eccentric exercise, despite increased serum antioxidant capacity [291], Glutathione
and ubiquinol supplementation reduce oxidative stress in animal models of acute
exercise [292], but their effects have not been fully characterised in humans.
Uric acid becomes oxidised in skeletal muscle during high intensity exercise [293],
Intracellular uric acid concentrations are rapidly replenished by uptake from plasma
after exercise [294], A previous study found a significant inverse relationship
between serum uric acid concentrations and oxidative stress during acute aerobic
exercise [295], These observations suggest that high uric acid concentrations could
confer protection against free radical activity in vivo, and indicate that uric acid may
be of biological importance in the setting of acute oxidative stress. The present study
aimed to characterise the effects of elevated serum uric acid concentration on




Healthy subjects were enrolled in a randomised two-way double blind crossover
study. Studies were performed at the same time of day on each visit and separated by
1 week. An 18-standard gauge venous cannula was inserted into a suitable vein in
each antecubital fossa, under local anaesthetic using aseptic technique. Subjects
remained seated for 20 min to establish baseline haemodynamic conditions, and
underwent systemic administration of uric acid 500 mg in 250 ml vehicle, or 250 ml
vehicle alone over 20 min via the non-dominant forearm cannula. Subjects
performed lower limb exercise using an upright electronically-braked ergometric
cycle (Ergometry System 380B, Siemens-Elema, Sweden) for 20 min. Pedalling rate
was sustained at 70 ± 10 Hz to maintain a constant workload of 80 W, equivalent to a
moderately intense riding speed of 3.8 ms-1 (8.5 mph) [296], Exercise was followed
by a 20 min recovery period during which subjects rested seated.
Heart rate, blood pressure and cardiac index measurements were recorded at
baseline, and at 5 min intervals up to 60 min after the start of the infusion. A 5 ml
venous blood sample was collected in serum gel tubes via the non-infused forearm
cannula, at baseline and 20, 40, and 60 min after the start of infusion, for
measurement of serum uric acid concentration and antioxidant capacity using the
'Total Antioxidant Status' assay. Additional 5 ml samples were collected in
potassium-EDTA tubes (Sarstedt Ltd., Leicester, UK) at baseline and 60 min after
the start of infusion for determination of plasma 8-Ao-PGF2a concentrations. Blood
samples were centrifuged at 1000 g for 10 minutes at 4°C, decanted immediately,
and serum and plasma were stored at -40°C until assays were performed.
11.3 Results
Table 28. Baseline characteristics of the study population
Characteristic Mean ± SD Characteristic Mean ± SD
Number/ men 20/ 10 Body mass index (kg/m ) 23.0 ±3.5
Age (y) 23 ±3 Serum creatinine (prnol/1) 72 ± 10
Height (m) 1.72 ±0.34 Serum cholesterol (mmol/1) 4.0 ±2.5
Weight (kg) 71.5 Serum uric acid (pmol/1) 293 ± 52
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11.3.1 Uric acid concentrations
Administration of vehicle and uric acid caused mean ± SEM increases in serum uric
acid concentrations of-9 ± 2 and 194 ± 8 pmol/1 respectively (p < 0.001).
Table 29. Mean ± SEM serum uric acid concentrations (pmol/1) at baseline, after
infusion of uric acid 500 mg in vehicle or vehicle alone, after exercise and after
recovery. *p < 0.001 compared to baseline.
Baseline Post-infusion Post-exercise Post-recovery
0 min 20 min 40 min 60 min
Vehicle 294 ± 19 286 ± 18 296 ± 19 293 ± 18
Uric acid 293 ± 16 487±16* 458±15* 429±14*
11.3.2 Haemodynamic variables
Intense physical exercise caused significant increases in heart rate, systolic blood
pressure, diastolic blood pressure and cardiac index, and a reduction in systemic
vascular resistance index. Uric acid administration did not influence haemodynamic
variables at rest nor the haemodynamic response to exercise.
Table 30. Mean ± SEM haemodynamic variables at baseline, after infusion of uric









Heart rate (bpm) Vehicle 75 ±2 73 ±2 138 ±6* 80 ±2
Uric acid 76 ±3 74 ±2 135 ±7* 80 ±3
Systolic BP Vehicle 93 ±5 97 ±6 147 ±6* 94 ±4
(mm Hg) Uric acid 94 ±5 94 ±5 153 ±6* 97 ±5
Diastolic BP Vehicle 66 ±2 67 ±3 101 ± 5* 69 ±2
(mm Hg) Uric acid 68 ±2 66 ±4 103 ± 6* 68 ±2
Cardiac index Vehicle 3.9 ±0.2 3.8 ±0.2 9.7 ±0.8* 3.8 ±0.2
(1/min.m2) Uric acid 3.9 ±0.2 3.7 ±0.1 9.4 ±0.6* 4.0 ±0.2
Sys. vascular Vehicle 22.0 ±2.0 23.2 ± 1.7 15.9 ±2.4* 22.0 ± 1.7





Figure 16, continued overleaf.
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Figure 16. Haemodynamic variables during infusion of uric acid 500 mg or vehicle
(0-20 min), exercise (20-40 min) and recovery (40-60 min) shown as mean ± SEM.
11.3.3 Serum antioxidant capacity
Administration of vehicle and uric acid caused respective changes in serum
antioxidant capacity from baseline of -22 ± 23 and 118 ± 18 p.mol/1 (p < 0.001
between infusions).
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Table 31. Mean ± SEM serum antioxidant capacity (p.mol/1) at baseline, after uric
acid or vehicle infusion, exercise and recovery. *p < 0.005 compared to baseline.
Baseline Post-infusion Post-exercise Post-recovery
0 min 20 min 40 min 60 min
Vehicle 1815±29 1769 ±46 1817 ± 27 1796 ±32
Uric acid 1786 ± 39 1899 ±45" 1937 ±44* 1895 ±47*
11.3.4 Plasma 8-isoprostaglandin F2a concentrations
Intense physical exercise caused a significant increase in plasma 8-iso-PGF2a
concentrations from 35.0 ± 4.7 pg/ml to 45.6 ± 6.7 pg/ml immediately after exercise
(p < 0.05), and 55.7 ±7.1 pg/ml after recovery (p < 0.01), following vehicle
administration. After uric acid administration, 8-Ao-PGF2a concentrations (37.1 ±
5.4 pg/ml) did not increase after exercise (31.6 ± 5.5 pg/ml) or recovery (37.9 ± 6.6
pg/ml). Plasma 8-Ao-PGF2a concentrations after vehicle and uric acid administration,
expressed as change from baseline, were 10.6 ± 5.5 and -5.5 ± 6.2 pg/ml (p < 0.05)
respectively after exercise, and 20.7 ± 6.5 and 0.8 ± 7.7 (p < 0.01) respectively after
recovery. Uric acid administration significantly reduced isoprostane concentrations













Baseline Exercise Recovery Baseline Exercise Recovery
Vehicle UA
Figure 17. Plasma 8-Ao-PGF2a concentrations at baseline, post-exercise and post-
recovery after systemic administration of uric acid 500 mg or vehicle alone.
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11.4 Discussion
Resting plasma free 8-Ao-PGF2a concentrations were consistent with those
previously reported in young, healthy people free from major cardiovascular risk
factors that could potentially exert independent effects on oxidative stress. Previously
reported in healthy subjects [297], The chosen exercise intensity and duration caused
a significant haemodynamic response in this group, who were unaccustomed to
regular strenuous exercise. Furthermore, single bouts of acute intense exercise
caused oxidative stress in the study population, reflected by increased plasma 8-iso-
PGF2cx concentrations immediately after exercise and after recovery. The magnitude
of the rise in plasma isoprostane concentrations was similar to previous observations
in healthy subjects and trained athletes after acute exercise [298].
Administration of uric acid 500 mg achieved a substantial increase in circulating uric
acid concentrations, associated with increased serum free radical-scavenging
capacity as indicated by the 'Total Antioxidant Status' assay. Moreover, uric acid
administration attenuated the exercise-induced increase in plasma 8-Ao-PGF2a
concentrations. It is likely that this effect was mediated by increased ability to
counter excess free radical activity, conferred by the antioxidant properties of uric
acid. These findings indicate that high circulating uric acid concentrations are able to
prevent oxidative stress in vivo during intense physical exercise, and raise the
possibility that uric acid could protect against oxidative stress in other situations.
The lack of effect of uric acid administration on resting and exercising
haemodynamic is consistent with observations described earlier in this thesis, and
support the earlier observations that high uric acid concentrations do not directly
influence vascular tone or systemic blood pressure, at least in the acute setting. A
potential limitation is that the validity of the Omron HEM-705CP device has not
been established in exercising subjects. It is accurate for measuring blood pressure up
to 160/ 100 mmHg in resting subjects, and has been validated according to criteria of




Intravenous Administration of Uric Acid and
Endothelial Function, Large Arterial Stiffness and
Systemic Haemodynamics in Regular Smokers
and Patients with Type 1 Diabetes Mellitus
12.1 Introduction
Endothelial dysfunction is characteristically impaired in regular cigarette smokers
and patients with type 1 diabetes mellitus [25, 28]. Endothelial dysfunction in the
setting ofmajor cardiovascular risk factors appears to be a consequence of increased
free radical activity, in the bloodstream or arterial intima. Endothelial function can be
restored by administration of supplementary natural antioxidants, including ascorbic
acid and tocopherol [299, 300], The potential role of uric acid as a protective
antioxidant has not been examined in this setting.
Regular smokers and patients with type 1 diabetes have low serum uric acid
concentrations, which could increase susceptibility to oxidative damage by the
excessive free radical production characteristically found in both groups. The
purpose of the present study was to investigate the hypothesis that administration of
uric acid or vitamin C, both powerful aqueous antioxidants, might improve vascular
function in regular smokers and patients with type 1 diabetes mellitus, groups
characteristically exposed to increased oxidative stress and endothelial dysfunction.
12.2 Methods
Eight regular smokers, 8 patients with type 1 diabetes, and 8 age-matched healthy
controls were recruited to a 4-way randomised placebo-controlled crossover study
that allowed at least one week between study visits. An 18-standard gauge cannula
was inserted into a vein in the antecubital fossa of each arm, using aseptic technique
and local anaesthetic. The non-dominant forearm cannula allowed infusion of uric
acid 1000 mg in 500 ml 4% dextrose/0.1% lithium carbonate vehicle, 500 ml vehicle
alone, 1000 mg vitamin C in 500 ml 0.9% saline, or 500 ml saline alone, over 1 h.
The brachial artery of the non-dominant forearm was cannulated to allow intra¬
arterial administration of acetylcholine, sodium nitroprusside and L-NMMA.
Venous blood (5 ml) was drawn from the non-infused forearm cannula, before and
after systemic administration for measurement of serum uric acid concentration and
antioxidant capacity. Heart rate, blood pressure, cardiac index, augmentation index
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and baroreflex sensitivity by sequence and spectral analysis methods were
determined before and after systemic infusion.
12.3 Results
Table 32. Baseline characteristics of the study population at screening, mean ± SEM.
*P < 0.05, **p < 0.001 compared to controls.
Regular Patients with Healthy
smokers type 1 diabetes Controls
Number (men) 8(8) 8(8) 8(8)
Age (y) 30 ±2 30 ±2 30 ±2
Systolic BP (mmHg) 120 ±2* 130 ± 2** 111 ±2
Diastolic BP (mmHg) 70 ± r* 77 ±2" 64 + 2
Heart rate (bpm) 60 ±3
* *
70 ±2 60 ± 1
Body mass index (kg/m2) 26 ± 1 24 ± 1 25 ± 1
Creatinine (pmol/1) 79 ±2 63 + 5* 82 ±3
Glucose (mmol/1) 4.7 ±0.1 8.5 ± 1.1** 4.6 ±0.1
Cholesterol (mmol/1) 4.2 ± 0.1* 4.2 ± 0.4* 3.6 ±0.2
Plasma glucose concentrations were significantly higher in patients with diabetes
compared to healthy subjects (p < 0.001) and smokers (p < 0.001), but did not vary
significantly between study visits.
12.3.1 Serum uric acid concentrations
Baseline serum uric acid concentrations, across all study visits, were significantly
lower among regular smokers (315 ± 11 pmol/1, p < 0.05) and patients with type 1
diabetes (245 ± 18 pmol/1, p < 0.001) than in healthy controls (336 ± 11 pmol/1).
Uric acid administration significantly increased serum concentrations by 286 ±17,
270 ± 20, and 262 ± 18 pmol/1 in each group respectively.
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Figure 18: Serum uric acid concentrations before and after administration uric acid
1000 mg in regular smokers, patients with type 1 diabetes, and healthy controls.
*P < 0.05, *p < 0.005 compared to controls, #P < 0 .001 compared to baseline.
12.3.2 Serum antioxidant capacity
Antioxidant capacity was significantly lower in regular smokers and patients with
type 1 diabetes than healthy controls. Administration of uric acid and vitamin C
increased serum antioxidant capacity in all groups, but saline and vehicle did not.
Table 33. Mean ± SEM serum antioxidant capacity in smokers, patients with type 1
diabetes and controls (pmol/1 Trolox eq.), before and after administration of uric acid







Vitamin C Before 1203 ±46* 1089 ±46* 1404 ±57
administration After 1316 ± 50* 1240 ± 48* 1532 ± 66*
Change 120 ± 12** 148±17" 131 ±13"
Uric acid Before 1224 ±54 1106 ±48* 1341 ±60
administration After 1402 ± 66* 1349 ± 52** 1578 ±67"
Change 203 ± 22" 221±19" 235 ± 30"
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12.3.3 Haemodynamic variables
Administration of neither uric acid, vehicle, vitamin C nor saline had any significant
effects on heart rate, blood pressure, cardiac index or systemic vascular resistance
index in regular smokers, patients with type 1 diabetes and healthy controls.
Table 34. Mean ± SEM haemodynamic variables in regular smokers, patients with
type 1 diabetes and healthy controls subjects, before and immediately after systemic








Heart rate (bpm) Before 71 ± 1 72 ±6 59 ±5
After 67 ±4 76 ±6 56 ±4
Systolic BP (mmHg) Before 125 ±5 124 ±3 115 ± 4
After 129 ± 5 132 ±9 117 ± 5
Cardiac index (1/m2) Before 3.0 ±0.4 3.6 ±0.3 3.2 ±0.3
After 3.1 ±0.2 3.8 ±0.5 3.1 ±0.2
SVRI (au) Before 32.6 ±4.9 26.0 ± 1.4 27.3 ±2.5
After 34.6 ±4.6 27.7 ±2.7 28.5 ±2.5
Vehicle administration
Heart rate (bpm) Before 71 ±2 71 ±7 58 ±3
After 71 ±4 67 ± 7 56 ± 5
Systolic BP (mmHg) Before 121 ±4 133 ±7 119 ± 5
After 125 ±3 134 ±7 113 ± 7
Cardiac index (1/m2) Before 3.6 ±0.2 3.5 ±0.4 3.4 ±0.8
After 3.1 ±0.2 3.7 ±0.3 2.8 ±0.3
SVRI (au) Before 24.8 ± 1.1 25.2 ±4.8 29.7 ±3.9
After 30.3 ± 1.5 27.3 ±2.6 31.7 ± 2.4
Uric acid administration
Heart rate (bpm) Before 71 ±4 68 ±5 63 ±3
After 68 ±6 70 ± 7 59 ±2










Systolic BP (mmHg) Before 124 ±3 131 ±5 119 ± 4
After 127 ±6 138 ± 4 118 ± 3
Cardiac index (1/m2) Before 3.0 ±0.5 3.6 ±0.3 3.0 ±0.3
After 3.0 ±0.4 3.3 ±0.3 2.9 ±0.3
SVRI (au) Before 32.9 ±4.7 26.7 ±2.3 28.7 ±2.5
After 33.4 ±4.8 30.9 ± 1.9 30.8 ±2.3
Vitamin C administration
Heart rate (bpm) Before 72 ±4 70 ± 5 60 ±4
After 69 ±3 71 ±6 58 ±4
Systolic BP (mmHg) Before 123 ±4 130 ± 5 118 ± 4
After 124 ±4 133 ±6 116 ± 3
Cardiac index (1/m2) Before 3.3 ±0.3 3.5 ±0.4 3.2 ±0.5
After 3.2 ±0.4 3.6 ±0.3 2.9 ±0.3
SVRI (au) Before 29.2 ±2.8 25.8 ±3.2 28.5 ±2.2
After 31.4 ± 3.1 27.2 ±2.7 30.4 ±2.0
12.3.4 Augmentation index
Baseline augmentation index values were significantly higher in regular smokers (p <
0.001) and patients with type 1 diabetes (p < 0.001) than healthy controls.
Vitamin C was associated with a non-significant trend towards reduced augmentation
index in patients with type 1 diabetes (p = 0.062), and had no effect in regular
smokers and healthy subjects. Neither uric acid, vehicle nor saline caused any




Smokers Type 1 Controls
diabetes
Figure 19. Mean ± SEM baseline augmentation index (%) in regular smokers,
patients with type 1 diabetes and healthy controls. *p < 0.001 compared to controls.
Table 35. Mean ± SEM augmentation index (%)in smokers, patients with type 1
diabetes and controls, before and after administration of 0.9% saline, vehicle, uric







Saline administration Before 5.3 ±3.6** 9.1 ±4.9** -12.3 ±4.7





9.6 ±4.5 -12.9 ±4.6
After 5.7 ±4.7 14.2 ±4.7 -10.5 ±5.0
Uric acid administration Before 4.8 ±3.5* 9.9 ±4.5** -11.2 ± 4.7
After 7.0 ±4.1 11.9 ± 4.8 -10.8 ±4.6
Vitamin C administration Before 5.2 ±3.4**
3k >k
9.8 ±4.7 -11.9 ± 4.5
After 5.6 ±4.4 6.3 ±4.4 -12.2 ±4.6
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12.3.5 Baroreflex sensitivity
Baroreflex sensitivity, determined by both sequence analysis and spectral analysis
methods, was significantly impaired in regular smokers and patients with type 1
diabetes mellitus compared to healthy controls.
□ Sequence analysis ■ Spectral analysis
Smokers Type 1 diabetes Healthy
Figure 20. Mean ± SEM baroreflex sensitivity in smokers, patients with type 1
diabetes and healthy controls, determined by sequence and spectral analysis methods.
Systemic administration of neither 0.9% saline, vehicle, uric acid 1000 mg nor
vitamin C 1000 mg caused any significant effect on baroreceptor reflex sensitivity
from baseline in smokers, patients with type 1 diabetes or controls (shown overleaf).
12.3.6 Endothelial function
Blood flow responses to acetylcholine and sodium nitroprusside after systemic saline
administration were used to represent baseline vascular function in each group.
Acetylcholine responses were lower in smokers (p < 0.005) and patients with type 1
diabetes (p < 0.001) than controls. Uric acid and vitamin C increased acetylcholine
responses in smokers (p < 0.05 both) and patients with diabetes (p < 0.01 both), but
not those to sodium nitroprusside. Vitamin C improved L-NMMA responses in
smokers and patients with diabetes (p < 0.05 both). Neither uric acid nor vitamin C
had any effect on blood flow responses in healthy subjects (see Figures 21 to 24).
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Table 36. Mean ± SEM baroreflex sensitivity (ms/mmHg) by sequence and spectral
analysis before and after administration of saline, vehicle, uric acid or vitamin C.
Regular Type 1 Healthy
smokers diabetes controls
Saline administration
Sequence analysis Before 14.6 ±2.2 10.5 ±2.0 18.4 ±3.3
After 13.1 ± 1.6 11.2 ± 2.2 20.9 ±2.5
Spectral analysis Before 13.6 ±2.9 9.1 ±2.0 17.7 ±2.5
After 12.7 ±2.4 10.0 ±2.3 17.5 ±3.2
Vehicle administration
Sequence analysis Before 13.5 ± 1.9 11.7 ±2.2 22.2 ±3.6
After 12.2 ±2.0 11.7 ±2.2 19.0 ±2.5
Spectral analysis Before 11.1 ± 1.5 11.4 ±2.5 20.9 ±4.7
After 11.0 ± 2.0 10.4 ±2.3 16.6 ±2.8
Uric acid administration
Sequence analysis Before 16.1 ±2.8 11.4 ± 2.1 21.7 ± 3.4
After 14.5 ±2.5 12.3 ± 1.5 19.9 ±2.8
Spectral analysis Before 12.8 ±2.7 10.4 ±2.1 20.3 ±3.4
After 12.3 ±2.7 10.4 ± 1.7 18.4 ± 3.1
Vitamin C administration
Sequence analysis Before 14.8 ±2.2 10.8 ±2.0 19.8 ± 3.1
After 14.9 ±2.6 11.2 ± 1.9 20.2 ±3.2
Spectral analysis Before 15.8 ±2.3 10.6 ± 1.8 18.9 ± 4.1
After 16.1 ±2.4 10.8 ±2.2 20.5 ±3.8
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Figure 21. Forearm blood flow responses to intra-brachial acetylcholine (ACh) 7.5-
30 pg/min, sodium nitroprusside (SNP) 2-8 pg/min and L-NMMA 2-4 pmol/min in
regular smokers, patients with type 1 diabetes and healthy controls. *p < 0.05, **p <
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Figure 22. Forearm blood flow responses to intra-brachial acetylcholine (ACh) 7.5-
30 pg/min, sodium nitroprusside (SNP) 2-8 pg/min and L-NMMA 2-4 pmol/min
after i.v. uric acid 1000 mg, vitamin C 1000 mg, vehicle, or 0.9% saline in regular
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Figure 23. Forearm blood flow responses to intra-brachial acetylcholine (ACh) 7.5-
30 pg/min, sodium nitroprusside (SNP) 2-8 pg/min and L-NMMA 2-4 pmol/min
after i.v. uric acid 1000 mg, vitamin C 1000 mg, vehicle, or 0.9% saline in patients
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Figure 24. Mean ± SEM forearm blood flow responses to intra-brachial acetylcholine
(ACh) 7.5-30 pg/min, sodium nitroprusside (SNP) 2-8 pg/min and L-NMMA 2-4




Consistent with previous studies, forearm blood flow responses to intra-brachial
acetylcholine were significantly impaired in regular smokers and patients with type 1
diabetes, indicating impaired endothelium-dependent vasodilator responses in these
groups. Responses to L-NMMA in smokers and patients with diabetes were
impaired, indicating reduced constitutive nitric oxide bioavailability in these groups,
consistent with previous reports. There were no differences in responses to sodium
nitroprusside between groups, indicating that endothelium-independent vascular
responses to nitric oxide-mediated stimuli are intact in regular smokers and patients
with type 1 diabetes. These observations indicate that uric acid and vitamin C
allowed restoration of dynamic endothelium-dependent nitric oxide bioavailability.
Baseline uric acid concentrations and serum antioxidant capacity were low in regular
smokers and patients with type 1 diabetes, consistent with previous reports. This may
be because ofmore rapid consumption in the presence of increased free radical
activity. Endothelium-derived nitric oxide is subjected to abnormally rapid
degradation and reduced bioavailability in the setting of oxidative stress. Systemic
administration of vitamin C and uric acid significantly enhanced circulating
antioxidant defences. This suggests that they might protect nitric oxide against
oxidative, and thereby explains the observed improvement in endothelial function.
This hypothesis is supported by a lack of influence of uric acid and vitamin C on
responses in healthy controls not exposed to oxidative stress and with normal
antioxidant defences. The observed effects of uric acid on endothelial function are
consistent with findings in a perfused guinea pig heart model, where addition of uric
acid in physiological concentrations allowed restoration of acetylcholine-mediated
coronary vasodilator responses in the presence of oxidative stress [301],
Vasoconstriction to L-NMMA is a marker of basal nitric oxide production, and was
significantly lower in regular smokers and patients with type 1 diabetes. Only
vitamin C improved L-NMMA responses in smokers and patients with diabetes.
These data indicate that vitamin C but not uric acid was capable of improving basal
vascular nitric oxide availability, and suggest different mechanisms might underlie
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the effects of each. However, differences between basal and stimulated endothelium-
dependent nitric oxide bioavailability have previously been observed in the presence
of other risk factors including regular smoking [302], hypercholesterolemia [303]
and hyperhomocysteinaemia [304], Stimulated nitric oxide dependent responses may
be a more sensitive marker of endothelial function than basal nitric oxide activity.
Other mechanisms might account for differences between the effects of vitamin C
and uric acid. For example, vitamin C is able to diffuse passively across endothelial
cell membranes, whereas uric acid depends on active carrier-mediated transport into
endothelial cells, and intracellular concentrations are lower than those found in the
circulation due to active cellular efflux. So it is possible that despite significant
increases in circulating uric acid concentration, there might be less impact on
intracellular antioxidant activity.
A weakness of the present findings is that the small numbers of study subjects and
comparatively wide confidence intervals do not fully exclude the possibility of an
effect of uric acid administration on L-NMMA responses in smokers and patients
with diabetes. A limitation of this study is the lack of circulating markers of
oxidative stress, and the mechanisms underlying the present findings require further
exploration. However, both regular smokers and patients with type 1 diabetes have
consistently been shown to be exposed to greater oxidant activity than healthy
individuals, and have higher circulating markers of vascular oxidative damage.
An additional limitation is that serum cholesterol and blood pressure appear to be
potentially important confounding factors because both were higher in regular
smokers and patients with type 1 diabetes than controls. Endothelial dysfunction has
been consistently reported in regular smokers and patients with type 1 diabetes,
irrespective of lipid profile. Although retrospective analyses did not identify any
relationship between blood pressure and blood flow responses, vitamin C can reverse
endothelial dysfunction in patients with hypertension. Further work is required to
explore whether uric acid restores endothelial function in patients with other risk
factors for cardiovascular disease and endothelial dysfunction.
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Chapter 13.
Intravenous Administration of Urate Oxidase and Vascular
Function in Patients With Type 2 Diabetes Mellitus
13.1 Introduction
Epidemiological studies have found that patients with type 2 diabetes have higher
serum uric acid concentrations than healthy people and, within this patient group,
high serum uric acid concentrations are associated with increased cardiovascular risk.
Clinical studies have found that blood flow responses to endothelial-dependent nitric
oxide-mediated responses are blunted in patients with type 2 diabetes. Increased
large arterial stiffness is a characteristic finding in patients with type 2 diabetes,
presumably as a manifestation of endothelial dysfunction and loss of nitric oxide
bioavailability in large arteries.
One previous study found that administration of allopurinol, to lower serum uric acid
concentrations, restored endothelial function in patients with type 2 diabetes. The
effect of allopurinol on endothelial function might be explained by the associated
reduction in serum uric acid concentration, which would support the hypothesis that
uric acid is an independent, causal cardiovascular risk factor. However, allopurinol
possesses additional intrinsic antioxidant properties, and inhibits xanthine oxidase-
dependent free radical liberation. Therefore, it is difficult to draw conclusions about
the potential benefits that might be achieved by uric acid lowering in patients with
type 2 diabetes.
The present study was constructed to directly examine the potential cardiovascular
effects of reducing serum uric acid concentration in patients with type 2 diabetes, by
means of urate oxidase administration. Urate oxidase is capable of lowering serum
uric acid concentrations by a greater extent than typically achieved by oxypurinol or
allopurinol administration, and avoids the confounding effects associated with
xanthine oxidase inhibition. If uric acid is an independent causal factor in mediating
endothelial dysfunction in patients with type 2 diabetes, then lowering serum uric
acid concentrations might allow restoration of endothelial function.
13.1.1 Urate oxidase
Urate oxidase (E.C. 1.7.3.3) is an enzyme that catalyses the oxidation of uric acid to
allantoin in virtually all other species apart from man and higher apes. Allantoin is
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around 5-10 times more water soluble at tubular pH than uric acid, and is readily
excreted by the kidneys [305], Humans remain exposed to low circulating
concentrations of allantoin arising from non-enzymatic oxidation, particularly in the
setting of oxidative stress. A normal reference range for allantoin (expressed as a
percentage of circulating uric acid concentrations) has been proposed as 2-8% in
healthy subjects [306, 307],
Early pharmaceutical preparations of fungal origin had been used to successfully
treat severe hyperuricaemia in patients who were allergic to allopurinol, but were
associated with a high rate of anaphylactoid reactions and allergy [308], More
recently, the enzyme has been synthesised on a much wider scale using recombinant
technology, and a number of highly purified preparations are now available. For
example, parenteral administration of rasburicase has been shown to be effective in
treating and preventing severe hyperuricaemia in the setting of tumour lysis
syndrome in children and adult patients [309], At present, it is licensed for use within
a number of European countries, and available in the United Kingdom on a named
patient basis only. It has been shown to cause profound reductions in circulating and
urinary uric acid concentrations, thereby allows restoration of normal renal function
in the setting of acute uric acid nephropathy [110]. Rasburicase is well tolerated, and
principal adverse effects reported are headache (1.8%), fever (1.4%) and allergic-
type reactions (0.7%) [309].
The use of rasburicase is associated with dramatic reductions in circulating serum
uric acid concentrations, for example lowering concentrations from 11.3 to 0.2 g/dl
(672 to 12 mmol/1) in children and from 13.1 to 0.3 g/dl (779 to 18 mmol/1) in adult
patients with severe hyperuricaemia [309], To reduce normal or modestly elevated
serum uric acid concentrations might require lower doses than have conventionally
been used in oncology patients. The present study was designed to identify the most
appropriate dose of urate oxidase that would allow substantial lowering of serum
concentrations, and yet minimise the potential risks associated with drug exposure.
This would allow the potential cardiovascular effects of uric acid lowering, by means
of urate oxidase administration, to be examined in subsequent studies. Urate oxidase
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itselfmight exert a direct effect on cardiovascular function, which might be an
important confounder. Therefore, an additional objective of the present study was to
characterise the duration of uric acid lowering after a single systemic administration
of urate oxidase. The optimum time to examine cardiovascular function in future
studies would be selected as the longest possible time after urate oxidase
administration at which substantially lowered uric acid concentrations persist.
13.2 Methods
13.2.1 Dose-finding study
Two healthy men aged 33 and 36 years were studied in a 5-step single ascending
dose study. Both underwent systemic administration of urate oxidase 0, 0.375, 0.75,
1.125 and 1.5 mg by bolus intravenous administration during separate visits at least 1
week apart. The timing of placebo during dose escalation was randomly allocated.
Venous blood was collected for serum uric acid measurement at baseline and at 0.25,
0.5, 0.75, 1, 2, 4, 12, 24, 48, 72, and 96 h after drug administration.
13.2.2 Main protocol
Eight patients with type 2 diabetes and 8 age and sex-matched healthy control
subjects were recruited to a two way, randomised, placebo-controlled, crossover
study. An 18-standard gauge intravenous cannula was inserted into a suitable vein of
the non-dominant antecubital fossa, using local anaesthetic and aseptic technique.
Subjects rested semi-supine for 20 min to establish baseline haemodynamic
conditions, and underwent intravenous administration of urate oxidase (rasburicase,
Sanofi-Synthelabo, Paris, France) 1.5 mg in 10 ml 0.9% saline, or saline alone, over
1 min. Augmentation index was determined by pulse wave analysis, heart rate and
blood pressure were recorded in the dominant arm immediately pre-dose, and at 15
min intervals up to 60 min after drug administration.
The venous cannula was removed, and subjects were allowed to leave and asked to
return the next day. At 24 h post-dose, subjects rested supine for at least 20 min, and
repeat haemodynamic measurements were recorded. Subjects underwent insertion of
a 27-standard wire gauge steel needle into the non-dominant forearm, using local
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anaesthetic and aseptic technique, to allow intra-brachial administration of
acetylcholine 7.5, 15 and 30 pg/min, sodium nitroprusside 2, 4 and 8 pg/min, and L-
NMMA 2 and 4 mmol/min. 0.9% saline was infused for 30 min before vasoactive
drug administration, and for 20 min between drugs to allow establishment of baseline
blood flow. The order of infusion of acetylcholine and sodium nitroprusside was
randomised between subjects, and kept constant between visits. Blood flow was
measured in both forearms by venous occlusion plethysmography during the last 3
min of each 6 min infusion.
Forearm blood flow responses after administration of urate oxidase or placebo were
compared using two-way analysis of variance and post-hoc t tests.
13.3 Results
The dose-finding study showed that administration of urate oxidase caused a dose
and time-dependent lowering of serum uric acid concentrations. The greatest
pharmacodynamic effect was observed between 12-24 h after administration of the
maximum dose studied (1.5 mg). No adverse events occurred in any subject enrolled
in either the dose-finding study or the main protocol.
Table 37. Mean ± SD percentage change in serum uric acid concentration after
systemic urate oxidase administration. *p < 0.05, **p < 0.01 compared to baseline.
Administered dosage of urate oxidase (mg)
Time post-dose (h) 0 0.375 0.75 1.125 1.5
1 0 ± 3 -10 ± 3* -10 ± 7 -30 ± 6** -40 ± 13**
2 -1 ±6
**
-10 ± 2 -10 ± 9 -23 ± 6**
. _ _ **
-43 ± 3
4 -3 ±8 -12 ± 10 -16 ± 11* -33 ± 15* -70 ±41**
12 -2 ±4 -6 ±4 -18 ± 12** -39 ±28 -79 ± 17**
24 6 ± 8 0 ± 22 -27 ± 21* -48 ± 22** $ *-79 ± 8
48 - - -6 ±4 -21± 12* **-56 ± 12
72 - - - -2 ±9
$
-19 ± 11
96 - - - 0 ± 3 -3 ±4
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Table 38. Baseline characteristics of the study population, shown as mean ± SEM.
*p < 0.05, **p < 0.01 compared to healthy controls.
Characteristic Healthy controls Patients with
type 2 diabetes
Number/ male 10/6 10/6
Age (y) 43 ±3 42 ±3
Height (m) 1.75 ± 0.11 1.76 ±0.10
Weight (kg) 96 ±8 114 ± 21*
Body mass index (kg/m2) 28.9 ±4.9 36.7 ±6.4*
Heart rate (min"1) 71 ±7 73 ±8
Systolic BP (mmHg) 123 ± 15 124 ± 17
Diastolic BP (mmHg) 76 ± 11 75 ± 10
Serum creatinine (pmol/1) 71 ± 12 77 ± 18
Serum cholesterol (mmol/1) 4.1 ±0.8 4.0 ±1.1
Total: HDL cholesterol ratio 4.4 ± 1.5 5.0 ±2.7
Serum triglycerides (mmol/1) 1.5 ±0.7 1.9 ± 1.0
Plasma glucose (mmol/1) 4.1 ±0.9 6.8 ±2.0**
HbAlc (%) 5.8 ± 1.9 7.7 ±2.6
Haematocrit (ratio) 0.41 ±0.03 0.39 ±0.04
Serum urate (p.mol/1) 268 ± 28 349 ± 54*
Patients with type 2 diabetes had higher mean plasma glucose and serum uric acid
concentrations compared to controls, but these did not vary significantly between
visits. Blood pressure and serum cholesterol concentrations were well matched.
13.3.1 Serum Uric Acid Concentrations
Table 39. Serum uric acid concentrations before and 24 h after systemic
administration of urate oxidase 1.5 mg. *p < 0.001 compared to baseline.
Healthy controls Patients with Type 2 diabetes
Saline Urate oxidase Saline Urate oxidase
Pre-dose 264 ± 28 276 ± 33 344 ± 58 350 ±45
24 h 249 ±31 102 ±14* 328 ±57 118 ±39*
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13.3.2 Large arterial stiffness and systemic haemodynamics
Patients with type 2 diabetes and healthy controls had mean ± SEM augmentation
index values of 2.0 ± 1.7 and 13.1 ± 2.3% respectively (p = 0.006). Administration of
urate oxidase had no acute effects on systemic haemodynamics in either group.
Furthermore, augmentation index and haemodynamic variables were similar between
pre-dose and 24 h post-dose values, despite lowered serum uric acid concentrations.
Table 40. Mean ± SEM augmentation index and systemic haemodynamic variables
before and after administration of urate oxidase 1.5 mg or saline.
Healthy controls Patients with type 2 diabetes
Saline Urate oxidase Saline Urate oxidase
AIx (%) Pre-dose 2.0 ± 1.5 1.8± 1.3 13.4 ±2.4 12.6 ±2.3
24 h 1.9 ± 1.4 2.1 ± 1.1 14.0 ±2.0 14.5 ±2.0
Heart rate Pre-dose 70 ±3 72 ±2 76 ±3 71 ±2
(min"1) 0.5 h 70 ±3 71 ±3 75 ±2 71 ±2
1 h 71 ±3 70 ±2 76 ±3 71 ±2
24 h 70 ±3 71 ±3 71 ±2 71 ±2
Systolic BP Pre-dose 123 ±4 123 ±4 124 ±4 124 ±5
(mmHg) 0.5 h 124 ±4 125 ±4 120 ±5 128 ±4
1 h 122 ±5 124 ±4 120 ±4 125 ±4
24 h 123 ±4 123 ±4 122 ±4 121 ±3
Diastolic BP Pre-dose 76 ±2 76 ±3 76 ±3 75 ±2
(mmHg) 0.5 h 75 ±3 76 ±3 74 ±2 75 ±3
1 h 76 ±3 77 ±3 75 ±2 80 ±3
24 h 77 ±3 76 ±3 76 ±2 76 ±2
13.3.3 Endothelial Function
Forearm blood flow responses to acetylcholine and L-NMMA were lower in patients
with type 2 diabetes than healthy controls (p = 0.008 and p = 0.02 respectively by
ANOVA). Blood flow responses to sodium nitroprusside did not differ significantly
between patients with type 2 diabetes and healthy controls. Urate oxidase
administration had no effect on forearm blood flow responses in either group.
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Figure 25. Mean ± SEM forearm blood flow responses to acetylcholine (ACh) 7.5-30
pg/min, sodium nitroprusside (SNP) 2-8 pg/min and L-NMMA 2-4 pmol/min in
patients with type 2 diabetes and healthy controls, 24 h after administration of 10 ml
0.9% saline. *p < 0.05, **p < 0.01 by ANOVA.
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Figure 26. Mean ± SEM forearm blood flow responses to acetylcholine (ACh) 7.5-30
pg/min, sodium nitroprusside (SNP) 2-8 pg/min and L-NMMA 2-4 pmol/min in
patients with type 2 diabetes 24 h after administration of urate oxidase 1.5 mg in 10

























































Figure 27. Mean ± SEM forearm blood flow responses to acetylcholine (ACh) 7.5-30
pg/min, sodium nitroprusside (SNP) 2-8 pg/min and L-NMMA 2-4 pmol/min in
healthy controls 24 h after administration of urate oxidase 1.5 mg in 10 ml 0.9%
saline or saline alone.
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13.4 Discussion
The pilot dose-finding study showed that administration of urate oxidase caused a
dose-dependent reduction in circulating uric acid concentrations. The maximum dose
(1.5 mg) caused around a four-fifths reduction from baseline concentrations at 24 h
after single administration. This was followed by a time-dependent restoration of
serum uric acid concentrations towards baseline values. On the basis of these
findings, the main protocol adopted a single bolus administration of 1.5 mg urate
oxidase 24 h before cardiovascular assessment. This dose is lower than that used in
the treatment of severe hyperuricaemia, typically 0.2 mg/kg daily for up to 7 days
[309]. Furthermore, administration of urate oxidase 24 h before studies of
cardiovascular function would coincide with maximal uric acid lowering. Urate
oxidase activity is likely to be negligible at this time, based on pharmacokinetic data
from animal and human studies [310, 311], thereby avoiding possible confounding
effects on vascular function.
Blood glucose control was good in patients with type 2 diabetes, as evidenced by the
haemoglobinAic values at baseline screening, and blood pressure and serum
cholesterol concentrations were well matched between patients and controls. Patients
with type 2 diabetes had higher serum uric acid concentrations than healthy subjects,
in keeping with previously published data. As expected, administration of urate
oxidase caused a significant reduction in serum uric acid concentration at 24 h post-
dose in patients with diabetes and healthy controls. The effect was of greater
magnitude than that reported for other pharmacological interventions in previous
studies, including administration of allopurinol.
Baseline augmentation index was significantly higher in patients with type 2 diabetes
indicating increased large arterial stiffness in this group, as reported in previous
studies. Despite achieving a substantial reduction in circulating uric acid
concentrations, urate oxidase administration had no effect on augmentation index
values in patients with diabetes or healthy controls. Therefore, lowering serum uric
acid concentrations, at least in the acute setting, had no effect on large arterial
compliance.
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Forearm blood flow responses to acetylcholine were lower in patients with type 2
diabetes, indicating impaired endothelium-dependent nitric oxide-mediated blood
flow in this group, as previously described. Responses to L-NMMA were
significantly lower in patients with diabetes, indicating that there is also impairment
of constitutive endothelium-dependent nitric oxide bioavailability. Forearm blood
flow responses to sodium nitroprusside were similar between both groups, although
the small subject numbers do not fully exclude a small difference in responsiveness
between groups, which might represent a type 2 statistical error. Nonetheless, this
observation indicates that endothelium-independent vascular responsiveness to nitric
oxide is preserved in patients with type 2 diabetes. These observations are consistent
with impaired nitric oxide-mediated endothelial function in patients with type 2
diabetes, as reported in previous studies. Urate oxidase administration had no effect
on forearm blood flow responses in either group, demonstrating that lowering serum
uric acid concentrations does not improve endothelial function in patients with type 2
diabetes. Previous reports have shown that administration of allopurinol improves
endothelial function in patients with type 2 diabetes. The present findings suggest
that mechanisms other than uric acid lowering might be responsible for the beneficial
effects of allopurinol, for example direct antioxidant effects or inhibition of xanthine
oxidase-dependent free radical liberation.
The lack of improvement in endothelial function in the setting of lowered uric acid
concentrations is distinct from the rapid restoration of endothelial function caused by
amelioration of other major cardiovascular risk factors, for example smoking
cessation, blood pressure lowering and cholesterol reduction. The present findings
suggest that raised serum uric acid concentrations in patients with type 2 diabetes do
not contribute to large arterial stiffness and endothelial dysfunction.
With respect to the control group, neither urate oxidase nor uric acid lowering per se
appeared to have any influence on vascular function in healthy individuals. This
suggests that acute withdrawal of uric acid, and its free radical scavenging
antioxidant properties, is not immediately detrimental. It is possible that very small
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amounts of uric acid, accompanied by the presence of other antioxidants, are
sufficient to maintain vascular integrity in the absence of oxidative stress.
A limitation of the present study is that only short-term measures of large arterial
stiffness and endothelial function were examined, and the effects of long-term
lowering of serum uric acid concentrations could not be addressed. A further
potential limitation is that plasma glucose concentrations were higher in patients with
type 2 diabetes than healthy subjects, and hyperglycaemia is a recognized cause of
impaired endothelial function. However, plasma glucose concentrations were less
than 9.8 mmol/1, and generally well controlled in patients, as evidenced by baseline
HbAic concentrations. Plasma glucose concentrations were similar between visits
and, therefore, unlikely to influence the effect of treatment.
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Chapter 14.
Conclusions and Future Research
14.1 Summary
This material presented in this thesis describes the development of an aqueous
vehicle to allow administration of uric acid in a research setting. This has allowed the
potential cardiovascular effects of raising serum uric acid concentrations to be
studied in vivo. Acute elevation of local and systemic uric acid concentrations does
not exert any direct effect on endothelial function, large arterial stiffness or systemic
haemodynamic variables in healthy people. High serum uric acid concentrations
confer increased antioxidant capacity, and protect against oxidative stress during
acute aerobic exercise in healthy people.
Regular smokers and patients with type 1 diabetes mellitus are characteristically
exposed to oxidative stress and vascular dysfunction in vivo, thought due to the
activity of excess oxygen-derived free radicals. Both groups were found to have
lower baseline serum uric acid concentrations than healthy subjects. Raising serum
uric acid concentrations, by means of systemic administration, was found to increase
serum antioxidant capacity and caused improvement of endothelium-dependent
vasodilator forearm responses in regular smokers and patients with type 1 diabetes.
These observations suggest that low serum uric acid concentrations might contribute
to vascular dysfunction in smokers and patients with type 1 diabetes, as a
consequence of diminished antioxidant defences, and that raising serum uric acid
concentrations confers protection against oxidative stress.
Patients with type 2 diabetes were found to have higher serum uric acid
concentrations than healthy controls, accompanied by impaired endothelium-
dependent vascular function and large arterial stiffening. Reducing serum uric acid
concentrations, by means of urate oxidase administration, did not influence
endothelial function, large arterial stiffness or resting haemodynamic variables in
patients with type 2 diabetes mellitus. These observations suggests that high serum
uric acid concentrations do not contribute to vascular dysfunction in patients with
type 2 diabetes mellitus or healthy subjects.
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A major limitation of the studies outlined in the thesis is that only short-term
cardiovascular effects of raising or lowering serum uric acid concentrations have
been examined. Cardiovascular risk, and the development of atherosclerosis are
likely to be influenced by chronic exposure to risk factors. The studies were designed
to address the potential effects of high and low serum uric acid concentrations on
mechanisms intimately linked to the development of atherosclerosis, which other
established cardiovascular risk factors are known to impair. However, this appears to
be a valid approach because there is good correlation between short-term and long-
term effects of exposure to cardiovascular risk factors and interventions that modify
cardiovascular risk [281, 282, 312],
14.2 Clinical Relevance
There is a widely held perception that uric acid is an independent cardiovascular risk
factor, based on strong epidemiological associations between high serum
concentrations and increased cardiovascular risk. To date, no biologically plausible
link between high serum uric acid concentrations and mechanisms of atherosclerosis
has been established. If the relationship between high serum uric acid concentrations
and cardiovascular risk were causal, then treatment to lower serum uric acid
concentrations might provide an effective means of preventing or treating
cardiovascular disease.
The studies described in this thesis found that acute exposure to high serum uric acid
concentrations caused no detrimental effects on vascular function in healthy people,
regular smokers or patients with diabetes. Lowering uric acid concentrations did not
cause improved endothelial function in healthy people or those with type 2 diabetes.
Moreover, high uric acid concentrations conferred protection against acute oxidative
stress, and improved vascular function in patients typically exposed to chronic
oxidative stress. These observations show that high serum uric acid concentrations
do not exert any acute detrimental effects on endothelial function, an important
surrogate marker for atherosclerosis, unlike established major cardiovascular risk
factors. These findings do not support the hypothesis that high serum uric acid
concentration might be an independent cardiovascular risk factor.
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14.3 Future Research
Overall, the data presented in this thesis support the view that high uric acid
concentrations are not deleterious to vascular function. Therefore, serum
concentrations might serve as a passive marker of risk, and further work is required
to explore the potential clinical utility of uric acid measurement, so as to allow better
cardiovascular risk stratification.
High uric acid concentrations were found to protect against oxidative vascular
damage in the setting of acute oxidative stress, and to restore vascular function in
patients exposed to chronic oxidative stress. The mechanisms by which uric acid
improved vascular function in regular smokers and patients with type 1 diabetes
require further evaluation. These observations suggest that high uric acid
concentrations might perhaps be a compensatory response, in the setting of increased
cardiovascular risk. Low serum uric acid concentrations might be an important
contributory factor to endothelial dysfunction in these groups, and the underlying
mechanisms need further exploration.
The increase in serum antioxidant capacity conferred by uric acid administration
might have therapeutic potential in conditions associated with oxidative stress. This
is likely to have greatest utility if applied in the setting of acute oxidative stress, for
example ischaemic stroke or myocardial reperfusion injury, so as to avoid the
potential adverse consequences of chronic exposure to high serum uric acid
concentrations. Uric acid administration has previously been found to minimise
tissue damage associated with acute ischaemia in animal models, and requires
confirmation in a clinical setting.
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APPENDIX
Comparison of enhanced chemiluminescence and 'Total Antioxidant
Status' assays
A number of assays have been developed for determining the total radical-
scavenging antioxidant capacity of biological fluids, which may be preferable to
measures of specific antioxidant concentrations or activities. Global antioxidant
measurements may be more physiologically relevant because they take account of
potential synergistic interactions between antioxidants that appear to be important in
vivo. Antioxidant capacity determines the ability of serum to oppose the effects of
oxidants, including free radicals, and provide a sensitive and reliable marker of
defences against oxidative stress in vivo, not easily reckonable from measures of
individual antioxidant concentrations.
The Total Radical trapping Ability of Plasma (TRAP) assay was one of the earliest
methods developed, and is based on inhibition of pro-oxidant activity by antioxidants
contained in biological fluids, and has been widely considered the gold standard
method [313], However, it is associated with significant variability and complex
methodology, and a variety ofmore simple, rapid methods based on
chemiluminescence or spectrophotometry have been described [314-316]. Assays of
antioxidant capacity provide a single measure within a dynamic system, which can
be influenced by several metabolic and physiological parameters not related to
oxidative stress. Therefore, interpretation depends on the conditions under which the
measurement is determined. Measurements of serum antioxidant capacity by
chemiluminescence and 'Total Antioxidant Status' assays were compared.
Methods
Baseline antioxidant capacity measurements were compared in 34 samples collected
from healthy subjects who had fasted overnight. Additionally, assay measurements
were compared across samples collected at 0, 15, 30, 45, 60, 90, and 120 min after
commencing systemic administration of uric acid 1000 mg or vitamin C 1000 mg,
over lh, in 10 healthy subjects.
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Intra-assay precision was calculated as the mean of duplicate standard deviations -r
grand mean of the duplicates. The inter-assay coefficient of variation was calculated
as the standard deviation of the duplicate means h- grand mean of the duplicates.
These measures of analytical precision were expressed as percentages and used to
represent reproducibility and repeatability respectively for each assay. Antioxidant
capacity was compared between assays using Spearman's Rank Correlation.
Results
Kolmogorov-Smirnov tests indicated that baseline chemiluminescence and 'Total
Antioxidant Status' assay measurements were normally distributed; Kurtosis values
were 0.68 and -0.96 respectively, and skewness values were 1.07 and 0.23
respectively. Baseline antioxidant values given by both assays were 469 ± 20 and
1272 ± 13 pmol/1 respectively. Intra-assay precision was 9.9 % and 7.9 %
respectively, inter-assay precision 8.9% and 5.4% respectively, and inter-individual
variation 34.6% and 8.3% respectively for chemiluminescence and 'Total
Antioxidant Status' assays.
In baseline samples (n = 34), correlation between both assays was poor (R = 0.37, p
= 0.03), and correlation between baseline serum uric acid concentrations and
antioxidant capacity was poor for chemiluminescence (R = -0.04, p = 0.01) and
'Total Antioxidant Status' (R = -0.29, p = 0.06) assays.
During vitamin C administration, correlation between both assays measurements was
poor (R = -0.17, p = 0.09). The increments in antioxidant capacity from baseline also
correlated poorly between both assays during vitamin C administration (R = -0.13, p
= 0.26). However, a good correlation was found between measurements given by
both assays during uric acid administration (R = 0.67, p < 0.01), and the increment
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Appendix Figure 1. Correlation between chemiluminescence (ECL) and 'Total
Antioxidant Status' (TAS) assays for (A) actual measurements and (B) changes from
baseline during systemic administration of vitamin C. p = 0.088 (n = 70) and p =
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Appendix Figure 2. Correlation between chemiluminescence (ECL) and 'Total
Antioxidant Status' (TAS) assays for (A) actual measurements and (B) changes from
baseline during systemic administration of uric acid 1000 mg. p < 0.001 (n = 70) and
p < 0.001 (n = 60) respectively by Spearman's Rank Correlation.
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Discussion
There was a poor correlation between the assays, suggesting that they are
predominantly influenced by different serum antioxidants. The much greater inter-
individual variation in the chemiluminescence assay reflects differences between
each method. Chemiluminescence is influenced by antioxidants that are capable of
completely suppressing light emission, and is heavily dependent on potent and
effective antioxidants, including urate and vitamin C, and is less sensitive to weaker
ones. On the other hand, the 'Total Antioxidant Status' assay is influenced by a
variety ofpotent and less potent antioxidants, which exert a cumulative antioxidant
effect on indicator absorption. The latter, therefore, provides a global measure of
antioxidant capacity that is based on a variety of factors, and does not discriminate
between them based on potency. The latter is more likely to be influenced by less
potent antioxidant factors, for example albumin, which may account for the lower
inter-individual variation seen because albumin concentrations are similar across
healthy individuals.
There was close correlation between the assays during uric administration, indicating
that both are comparatively sensitive to the contribution of urate to overall serum
antioxidant capacity. Surprisingly, no correlation was found between baseline serum
urate concentrations and antioxidant capacity measurements given by either assay.
Such a relationship may not have been apparent because of the low urate
concentrations and narrow range of values found in the present study population. A
relationship between urate concentration and antioxidant capacity has previously
been demonstrated more clearly in populations with a broad range of serum urate
concentrations, for example in patients with sepsis and obesity [316, 317].
Overall there was no correlation between baseline serum antioxidant measurements
made by both assays in a healthy population. Both appear sensitive to increases in
circulating serum urate concentrations. However, the marked difference in inter-
individual variability between the ECL and TAS assay strongly implies that each is
sensitive to different antioxidant factors.
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Hyperuricaemia does not impair cardiovascular function in
healthy adults
W S Waring, S H Adwani, 0 Breukels, D J Webb, S R J Maxwell
Heart 2004;90:155-159. doi: 10.1136/hrt.2003.016121
Objective: To investigate the possibility that uric acid (UA) can impair endothelial function, an important
surrogate for atherosclerosis.
Design: UA was administered locally or systemically to healthy adult men and women in a series of
randomised placebo controlled studies. This temporarily raised serum UA concentrations, so that the
potential effects of hyperuricaemia on mechanisms of cardiovascular disease could be studied.
Main outcome measures: The effects of UA administration on basal blood flow and responses to locally
administered acetylcholine, sodium nitroprusside, and l-N^monomethylarginine were studied in the
forearm vascular bed with venous occlusion plethysmography. The effects of hyperuricaemia on systemic
vascular resistance, large artery compliance, and baroreflex sensitivity were examined by validated non¬
invasive techniques.
Results: UA administration caused a twofold increase in serum concentrations. However, there were no
acute effects on haemodynamic variables, basal forearm blood flow, or nitric oxide dependent endothelial
function.
Conclusion: Unlike other risk factors associated with endothelial dysfunction, acute exposure to high
concentrations of UA does not impair cardiovascular function in healthy men. These findings do not
support a causal link between hyperuricaemia and atherosclerosis.
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Uric acid (UA) is formed as a natural product of purinemetabolism. Humans are exposed to comparativelyhigh serum and tissue concentrations because of th
lack of urate oxidase, an enzyme that is responsible for
further metabolism of UA in virtually all other species.1 A
physiological role of UA has been suggested on the basis of its
potent antioxidant properties,2 although this potential benefit
may be gained at the cost of an increased risk of joint and
kidney disease. Epidemiological studies have identified a
strong relation between hyperuricaemia and subsequent
cardiovascular disease risk in unselected populations'" and
high risk groups, including patients with hypertension,
diabetes mcllitus, and chronic cardiac failure.*"* This relation
has been attributed to associations between UA and potential
confounding risk factors.' However, several epidemiological
studies have shown that the predictive power of hyper¬
uricaemia persists, even after considering these risk factors.4 5
The distinction between UA as a coincidental or causal risk
factor is important because, if UA is causal, treatment to
lower scrum UA concentrations may potentially reduce
cardiovascular disease risk. Epidemiological studies are
unlikely to resolve this issue. Given the high prevalence of
cardiovascular disease, there is a pressing need to identify
additional treatable risk factors. The role of UA in the
cardiovascular system is poorly understood and potential
mechanisms by which it may promote atherogcncsis have
received little attention."
In health, the endothelium plays a pivotal part in
regulating the cardiovascular system through the release of
nitric oxide, which causes vasodilatation, inhibits platelet
aggregation, and reduces local vascular inflammation."'
Impaired blood flow responses to endothelium dependent
vasodilators are a characteristic finding in patients with any
one of several major cardiovascular risk factors and are
thought to be an important early step in the development of
atherosclerosis." 12 Disruption of endothelium dependent
nitric oxide bioavailability also manifests as reduced large
artery compliance" and impaired baroreflex sensitivity
(BRS)." An inverse relation between serum UA concentra¬
tion and nitric oxide activity has been identified," and it is
therefore possible that UA directly influences endothelial
function, either by causing endothelial dysfunction or, as an
antioxidant, by protecting against the impairment of
endothelial function. One study has reported a lower
cardiovascular mortality among patients with heart failure
treated with allopurinol and the authors attributed this to
lowering of serum UA," although there may be other
explanations. The feasibility of administering UA in solution,
for clinical studies, has recently been established." The
purpose of the present research was to determine whether
raised UA concentrations disrupt nitric oxide mediated
vascular function, in the same manner as established
cardiovascular risk factors. Therefore, the cardiovascular
effects of acute hyperuricaemia were studied in healthy




The local research ethics committee granted approval for the
studies and written informed consent was obtained from
each participant. The investigation conforms to the principles
outlined in the Declaration of Helsinki. Participants were
recruited from a community database of healthy volunteers
held at the Clinical Research Centre of the University of
Edinburgh. Studies were performed in the morning, after an
overnight fast, in a quiet room maintained at 24-26°C.
Inclusion criteria were male or female sex and age 18 to 45
Abbreviations: ACh, acetylcholine; BP, blood pressure; BRS, baroreflex
sensitivity; L-NMMA, L-f/'-monomethylarginine; PI, pulse interval; SNP,
sodium nitroprusside; UA, uric acid
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years. Exclusion criteria were increased blood pressure (BP)
(> 160/100 mm Hg), clinical history of joint, kidney or
cardiovascular disease, any medication being taken, regular
tobacco use, scrum creatinine >110 pmol/1, or scrum UA
> 400 pmol/1.
Intra-arterial drug administration
The brachial artery of the non-dominant arm was cannulated
with a 27 standard wire gauge steel needle (Cooper's Needle
Works Ltd, Birmingham, UK) under local anaesthesia by an
aseptic technique. Vasoactive drugs were administered
through a 16 gauge epidural catheter (Portex Ltd, Kent,
UK) connected to an IVAC PI000 syringe pump (Alaris
Medical Ltd, Hampshire, UK)." Saline was infused for 30
minutes at the start of the study and for 20 minutes between
drugs to establish baseline blood flow. Vasoactive drugs were
infused for six minutes at each dose and the rate of infusion
was kept constant at 1 rnl/min throughout.
Measurement of forearm blood flow
Blood flow was measured in both forearms by venous
occlusion plethysmography, as previously described." "
Measurements were taken during the last three minutes of
each six minute infusion. The last five recordings were
averaged to determine flow in each arm. Responses were
expressed as percentage change from baseline, where the
ratio of blood flow in the infused to that in the non-infused
limbs was considered, to account for any systemic effects."
Systemic vascular resistance
BP was recorded in the dominant arm with a validated
oscillometry device (HEM-705CP, Omron, Kyoto, Japan)."
Cardiac index was assessed by transthoracic bioimpedance
(NCCOM3-R7, BoMed, Irvine, California, USA).2" The sys¬
temic vascular resistance index was calculated as the mean
arterial pressure divided by the cardiac index.
Pulse wave analysis
The dominant radial artery pulse waveform was assessed by
applanation tonometry (SPC-301 micromanometer, Millar
Instruments, Houston, Texas, USA). A corresponding aortic
pressure waveform was generated by pulse wave analysis
software (SphygmoCor, PWV, Sydney, Australia).2' The
augmentation index is a validated measure of large artery
stiffness, calculated as the difference between the first and
second central systolic BP peaks, expressed as a percentage of
pulse pressure.22
Spontaneous BRS
Study participants rested supine. Systolic BP was recorded
continuously by a Portapres system (TNO, Amsterdam, the
Netherlands) and an ECG was measured simultaneously.2124
Signals from both devices were recorded over 15 minutes and
analysed off line by Chart HRV software (ADInstruments,
Hastings, UK). BRS was determined by two independent
methods. Parallel increases or decreases in BP and pulse
interval (PI) arc thought to represent spontaneous baroreflcx
activity.2' Sequences of parallel increases or decreases over
two or more consecutive beats were analysed and the
resulting slope (API/ABP) was used to represent BRS by
sequence analysis.25 Fast Fourier transformation of BP and PI
data gave the total spectral power of the variability of each
and the formula (powerI!P/powerPI) 71 gave spontaneous BRS
by spectral analysis.26
Measurement of biochemical variables
Blood was collected in gel tubes (Sarstedt Ltd, Leicester, UK),
allowed to clot, and centrifuged at 1000 g for 10 minutes.
Serum was separated and UA concentration was determined
by a colorimetric dry slide method (Vitros, Ortho-Clinical
Diagnostics, Amersham, UK).
Drugs and reagents
UA and lithium carbonate (Ultrapure preparations, Sigma
Chemical Company, Poole, UK) were reconstituted in a sterile
dextrose solution (Baxter Healthcare, Norfolk, UK) and
filtered (0.22 pm Millcx, Milliporc, Molshcim, France).
The drugs used were acetylcholine (ACh; CIBAVision-
Ophthalmics, Southampton, UK), sodium nitroprusside
(SNP; David Bull Laboratories, Warwick, UK), and l-Ng-
monomethylarginine (L-NMMA; Calbiochem-Novobiochem,
Nottingham, UK).
Basal forearm blood flow
Six healthy men aged 29 (4) years (SEM) were recruited to a
two way randomised placebo controlled study. Participants
underwent intra-arterial administration of saline for 20
minutes to establish baseline blood flow, followed by
infusion of 0, 0.5, 1.0, 2.0, and 4.0 mg/min UA in 4%
dextrose/0.1% lithium carbonate vehicle for six minutes at
each dose and for 12 minutes at the maximum dose. Forearm
blood flow was assessed at baseline and during each infusion.
Local hyperuricaemia and endothelial function
Ten healthy men were recruited to a two way randomised
placebo controlled study. They underwent intra-arterial
administration of saline for 30 minutes to establish baseline
blood flow, followed by ACh 7.5, 15, and 30 mmol/min, SNP
2, 4, and 8 mmol/min, and L-NMMA 2 and 4 pmol/min,
where the order of infusion of ACh and SNP was randomised
between subjects. Drug infusions were separated by saline for
20 minutes to allow restoration of basal blood flow. Dntgs
were infused for six minutes at each dose." UA 2.0 mg/min
in 4% dextrose/0.1% lithium carbonate vehicle or vehicle
alone was co-infused locally. Effluent venous blood (5 ml)
was collected from each forearm during infusion for UA
measurement.
Systemic hyperuricaemia and endothelial function
Ten healthy men were recruited to a two way randomised
placebo controlled study. An 18 standard gauge venous
cannula was inserted into a suitable vein in each antecubital
fossa under local anaesthetic. Participants underwent sys¬
temic administration of 1000 mg UA in 4% dextrose/0.1%
lithium carbonate vehicle or vehicle alone over one hour
through the cannula in the non-dominant forearm.
Immediately after infusion, endothelial function was studied
as described above. Venous blood (5 ml) was drawn from the
non-infused forearm cannula at baseline, immediately after
infusion, and one hour after infusion for UA measurement.
Systemic haemodynamic variables
Eight healthy men were recruited to a three way randomised
placebo controlled study. An 18 standard gauge venous
cannula was inserted into a suitable vein in each antecubital
fossa under local anaesthetic. Portapres finger cuff and
BoMed electrodes were applied. Participants rested supine for
30 minutes, then underwent systemic administration of
1000 mg UA in 500 ml 4% dcxtrose/0.1% lithium carbonate
vehicle, vehicle alone, or 0.9% saline over one hour through
the non-dominant forearm cannula. Electrocardiogram and
Portaprcs signals were recorded for BRS determination at
baseline and at the end of the infusion. BP, cardiac index,
and pulse wave analysis (PWA) were measured at baseline
and at 15 minute intervals. Venous blood (5 ml) was drawn
through the non-infused forearm cannula at baseline and
immediately after infusion for UA measurement.
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Data analysis and statistics
Numbers of study participants were determined to give at
least 80% power to detect a 10% difference in the primary
outcome variables (forearm blood flow response to ACh,
augmentation index, and BRS). Responses were compared by
two way analysis of variance and paired Student's t tests,
where appropriate. Significance was accepted at the 5% level
in all cases. All values are reported as mean (SEM).
RESULTS
Table 1 shows baseline characteristics of the study partici¬
pants.
Basal blood flow
Local administration of neither vehicle nor UA had any effect
on basal forearm blood flow (fig 1). Local UA and vehicle
administrations caused systemic UA concentrations to rise by
62 (13) and -4 (3) pmol/1, respectively (p < 0.001); 69 mg
(about 410 pmol) UA was administered to each subject and
the mean volume of distribution was calculated to be 22.6
(2.0) 1.
Local hyperuricaemia and endothelial function
Venous effluent UA concentrations in the infused and non-
infused forearms were 384 (7) and 280 (1) pmol/1, respec¬
tively, during UA administration (p < 0.001) and 290 (4)
and 283 (1) pmol/1, respectively, during vehicle administra¬
tion. This was an increase of 33 (3)% and of -1 (0)% during
UA and vehicle administration, respectively (p < 0.001).
Despite this, responses to ACh, SNP, and L-NMMA were
unaltered in the forearm vascular bed (fig 2).
Systemic hyperuricaemia and endothelial function
Scrum UA concentrations before, immediately after, and one
hour after infusion were 227 (8), 534 (18), and 452
(11) pmol/1, respectively, for UA administration and 224
(27), 220 (27), and 217 (27) pmol/1, respectively, for vehicle
administration. These were increases of 145 (19)% and -4
(1)% for UA and vehicle, respectively (p < 0.001). Forearm
blood flow responses to ACh, SNP, and L-NMMA infusion
were not altered by systemic hyperuricaemia (fig 3).
Systemic haemodynamic variables
Baseline versus post-infusion serum UA concentrations were
336 (12) v 350 (1) pmol/1, 370 (17) v 361 (17) pmol/1, and 370
(16) v 627 (23) pmol/1 (p < 0.001) for saline, vehicle, and UA
administration, representing increases from baseline of
-4 (1)%, -2 (1)%, and 79 (7)%, respectively (p < 0.001).
Augmentation index, central systolic BP, BRS by sequence
analysis, and BRS by spectral analysis were not altered by
systemic hyperuricaemia (table 2). The systemic vascular
Table 1 Study subjects baseline characteristics
Local UA Systemic Systemic
and UA and UA and
endothelial endothelial haemodynamic
function function variables
Number/men 10/10 10/6 8/8
Age (years) 23(1) 24(1) 30 (4)
Systolic BP (mm Hg) 110 (4) 107 (6) 108 (3)
Diastolic BP (mm Hg) 68 (5) 71 (4) 72 (3|
Heart rate (beats/min) 59(2) 58 (3) 60(2)
Body mass index (kg/m2) 23 (1) 22(1) 23 (0)
Creatinine (pmol/l) 84 (4) 84 (6) 86 (3)
Glucose (mmol/l) 4.6 (0.2) 4.8 (0.1) 4.7 (0.3)
Cholesterol (mmol/l) 4.1 (0.2) 4.1 (0.2) 4.8 (0.2)
Uric acid (gmol/l) 258(13) 252(14) 366(12)
Data are mean (SEM).
BP, blood pressure; UA, uric acid.
Figure 1 Pilot study. Forearm blood flow, as the ratio of the infused to
the non-infused forearm, expressed as percentage change from baseline
during local administration of uric acid (UA; 0, 0.5, 1.0, 2.0, and
4.0 mg/min) in the vehicle (n = 6).
resistance index increased during all infusions, with a non¬
significant trend towards lower increases during UA infusion
(table 2).
DISCUSSION
The importance of high serum UA concentration as a marker
of increased cardiovascular risk has been recognised for more
than 50 years.27 However, no biologically plausible causal link
to atherosclerosis has been shown in vivo. In the current
study, UA administration had no effect on basal forearm
blood flow or response to L-NMMA, indicating that short
lived hyperuricaemia does not have a direct impact on resting
vascular tone or basal nitric oxide release. Lack of effect on
endothelium dependent and endothelium independent vaso¬
dilator responses suggests that high UA concentrations do
not affect vascular smooth muscle nitrate responsiveness or
stimulate nitric oxide release in health.
There is a strong association between disease states
characterised by loss of vascular nitric oxide activity and
high serum UA concentrations. The present findings indicate
that acute hyperuricaemia does not directly influence
constitutive, or stimulated, nitric oxide liberation from the
vascular endothelium. A previous study has shown that
enhancing vascular nitric oxide bioavailability by L-argininc
supplementation causes a reduction in circulating UA
concentrations." Therefore, UA may be responsive to vascular
nitric oxide activity, consistent with a non-causal association
between endothelial dysfunction and increased serum UA
concentrations. Furthermore, UA is an important intracel¬
lular free radical scavenger during metabolic stress,2" for
example, in vascular smooth muscle and endothelial cells,2"
and circulating concentrations are thought to be responsive
to the local redox state.'"" Therefore, it is possible that
increased UA concentrations are a compensatory response, in
view of the antioxidant properties of UA.
Hyperuricaemia coexists with impaired large artery com¬
pliance in several disease states characterised by reduced
vascular nitric oxide bioavailability. UA had no impact on the
large conduit vessels that determine pulse waveform con¬
duction, suggesting that high concentrations are not causally
linked to increased vascular stiffness. BRS, determined by
two discrete methods," 26 was unaffected by UA, consistent
with the lack of effect on constitutive nitric oxide activity and
large artery compliance, which are important vessel wall
properties that can influence BRS. The lack of effect on BRS
also indicates that barorcceptor function, and indeed cardiac
sensitivity to autonomic outflow, was not affected by local
www.heartjnl.com





































Figure 2 Forearm blood flow responses to acetylcholine (ACh) 7.5, 15,
and 30 gg/min, nitroprusside (SNIP) 2, 4, and 8 gg/min, and L-P/3-
monomethylarginine (L-NMMA) 2 and 4 pmol/min, as a ratio of the
infused to the non-infused forearm and expressed as percentage change
from baseline during local co-administration of 2 mg/min UA in vehicle
or of vehicle alone (p = 0.74, 0.47, and 0.87, respectively; n = 10).
Figure 3 Forearm blood flow responses to ACh 7.5, 15, and 30 pg/
min, SNP 2, 4, and 8 pg/min, and L-NMMA 2 and 4 pmol/min, as a
ratio of the infused to the non-infused forearm and expressed as
percentage change from baseline after systemic administration of
1000 mg UA in vehicle or of vehicle alone (p = 0.87, 0.65, and 0.38,
respectively; n = 10).
increases in UA concentration, irrespective of vessel wall
conditions.
There arc several important limitations of these findings.
This scries of acute, mechanistic studies did not address the
effects of chronic exposure to increased serum UA concen¬
trations, which may be a more important determinant of
future cardiovascular risk. However, it is less feasible to
examine chronic hyperuricaemia in a controlled manner
because of the potential risks of joint and kidney disease. A
further potential limitation is that the current studies
addressed the effects of an acute increase of UA in a young,
healthy population, free from major cardiovascular risk
factors. Nonetheless, if UA were an independent causal risk
factor for atherosclerosis, then its presence should be
expected to impair endothelial function. Other atherosclerotic
risk factors cause acute impairment of endothelial function in
young, healthy people—for example, increased homocysteine
concentrations after methionine administration" or ingestion
Table 2 Systemic haemodynamic variables before and after systemic administration of 1000 ma UA in vehicle, vehicle alone,
or saline (n = 8) j, *. HI Hl-;"- 1
Saline Vehicle UA





SBP [mm Hg) ' ' Ajp 96 (3| 97(3) 93 (2) 97 |5) 96 (4) 100 (4)
DBP (mm Hg) 61 (2) 65 (2) 63 (3) 68 (3) 62 (4) 71 (3)
HR (beats/min) 55 (3) 53 (3) 57 (4) 58 13) 58 (3) 59 (21
Alx [%) -6.7 (6.0) -3.1 (6.1) -2.6 (6.0) -1.1 (6.1) -3.6 (5.1) -6.1 (6.2)
CI (l/min/m2) 3.3 (0.2) 3.0 (0.2) 3.3 (0.4) 3.3 (0.3) 3.1 (0.2) 3.2 (0.3)
5VRI (au) 12.0(1.0) 13.7(0.9) 10.2 (1.5) 11.7 (2.0) 12.3 (1.0) 13.0(1.0)
BRS^ (ms/mm Hg) 22.3 (4.7) 21.2 (4.0) 19.7 (4.9) 22.8 (5.0) 21.8 (4.4) 20.3 (4.4)
BRSjpec (ms/mm Hg) 24.3 (5.8) 19.4 (3.4) 22.2 (6.6) 26.8 (6.4) 23.4 (5.0) 21.7(5.9)
Data are mean (SEM).
Alx, augmentation index; au, arbitrary units; BRS„,q, baroreflex sensitivity by sequence anaiysis; BRSspeq, baroreflex sensitivity by spectral analysis; CI, cardiac
index; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure; SVRI, systemic vascular resistance index
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of a fatty meal." Additionally, amelioration of established
risk factors allows rapid restoration of endothelial function,
including correction of hypertension, hypercholesterolaemia,
or hypcrhomocystcinacmia.
A further limitation is that the effects of raising UA
concentrations on endothelial function were studied only in
healthy men. Previous studies have shown that the relation
between hyperuricaemia and increased cardiovascular risk is
more apparent in women, in both unselected populations'"
and those with established coronary artery disease."
Additional research is required to investigate the effects of
raised serum UA concentrations on endothelial function in
women. Furthermore, the effects of raised serum UA
concentrations merit further investigation in men and
women with established cardiovascular risk factors.
The effects of raising UA concentrations may be modest
because of the comparatively high background concentra¬
tions to which humans, as a species, are ordinarily exposed.
Further work is required to establish the cardiovascular
effects of lowering serum UA concentrations. Xanthine
oxidase inhibitors—for example, allopurinol—cause a mod¬
est reduction in circulating UA concentrations. Xanthine
oxidase activity produces hydrogen peroxide, an important
source of free radicals in vivo,'" which confounds the relation
between xanthine oxidase inhibitors and UA lowering.
Methods that lower UA directly should allow more useful
interpretation of any cardiovascular effects—for example,
using urate oxidase, which causes rapid and substantial
reductions in circulating UA concentrations."
In summary, high serum UA concentrations, at least in the
acute setting, do not impair cardiovascular function in
healthy men. These findings do not support a causal role
for UA in the development of atherosclerosis.
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Abstract
Background: Over recent years, interest in total antioxidant capacity measurement in biological fluids has increased. A
number of assays are now available, and we wished to compare an enhanced chemiluminescence (ECL) method to a
spectrophotometric method, the total antioxidant status (TAS) assay. Methods: Serum urate concentration, ECL and TAS were
measured in 34 healthy subjects. Additionally, 10 subjects participated in a two-way, randomised crossover study, and received
urate 1000 mg or vitamin C 1000 mg intravenously over 1 h. Serum ECL and TAS were measured at 0, 15, 30, 45, 60, 90 and
120 min after commencing infusion. Results: Baseline measurements were poorly correlated between ECL and TAS assays, and
between serum urate concentration and each antioxidant assay. There was good correlation between the change in antioxidant
capacity detected by both assays during urate infusion (/? = 0.79, /> < 0.001, n = 60), but not vitamin C infusion. Conclusions:
ECL and TAS measures of serum antioxidant capacity correlate poorly in a healthy population, although both are sensitive to
increases in circulating urate concentrations. Therefore, ECL and TAS appear sensitive to different factors. The comparative
strengths and weaknesses of various antioxidant assays should be reviewed.
© 2003 Elsevier B.V. All rights reserved.
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1. Introduction
Recently, there has been increasing interest in the
contribution of free radical-mediated oxidative stress
to several disorders, including atherosclerosis, diabe¬
tes mellitus, and degenerative neurological diseases
[1-3]. This has stimulated interest in the role of
protective physiological antioxidants, and assay meth¬
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ods used for their quantification. Antioxidants act in
various ways to prevent oxidative damage; however, it
is scavenging or 'chain-breaking' antioxidants that are
believed to confer greatest protection, and these in¬
clude a variety of compounds such as ascorbate,
alpha-tocopherol, urate, thiols and flavinoids [4,5],
A number of assays have been developed for deter¬
mining the total radical-scavenging antioxidant capac¬
ity of biological fluids, which may be preferable to
measures of specific antioxidant concentrations or
activities. Global antioxidant measurements may be
more physiologically relevant because they take ac¬
count of potential synergistic interactions between
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antioxidants that appear to be important in vivo [6],
Antioxidant capacity determines the ability of serum
to oppose the effects of oxidants, including free
radicals. These assays are thought to provide a sensi¬
tive and reliable marker of defences against oxidative
stress in vivo, not easily reckonable from measures of
individual antioxidant concentrations.
The total radical trapping ability of plasma (TRAP)
assay was one of the earliest methods developed, and
is based on inhibition of pro-oxidant activity by anti¬
oxidants contained in biological fluids, and has been
widely considered the gold standard method [7].
However, it is associated with significant variability
and complex methodology, and a variety of more
simple, rapid methods based on chemiluminescence
or spectrophotometry have been described [6,8,9],
Assays of antioxidant capacity provide a single mea¬
sure within a dynamic system, which can be influenced
by several metabolic and physiological parameters not
related to oxidative stress. Therefore, interpretation
depends on the conditions under which the measure¬
ment is determined. We wished to compare two
separate assays used to determine serum antioxidant
capacity, and to compare the performance of each
assay during systemic administration of one of two
important aqueous antioxidants, urate or vitamin C.
2. Methods
2.1. Study subjects
Subjects were recruited from a community volun¬
teer database held at the Clinical Research Centre of
the University of Edinburgh. Inclusion criteria were
men and women aged 20-40 years. Exclusion cri¬
teria were regular smoking, blood pressure> 140/90
mm Hg, cholesterol>6.5 mmol/1, diabetes mellitus,
serum urate>250 pmol/1, creatinine>100 pmol/1, tak¬
ing any regular prescription medication or over-the-
counter medication in the week before the study, or
pregnancy determined by a human chorionic gonad-
otrophin-based urinary test. The study was in per¬
formed in accordance with the principles of the
Declaration of Helsinki. The study protocol had been
approved by the local research ethics committee, and
all subjects provided written informed consent before
participation.
2.2. Study protocol
Thirty-four healthy subjects fasted overnight and
studies were performed in the morning in a quiet,
comfortable, temperature-controlled room (24-26
°C). After resting supine for 20 min, a 5 ml blood
sample was collected from an antecubital fossa vein
into a serum gel tube (Sarstedt, Leicester, UK) using
aseptic technique. Samples were allowed to clot, then
centrifuged at 1000 xg for 10 min at 4 °C. Serum
was decanted immediately, and stored at — 40 °C
prior to determination of antioxidant capacity. All
samples were labelled with an anonymous identifier
so that the investigator performing the assays was
blinded to the subject, sample time, and treatment.
Ten subjects participated in a randomised, double-
blind, two-way crossover study. Each underwent in¬
sertion of an 18-standard gauge venous cannula into a
large vein in both antecubital fossae using local
anaesthesia and aseptic technique. Either 1000 mg
vitamin C (5682 pmol) or 1000 mg uric acid (5952
pmol) in 500 ml 4% dextrose/0.1% lithium carbonate
vehicle was infused via the nondominant forearm
cannula over 60 min. Lithium carbonate based vehicle
allows stable dissolution of urate in aqueous solution
[10], and does not exert a direct effect on serum
antioxidant capacity measured by either the ECL or
TAS method [11]. Venous blood samples (5 ml) were
drawn via the other forearm cannula at 0, 15, 30, 45,
60, 90 and 120 min after the start of the infusion.
2.3. Urate measurement
Serum urate concentrations were determined using
an automated colorimetric dry slide assay (Vitros
Chemistry Products, Johnson & Johnson, USA).
2.4. Chemihtminescence-based antioxidant assay
Enhanced chemiluminescence (ECL) is based on
the emission of light that occurs when luminol is
oxidised by hydrogen peroxide, catalysed by horse¬
radish peroxidase, and enhanced by phenol [9]. Light
emission is dependent on continuous production of
free radicals, and is extinguished by biological fluids
for a lag period that is proportional to their antioxidant
content. A luminometer (Model 1251; BioOrbit,
Turku, Finland) was used to establish the duration
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Table 1
Baseline characteristics of the study population
Characteristic Mean ± S.E.M.
Number (male) 34 (20)
Age (years) 26 ± 1
Height (m) 169 ±3
Weight (kg) 63 ±3
Systolic blood pressure (mm Hg) 106 ±5
Diastolic blood pressure (mm Hg) 69 ±3
Serum urate (gmol/1) 259 ±3
Serum cholesterol (mmol/1) 4.2 ±0.2
Serum creatinine (pmol/1) 87 ±5
determined by ECL and TAS assays was compared
using Spearman's rank correlation. Statistical signifi¬
cance was accepted at the 5% level in all cases.
3. Results
Baseline characteristics of the study subjects are
shown in Table 1. Kolmogorov-Smirnov tests indi¬
cated that baseline ECL and TAS antioxidant measure¬
ments were normally distributed. Baseline antioxidant
of the lag period caused by addition of serum. This
was calibrated against a standard curve generated by
addition of 0.16, 0.32, 0.48 and 0.64 pmol/1 Trolox, a
water-soluble tocopherol analogue (6-hydroxy-2,5,8-
tctramethyIchroman-2-carboxylic acid, Sigma, Dorset,
UK), and serum antioxidant capacity was expressed as
pmol/1 of Trolox equivalent.
2.5. Spectrophotometry-based antioxidant assay
The total antioxidant status (TAS) assay (Randox
Laboratories, Cramlin, UK) is based on the activity of
the free radical ferrylmyoglobin, which is formed by
oxidation of metmyoglobin by hydrogen peroxide
[12,13]. Ferrylmyoglobin interacts with the chromogen
ABTS (2,2'-amino-di-[3-ethylbenzthiazole sulfonate])
to form a blue-green chromophore radical (ABTS.),
which has maximal absorbance at 417, 645, 734 and
815 nm. Addition of serum causes a reduction in
ABTS. radical activity that is proportional to its anti¬
oxidant content. ABTS. absorbance was determined at
600 nm using a Cobas Fara (Roche Diagnostics, East
Sussex, UK), and measurements were calibrated
against a Trolox standard curve. Serum antioxidant
capacity was expressed as pmol/1 Trolox equivalent.
2.6. Data analysis
Intra-assay precision was calculated as the mean of
duplicate standard deviations/grand mean of the dupli¬
cates. The inter-assay coefficient of variation was
calculated as the standard deviation of the duplicate
mean/grand mean of the duplicates. These measures
of analytical precision were expressed as percentages
and used to represent reproducibility and repeatability,
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Fig. 1. Correlation between ECL and TAS assay methods (as pM
Trolox equivalent) for (A) actual measurements and (B) changes
from baseline during systemic administration of urate 1000 mg.
/7<0.001 (« = 70) and /)<0.001 (n = 60), respectively, by Spear¬
man's rank correlation.
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values given by the ECL and TAS assays for the study
population were 469 pmol/l (95% confidence interval
428-511 pmol/1) and 1272 gmol/l (1244-1299 pmol/
1), respectively. Precision values were calculated
across a wide range of antioxidant measures for both
ECL (260-1136 pmol/l) and TAS (940-1890 pmol/l)
assays. Values for intra-assay precision were 9.9% and
7.9%, respectively, inter-assay precision 8.9% and
5.4%, and inter-individual variation 34.6% and 8.3%
for ECL and TAS assays, respectively.
In samples collected from the whole study popu¬
lation (n = 34), correlation between the ECL and TAS
assays was poor (R = 0.37, /; = 0.03), and correlation
between baseline serum urate concentrations and
antioxidant capacity was poor for ECL (R= — 0.04,
/? = 0.01) and TAS (R= — 0.29, p = 0.06) assays.
During vitamin C administration, correlation be¬
tween both assays measurements was poor (/? =— 0.17,
p = 0.09). The increments in antioxidant capacity from
baseline also correlated poorly between both assays
during vitamin C administration (R = — 0.13, p = 0.26).
However, a good correlation was found between
measurements given by the ECL and TAS assays
during urate administration {R = 0.67, < 0.01), and
the increment from baseline values obtained from each
assay (R = 0.79, p <0.01) (Fig. 1).
4. Discussion
The baseline characteristics indicate a young,
healthy population with normal blood pressure, body
mass index, and serum glucose and cholesterol con¬
centrations. The comparatively high baseline serum
antioxidant capacity measurements are consistent with
a healthy population, free of any major cardiovascular
risk factors that can influence serum antioxidant
capacity [12,13]. There was a poor correlation be¬
tween the ECL and TAS assays, suggesting that they
are predominantly influenced by different serum anti¬
oxidants. The much greater CV in the ECL assay
compared to the TAS assay is consistent with previous
reports [13], and provides further evidence that each is
influenced by different factors. The discrepancy is
likely to arise because of the differing methodology
underlying each assay. The ECL assay is influenced
by antioxidants that are capable of completely sup¬
pressing light emission. Therefore, it is heavily de¬
pendent on the presence of potent and effective
antioxidants, including urate and vitamin C [1], and
less sensitive to weaker ones. On the other hand, the
TAS assay is influenced by a variety of potent and
less potent antioxidants, which exert a cumulative
antioxidant effect on indicator absorption. The latter,
therefore, provides a global measure of antioxidant
capacity that is based on a variety of factors, and does
not discriminate between them based on potency.
Therefore, the TAS assay, as with other spectropho-
tometric assays, is more easily influenced by less
potent antioxidant factors including albumin, which
may account for as much as 43% of the total mea¬
surement. There is little variation in serum protein
concentration within a healthy population and the
effects of this are seen clearly in our results, where
inter-individual variation of reported antioxidant
capacity was considerably lower using the TAS
(8.3%) rather than ECL (34.6%) method. Relative
insensitivity of the ECL assay to protein thiols could
be interpreted at first sight as a potential disadvantage.
However, the physiological relevance of protein thiols
is still a matter of some contention, and their potential
role has been less clearly defined than other more
potent antioxidants, for example, vitamins C and E
[1]. The ECL assay may offer important advantages
conferred by its ability to measure the activity of
highly efficient antioxidant molecules, without being
flooded by high concentrations of relatively ineffi¬
cient ones.
There was close correlation between ECL and TAS
assays during urate administration when considering
actual antioxidant measurements, and changes in
antioxidant capacity from baseline measurements.
These findings indicate that both assays are compar¬
atively sensitive to the contribution of urate to overall
serum antioxidant capacity, which is in line with
previously reported data. Surprisingly, no correlation
was found between baseline serum urate concentra¬
tions and antioxidant capacity measurements given by
either assay. Such a relationship may not have been
apparent because of the low urate concentrations and
narrow range of values found in the present study
population. A relationship between urate concentra¬
tion and antioxidant capacity has previously been
demonstrated more clearly in populations with a broad
range of serum urate concentrations, for example,
patients with sepsis or obesity [14,15].
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We conclude that there is no correlation between the
serum antioxidant measurements made by the ECL and
TAS assays in a healthy population. Both assays appear
to be sensitive to increases in circulating serum urate
concentrations. However, the marked difference in
inter-individual variability between the ECL and TAS
assay strongly implies that each is sensitive to different
antioxidant factors. We believe that it is important to
avoid confusion in the literature regarding this inter¬
esting field of research. Therefore, we suggest that
there should be a systematic comparative review of
these and other global antioxidant assays, so that their
relative strengths and weaknesses can be identified.
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Uric acid reduces exercise-induced oxidative
stress in healthy adults
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ABS TRACT
Uric acid (UA) possesses free-radical-scavenging properties, and systemic administration is known
to increase serum antioxidant capacity. However, it is not known whether this protects against
oxidative stress. The effects of raising UA concentration were studied during acute aerobic physical
exercise in healthy subjects, as a model of oxidative stress characterized by increased circulating
8-iso-prostaglandin F2ff (8-iso-PGF2„) concentrations. Twenty healthy subjects were recruited to
a randomized double-blind placebo-controlled crossover study, and underwent systemic admin¬
istration of 0.5 gofUAin250 ml of 0.1 % lithium carbonate/4% dextrose vehicle or vehicle alone as
control. Subjects performed high-intensity aerobic exercise for 20 min to induce oxidative stress.
Plasma 8-iso-PGF2a concentrations were determined at baseline, after exercise and after recovery
for 20 min. A single bout of high-intensity exercise caused a significant increase in plasma 8-iso-
PGF2q. concentrations from 35.0 + 4.7 pg/ml to 45.6 + 6.7 pg/ml (P < 0.01). UA administration
raised serum urate concentration from 293+ 16 to 487+ 16 yzmol/l (P < 0.001), accompanied
by increased serum antioxidant capacity from 1786 + 39 to 1899 + 45 yzmol/l (P < 0.01). UA
administration abolished the exercise-induced elevation of plasma 8-iso-PGF2Q, concentrations.
High UA concentrations are associated with increased serum antioxidant capacity and reduced
oxidative stress during acute physical exercise in healthy subjects. These findings indicate that the
antioxidant properties of UA are of biological importance in vivo.
INTRODUCTION
Oxidative stress is characterized by excess free radical
activity and is believed to play an important role in the
development of atherosclerosis [1], This has stimulated
interest in the possibility that antioxidants could offer
protective effects within the cardiovascular system. Until
recently, the lack of an adequate biological marker of
oxidative stress in vivo has limited studies of the efficacy
of antioxidant supplementation. A number of oxidative
reaction products have been explored, including lipid
hydroperoxides, malonyl dialdchydc and prostaglandin
F2-like substances, so called F2-isoprostancs. F2-
isoprostanes are a family of compounds formed by non-
enzymic oxidative modification of arachadonic acid, and
result from free radical attack of phospholipids in cell
membranes or circulating low-density lipoproteins [2],
They are formed in situ in the cell membrane, from which
they are cleaved by phospholipase, and circulate in a free
form or as a phospholipid-bound ester in a bound/
free ratio of approx. 1:2 [3]. Of the F2-isoprostancs, 8-iso-
prostaglandin F2„ (8-iso-PGF2o; also known as iPF2f,-III)
has been shown to be capable of exerting a number of
biological effects, such as smooth muscle contraction,
vasoconstriction and increased platelet aggregability
[4,5]. Ffowever, the relevance of these effects remains
Key words: antioxidant, crgomctric exercise, isoprostanc, oxidative stress, systemic vascular resistance, uric acid.
Abbreviations: ABTS, 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulphonic acid); BP, blood pressure; CI, cardiac index; 8-iso-PGF2a,
8-iso-prostaglandin F2lY; UA, uric acid.
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uncertain, because they are caused by significantly higher
8-iso-PGF2a concentrations than typically found in hu¬
man plasma. Concentrations of 8-iso-PGF2„ are stable in
isolated body fluids and quantification in plasma or urine
provides a marker of free radical generation in vivo.
Its concentrations in biological fluids are increased
in the presence of major cardiovascular risk factors
characterized by oxidative stress, for example hypercho-
lesterolaemia [6], cigarette smoking [7] and diabetes mel-
litus [8]. Elevated 8-iso-PGF2a concentrations in these
conditions support the hypothesis that oxidative modi¬
fication is an important early step in the development of
atherosclerosis. Circulating 8-iso-PGF2o concentrations
provide a non-invasive quantitative measure of lipid
peroxidation and represent a major advance in assessment
of vascular oxidative stress in vivo.
Moderately intense physical exercise increases oxygen
utilization and causes excess oxygen-derived free radical
liberation through mitochondrial lipid peroxidation,
neutrophil degranulation and up-regulation of xanthine
oxidase activity, which liberates superoxide (Oj) [9],
Intense physical exercise provides a model for studying
the effects of acute oxidative stress in vivo and has been
shown to increase susceptibility of low-density lipo¬
protein to oxidation and impair endothelial-dependent
vasodilatation in the forearm vascular bed [10,11].
Oxidative stress during acute exercise is characterized by
elevated circulating 8-iso-PGF2„ concentrations, which
has provided an opportunity to examine the effects of
antioxidant administration on free radical activity in vivo
[9]. Supplementation with vitamin C or E increases
resistance to exercise-induced lipid peroxidation in
healthy individuals [12]. However, /3-carotene does not
reduce oxidative stress during acute physical exercise
[13], and combined administration of vitamin C and
iV-acetyl-cysteine paradoxically increase 8-iso-PGF2„
concentrations after acute eccentric exercise, despite
increased serum antioxidant capacity [14], Glutathione
and ubiquinol supplementation reduce oxidative stress in
animal models of acute exercise [15], but their effects have
not been fully characterized in humans.
Uric acid (UA) is an abundant aqueous antioxidant
that accounts for almost two thirds of all free-radical-
scavenging activity in human serum [16]. UA reacts with
oxygen-derived free radicals and becomes oxidized in
skeletal muscle during high-intensity exercise [17]. In¬
tracellular UA concentrations are rapidly replenished by
uptake from plasma after exercise [18]. A previous study
[19] found a significant inverse relationship between
serum UA concentrations and oxidative stress during
acute aerobic exercise. These observations suggest that
high UA concentrations could confer protection against
free radical activity in vivo and indicate that UA
may be of biological importance in the setting of acute
oxidative stress. The feasibility of systemic UA admin¬
istration, to increase serum antioxidant capacity, has
recently been established in a research setting [20]. The
present study aimed to characterize the effects of elevated
serum UA concentrations on oxidative stress induced by




Twenty healthy men and women were recruited from
a community database of healthy subjects held at the
Clinical Research Centre of the University of Edinburgh.
The protocol was reviewed and approved by the Local
Research Ethics Committee, and written informed con¬
sent was obtained from each participant. Inclusion cri¬
teria were men or women aged 18-45 years. Exclusion
criteria were elevated blood pressure (BP; > 160/
100 mmHg), clinical history of joint, kidney or cardi¬
ovascular disease, those taking any regular medication
or non-prescription medication in the past week, serum
creatinine >110 mmol/1, or serum UA > 400 mmol/1.
Drugs and reagents
UA and lithium carbonate (Ultrapure preparations;
Sigma, Poole, Dorset, U.K.) were reconstituted in
sterile dextrose solution (Baxter Healthcare, Thetford,
Norfolk, U.K.), filtered (0.22 mmMillex filter; Millipore,
Molsheim, France), and prepared on the day of
administration. UA (0.5 g) was dissolved in 250 ml
of 0.1 % lithium carbonate/4% dextrose vehicle. This
vehicle was chosen because it allows stable dissolution
of UA [21] and does not influence serum antioxidant
capacity [20],
Protocol
Subjects were enrolled in a randomized two-way double-
blind placebo-controlled crossover study. Investigations
were performed in a quiet room maintained at 24-26 °C.
An 18-standard gauge venous cannula was inserted into
a suitable vein in each antecubital fossa, under local
anaesthetic using aseptic technique. Subjects remained
seated for 20 min to establish baseline haemodynamic
conditions, and underwent systemic administration of
0.5 g of UA in 250 ml of vehicle or 250 ml of vehicle
alone over 20 min via the non-dominant forearm cannula.
Subjects performed lower limb exercise using an upright
electronically braked ergometric cycle machine (Er-
gometry System 380B; Siemens-Elema, Solna, Sweden).
Pedalling rate was sustained at 70 + 10 Hz to maintain
a constant workload of 80 W, equivalent to a modestly
intense riding speed of 3.8 m s"1 (8.5 miles/h) [22],
Exercise was sustained for 20 min, followed by a 20 min
recovery period during which subjects rested while
seated. Study visits were performed 1 week apart at the
same time of day on each visit.
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A venous blood sample (5 ml) was collected in serum
gel tubes (Sarstedt, Leicester, U.K.), via the non-infused
forearm cannula, for measurement of serum UA and
total serum antioxidant capacity at baseline and 20, 40
and 60 min after the start of the infusion. Additional
5 ml samples were collected in potassium/EDTA tubes
(Sarstedt) for determination of plasma 8-iso-PGF2„
concentrations at baseline and 60 min after the start
of infusion. Blood samples were centrifuged at 1000 g
for 10 min at 4°C, decanted immediately, and serum
and plasma were stored at — 40 °C until assays were
performed.
Haemodynamic variables were determined at baseline
and at 5 min intervals up to 60 min after the start of the
infusion. BP was recorded in the dominant arm using
a validated oscillometric device (HEM-705CP; Omron,
Tokyo, Japan) [23], and the cardiac index (CI) was
assessed using transthoracic bioimpedance (NCCOM3-
R7; BoMed, Irvine, CA, U.S.A.) [24], Systemic vascular
resistance index was calculated as mean arterial pressure
divided by CI.
Serum UA concentration
UA concentration was determined by an automated
colorimetric assay (Vitros; Ortho-Clinical Diagnostics,
Amersham, Bucks, U.K.).
Serum antioxidant capacity
Antioxidant capacity was measured using the Total Anti¬
oxidant Status assay (Randox Laboratories; Crumlin,
County Antrim, U.K.). This assay is based on the
interaction between a chromogen [2,2'-azinobis-(3-
ethylbenzothiazoline-6-sulphonic acid) (ABTS)] and
ferrylmyoglobin, a free radical formed by the reaction
of metmyoglobin and H2O2, which forms the cation
ABTS*+, a blue/green chromophore with maximal ab-
sorbance at 417, 645, 734 and 815 nm [25]. Antiox¬
idants in added serum scavenge ABTS,+ and prevent
absorbance to a degree related to the overall serum
antioxidant capacity. Absorbance was determined at
600 nm using a Cobas Fara (Roche Diagnostics, Lewes,
East Sussex, U.K.), calibrated using 6-hydroxy-2,5,8-
tetramethylchroman-2-carboxylic acid (Trolox, a water
soluble tocopherol analogue) and expressed as /xmol/1
of Trolox equivalent. The Total Antioxidant Status assay
gives a global measurement of ex vivo serum free-radical-
scavcnging capacity and takes account of summation
and interaction between constituent antioxidants [25].
The standard reference range for this assay was 1494—
2107 jxmol/1 and the intra-assay precision was 6.5 %.
Plasma 8-iso-PGF2a concentrations
Solid-phase extraction was performed using an Isosolute
C18(EC) 100 mg/3 ml silica-sorbent column (Interna¬
tional Sorbent Technology, Hengoed, Mid Glamorgan,
Table I Baseline characteristics of the study
population
Values are means ± S.D.
Characteristic Value
Number (male) 20 (10)
Age (years) 23 ±3
Height (m) 1.72 ±0.34
Weight (kg) 71 + 5
Body mass index (kg/m2) 23.0 ±3.5
Serum creatinine (yzmol/l) 72 ± 10
Serum cholesterol (mmol/l) 4.0 ± 2.5
Serum urate (/rmol/l) 293 ± 52
U.K.), and 8-iso-PGF2„ was eluted with ethylacetate/
methanol (99:1, v/v) buffer. Assays were performed on
undiluted samples and after 1:2 dilution with buffer, and
each concentration was assayed in duplicate. 8-iso-PGF2„
concentrations were measured using an ELISA (Cayman
Chemical Co., Ann Arbor, MI, U.S.A.). The assay is
based on the competition between 8-iso-PGFj„ and an
acetylcholinesterase-8-iso-PGF2o conjugate for limited
amounts of 8-iso-PGF2a-specific rabbit IgG bound
to 96-well plates [3], Ellman's reagent [5,5'-dithiobis-
(2-nitrobenzoic acid)] contains an acetylcholinesterase
substrate,which forms a distinctive yellow reaction prod¬
uct whose absorbance was detected at 412 nm using a
Vmax kinetic microplate spectrophotometer (Molecular
Devices, Winnersh, U.K.). The extent of absorbance is
proportional to the amount of conjugate in each well,
which is inversely proportional to free 8-iso-PGF2t,
concentrations during incubation. Mean values were
expressed as a percentage ofmaximal binding absorbance,
and 8-iso-PGF2o content was determined by comparison
with absorbance of standard isoprostane concentrations
(3.9, 7.8, 15.6, 31.3, 62.5, 125, 250 and 500 pg/ml).
The standard reference range was 4.6-65.9 pg/ml and the
intra-assay precision was 6.0 %.
Data analysis and statistics
Responses were compared using two-way ANOVA and
paired Student's t tests where appropriate, and statistical
significance was accepted at the 5 % level in all cases.
RESULTS
Baseline characteristics of study subjects are shown in
Table 1. As expected, UA administration caused serum
concentrations to increase by 194 ± 8 yrmol/1 (P < 0.001)
from baseline (Table 2), Administration of vehicle
alone did not significantly change circulating UA
concentrations from baseline (— 9 + 2 ycmol/1). There
was a corresponding increase in antioxidant capacity from
baseline of 118 + 18 /xmol/1 (P< 0.001) following UA
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Table 2 Serum UA concentration, antioxidant capacity and haemodynamic variables at baseline, after infusion of 0.5 g of
UA in 250 ml of vehicle or vehicle alone, after exercise and after recovery
Values are means + S.E.M. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with vehicle alone. SVRI, systemic vasculature resistance index.
Tretment Baseline (0 min) Post-infusion (20 min) Post-exercise (40 min) Post-recovery (60
Serum urate (/rmol/l) Vehicle 294 +19 286 + 18 296± 19 293 ± 18
UA 293 + 16 487 ± 16*** 458 ± 15"* 429 ± 14***
Antioxidant capacity (/xmol/l) Vehicle 1815 + 29 1769 ±46 1817 ± 27 1796 ±32
UA 1786 ±39 1899 ±45" 1937 ±44* 1895 ±47*
Heart rate (beats per min) Vehicle 75 + 2 73 ± 2 138 ±6* 80 ± 2
UA 76 + 3 74 ±2 135 ±7* 80 ±3
Systolic BP (mmHg) Vehicle 93 + 5 97 ± 6 147 ±6* 94 ± 4
UA 94 ±5 94 ±5 153 ±6* 97 ± 5
Diastolic BP (mmHg) Vehicle 66 + 2 67 ± 3 101 ±5* 69 ±2
UA 68 ±2 66 ± 4 103 ±6* 68 ±2
Cardiac index (l/min per m1) Vehicle 3.9 + 0.2 3.8 ± 0.2 9.7 ± 0.8* 3.8 ±0.2
UA 3.9 ± 0.2 3.7 ±0.1 9.4 ±0.6* 4.0 ± 0.2
SVRI Vehicle 22.0 ± 2.0 23.2 ± 1.7 15.9 ±2.4* 22.0 ±1.7
UA 22.4+1.9 23.6 ± 1.6 14.5 ± 1.2* 23.0 ±2.0
administration, but no change following vehicle alone
(— 22 ± 23 yc.mol/1).
Plasma 8-iso-PGF2a concentrations in the study
population were 41.8 ± 3.0 pg/ml at baseline. Intense
physical exercise caused a significant increase in plasma
8-iso-PGF2c( concentrations from 35.0 ± 4.7 pg/ml to
45.6 + 6.7 pg/ml immediately after exercise (P<0.05),
and 55.7 + 7.1 pg/ml after recovery (P < 0.01) following
vehicle administration (Figure 1). However, after sys¬
temic administration of UA, there was no significant
increase from baseline plasma 8-iso-PGF2o concentra¬
tions (37.1 + 5.4 pg/ml) after exercise (31.6 + 5.5 pg/ml)
or after recovery (37.9 + 6.6 pg/ml). Plasma 8-iso-PGF2a
concentrations after vehicle and UA administration,
expressed as a change from baseline, were +10.6 + 5.5
and —5.5 + 6.2 pg/ml (P<0.05) respectively, after ex¬
ercise, and +20.7 + 6.5 and + 0.8 + 7.7 pg/ml (P<
0.01) respectively, after recovery. Two-way ANOVA
showed a significant effect of UA administration
on isoprostane concentrations (P = 0.02) and changes
in isoprostane concentrations from baseline (P<0.01)
during exercise and recovery.
Administration of neither vehicle nor UA caused any
significant changes in resting haemodynamic variables
from baseline (Table 2). Intense physical exercise caused
significant increases in heart rate (P < 0.001), systolic BP
(P< 0.001), diastolic BP (P< 0.001) and CI (P< 0.005),
and a reduction in systemic vascular resistance index
(P < 0.005), whereas administration of UA did not
influence the haemodynamic responses. No adverse
events were reported in any of the subjects.
75
Baseline Exercise Recovery Baseline Exercise Recovery
Vehicle UA
Figure I Plasma 8-iso-PGF2a concentrations at baseline,
after acute physical exercise and after recovery following
administration of 0.5 g of UA in 250 ml of vehicle or vehicle
alone
Values are means + S.E.M. *P < 0.05 and **P < 0.01 compared with baseline.
DISCUSSION
In the present study, the baseline characteristics were
consistent with those of a young healthy population free
from major cardiovascular risk factors that could poten¬
tially exert independent effects on antioxidant capacity
and oxidative stress. The chosen exercise intensity and
duration caused a significant haemodynamic response in
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this group, who were unaccustomed to regular strenuous
exercise. Resting plasma free 8-iso-PGF2c( concentrations
were consistent with those reported previously [26] in
healthy subjects. The single bout of acute intense exercise
caused oxidative stress in the study population, reflected
by increased plasma 8-iso-PGF2o concentrations imme¬
diately after exercise and recovery. The magnitude of
the rise in plasma isoprostane concentrations was similar
to previous observations in healthy subjects and trained
athletes after acute exercise [27],
Vehicle administration had no significant effect on
circulating UA concentrations or serum antioxidant
capacity, as found previously [20], Administration ofUA
(0.5 g) achieved a substantial increase in circulating
UA concentrations to levels characteristic of the upper
limit of the normal reference range (120-420 ytmol/1).
Raised UA concentrations were associated with increased
serum free-radical-scavenging capacity, as indicated by a
global antioxidant measurement. Prior administration of
UA attenuated the exercise-induced increase in plasma 8-
iso-PGF2„ concentrations. It is likely that this effect was
mediated by the increased ability to counter excess free
radical activity, conferred by the antioxidant properties
of UA. These findings indicate that high circulating
UA concentrations are able to prevent oxidative stress
in vivo during intense physical exercise and raise the
possibility that UA could protect against oxidative stress
in other situations. Interestingly, a number of earlier
observations suggest that local UA concentrations may be
regulated, at least in part, by prevailing redox conditions.
For example, oral administration of L-arginine has been
found to cause a reduction in systemic oxidative stress,
which is accompanied by a fall in circulating UA con¬
centrations [28], Furthermore, acute ischaemia in several
vascular beds, for example the coronary circulation, is
associated with oxidative stress and causes an increase in
circulating UA concentrations locally [29,30], Raised UA
concentrations could, therefore, provide a physiological
mechanism to protect against excess free radical activity.
The lack of effect of vehicle or UA administration on
resting BP and systemic vascular resistance indicate that
high UA concentrations, at least in the acute setting, do
not directly influence vascular tone.
Cardiovascular risk and the development of athero¬
sclerosis are likely to be influenced by exposure to chronic
oxidative stress. A limitation of the present study is
that only short-term measures of antioxidant capacity and
oxidative stress were examined. However, this appears
to be a valid approach because there is good correlation
between short-term and long-term effects of a variety
of cardiovascular risk factors on oxidative stress, for
example cigarette smoking [31] and hyperglycaemia [32].
A further potential limitation is that the validity of the
Omron HEM-705CP device has not been established
in exercising subjects. It is accurate for measuring BP
up to 160/100 mmHg in resting subjects and has been
validated according to criteria of the British Hypertension
Society and Association for the Advancement of Medical
Instrumentation [23].
In conclusion, the present study has shown that UA
administration temporarily raises circulating UA con¬
centrations, which increases serum antioxidant capacity
and reduces exercise-induced oxidative stress in a young
healthy population. These findings indicate that the
antioxidant properties of UA are of physiological con¬
sequence and support the view that UA confers poten¬
tially important free-radical-scavenging effects in vivo.
The implications of raised serum UA concentrations,
in the setting of chronic oxidative stress, require further
evaluation. Additional research is required to investigate
the potential role of high UA concentrations in patients
exposed to major cardiovascular risk factors.
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Uric acid: an important antioxidant in acute ischaemic
stroke
W.S. WARING
From the Clinical Pharmacology Unit and Research Centre, The University of Edinburgh,
Western General Hospital, Edinburgh, UK
Introduction
An association between raised serum uric acid (UA)
concentration and increased cardiovascular risk
has been recognized for over 50 years.1 A number
of major epidemiological studies have identified
high UA concentrations as an important risk marker
for stroke in unselected populations. Furthermore,
raised serum UA concentrations are associated with
increased risk of stroke in high risk patient groups,
for example those with hypertension or type 2
diabetes mellitus.2,3 However, the significance of
these relationships remains subject to considerable
debate. Both in vitro and in vivo studies have shown
UA to be a powerful free radical scavenger in
humans and, paradoxically, these antioxidant pro¬
perties could be expected to offer a number of
benefits within the cardiovascular system.4 No
potential biological mechanisms are known by
which raised UA concentrations could influence
the development of stroke. Therefore, it is unclear
whether high UA concentrations promote or protect
against the development of cardiovascular disease,
or simply act as a passive marker of increased risk.
Not only has there been speculation surrounding
the possible effects of UA on development of
atherosclerosis but, over recent years, increasing
attention has been paid to its potential role in the
disease manifestations that ensue. In particular,
emerging evidence suggests that UA plays an
important role in acute ischaemic stroke, as a
consequence of its antioxidant properties.
Antioxidants and stroke
Cerebral infarction initiates a complex cascade of
metabolic events in the surrounding tissue, and
free-radical-mediated oxidative damage plays a key
role in the pathogenesis of cerebral ischaemia.5
Free radicals are liberated from a variety of sources,
including inflammatory cells, dysfunctional mito¬
chondria and excitotoxic mechanisms stimulated by
increased glutamate and aspartate concentrations.6
Hydroxyl radicals (formed from hydrogen peroxide)
peroxynitrite and superoxide are powerful radicals
that can cause lipid peroxidation, a self-propagating
chain reaction, that irreversibly damages plasma
and mitochondrial membranes.7 Products of lipid
peroxidation, for example malondialdehyde, irre¬
versibly disrupt enzymes, receptors, and membrane
transport mechanisms. In acute ischaemic stroke,
in vivo concentrations of lipid peroxidation products
are significantly increased, arising from excess free
radical activity (Figure 1).8 Plasma concentrations
of cholesteryl ester hydroperoxides (CEOOH) are
sensitive and specific markers of lipid peroxid¬
ation, and correlate positively with infarct volume,
calculated by computed tomography, and clinical
severity, determined by the National Institute of
Health Stroke Scale.8 This emphasizes the role of
oxidative stress in mediating cerebral ischaemic
tissue damage, and is consistent with the observation
that stroke volume is greater in patients with dimi¬
nished antioxidant capacity.9 These observations
have stimulated interest in the possibility that
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Figure 2. Mean±SEM UA concentrations in cortex and
thalamus at 0, 1, 8, 24, and 48 h after experimental brain
injury in Wistar rats (n = 4-5 at each time point).
Ipsilateral cortical and thalamic concentrations were
higher than contralateral concentrations; p<0.0001 by
ANOVA for both, *p<0.01, **p<0.001 using Bonferroni
two-tailed tests. Reprinted from reference 11 with
permission from Elsevier Science.
Cortical stroke
Lacunar stroke
Figure 1. Mean + SEM plasma cholesterol ester hydro¬
peroxide (CEOOH) concentrations, an index of lipid
peroxidation, in patients with large artery cortical stroke
(n = 32), and age-matched patients with lacunar stroke
(r? = 13); p<0.05 by two-way ANOVA. Reprinted from
reference 8 with permission from Elsevier Science.
P<0.001
Time (days)
Time after injury (hours)
antioxidant treatments could offer benefits in acute
ischaemic stroke, through their ability to defend
against excess free radical activity.
Uric acid
UA is the most abundant aqueous antioxidant in
humans, and contributes as much as two-thirds of
all free radical scavenging capacity in plasma. It is
particularly effective in quenching hydroxyl, super¬
oxide and peroxynitrite radicals, and may serve a
protective physiological role by preventing lipid
peroxidation.10 In a variety of organs and vascular
beds, local UA concentrations increase during acute
oxidative stress and ischaemia, and the increased
concentrations might be a compensatory mechan¬
ism that confers protection against increased free
radical activity.4 In animal models, local UA con¬
centrations significantly increase in acute brain
injury (Figure 2).11 For example, in the rat, middle
cerebral artery occlusion causes a significant
increase in cerebral UA concentrations, which can
persist for several days after the injury.12 These
observations have prompted interest in the potential
impact of raised local UA concentrations in the
setting of acute ischaemic stroke.
Models of ischaemic neuronal injury have shown
that the addition of physiological concentrations
of UA protects hippocampal neurons against excito-
toxic and metabolic injury in vitro,13 The effects
of raising circulating UA concentrations, by direct
administration, have also been studied in vivo in
a rat model of acute ischaemic stroke, involving
transient occlusion of one middle cerebral artery for
2 h. Administration of UA, prior to ischaemia or
during the subsequent reperfusion period, caused a
significant reduction in infarct volume, and led to
improved behavioural outcome at 24 h (Figure 3).13
These findings suggest that early elevation of UA,
during or shortly after acute ischaemic stroke, could
confer significant protection against neurological
deficit. This is consistent with the protective effects
of UA observed in other models of cerebral diseases
mediated by free radicals.
A recent study lends support to this hypothesis
in a clinical setting. Serum UA concentrations
measured in 881 consecutive ischaemic stroke
patients at the onset of ischaemic symptoms were
found to correlate inversely with early neurological
impairment and final infarction size on computed
tomography or magnetic resonance imaging.14
Additionally, serum UA concentrations were posi¬
tively associated with a good clinical outcome at
hospital discharge (Matthew score of > 75), where
each mg/dl UA increase (equivalent to 60 pmol/l;
reference range 120-420 pmol/l) was associated
with a 12% increase in the odds of a good outcome.
Importantly, these relationships were independent
of potential confounders, including age, diuretic
use, renal function or the presence of major cardio¬
vascular risk factors. This is the first study to
characterize the relationship between serum UA
concentration and neurological severity of acute
ischaemic stroke in a large series of patients. A
potential limitation of this observational data is
that it does not directly address the potential
mechanisms by which UA could improve stroke
Uric acid 693
Control UA Control UA
Ischaemia Raperfusion
Control UA Control UA
Ischaemia Reperfusion
Figure 3. Mean±SEM infarct volume and behavioural
deficits 24 h after middle cerebral artery occlusion for 2 h
in male Sprague Dawley rats, showing the effects of UA
or saline (control) administration prior to ischaemia or
during reperfusion. *p<0.05, **p<0.01, ***p<0.001, by
paired Student's t tests. Reprinted from reference 13 with
permission from Wiley.
outcome, for example measurements of antioxi¬
dant capacity or oxidative stress. However, its
findings support the potential benefits of raised
UA concentrations observed in in vitro and in vivo
experimental models.
Despite the widely held view that elevated
serum UA concentrations confer increased risk of
atherosclerotic disease, there is no compelling
biological evidence of a causal link. Free radical
activity is characteristically increased in patients
with any one of several major cardiovascular risk
factors, and is thought to play a key role in the
early development of atherosclerosis. As an anti¬
oxidant, UA could be expected to confer protection
against free radicals. In the context of acute
ischaemic stroke, there is growing evidence to
support a protective role for UA. This underpins
the importance of oxidative stress in the pathogen¬
esis of acute stroke, and strengthens the rationale for
further investigation of antioxidant treatments in this
condition. The feasibility of UA administration to
temporarily increase circulating concentrations has
recently been established,15 and might allow its
potential therapeutic impact to be examined in a
clinical setting. Ongoing basic research is likely to
shed new light on the cardiovascular effects of UA,
and will hopefully allow the significance of serum
concentrations to be interpreted more clearly.
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1888 Letters to the Editor
The authors observe that mortality
from the combined effects of systolic
blood pressure and serum cholesterol
although higher in men than women,
is not supported by any definite cause.
We would like to offer the following
suggestions.
The use of hormone replacement
therapy (HRT) in women in the age
group 45-55 has become common. It
is also well known that this therapy
raises high density lipoprotein choles¬
terol levels and lowers low density
lipoprotein cholesterol levels. There¬
fore, the possibility of exogenous/
endogenous oestrogen playing a role
in the lower mortality rate observed in
women cannot be excluded. Maybe if
the authors analysed the number of
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Uric acid concentrations and the
mechanisms of cardiovascular disease
We read with interest the article by
Yusuf and Bosch1'1, which addresses
the potential role of uric acid (UA)
as a causal factor in cardiovascu¬
lar disease. The association between
raised serum UA concentrations
and increased cardiovascular risk is













Figure I Uric acid metabolism.
epidemiological data are unlikely to
resolve whether UA is a causal, com¬
pensatory, or co-incidental factor. We
support the authors' view that basic
and experimental studies are now
needed to identify potential biological
links between UA and mechanisms
of atherosclerosis. We also agree that
allopurinol may have therapeutic
potential in this setting. However, we
are not convinced that the proposal
of the authors, to use allopurinol to
lower serum UA concentrations, will
effectively address the mechanistic
issues.
Allopurinol causes a modest reduc¬
tion in serum UA concentration, up to
30%[2), by inhibiting xanthine oxidase
(XO), which normally catalyses con¬
version of hypoxanthine to xanthine,
and xanthine to UA, an end product
of purine metabolism in man (Fig. 1).
However, XO activity also results
in formation of hydrogen peroxide
(H2Oz), a potentially detrimental free
radical, which is thought to contribute
to vascular dysfunction, for example
in patients with hypertension. In Dahl
hypertensive rats, endothelial XO
activity makes an important contribu¬
tion to oxidative stress131. In humans,
hypertensive patients have signifi¬
cantly greater H202 production than
normotensive individuals, and the
consequent increase in oxidative stress
raises blood pressure and promotes
target organ damage141. Inhibition
of XO significantly reduces H202 pro¬
duction, and ameliorates vascular
oxidative stress.
Additionally, allopurinol has anti¬
oxidant properties, which are inde¬
pendent of its effects on XO activity151.
The potential cardiovascular effects of
allopurinol could be due to inhibition
of XO-mediated free radical gener¬
ation, or direct antioxidant quenching
of free-radical activity, and its use as a
urate lowering agent requires cautious
interpretation. The potential clinical
benefits of allopurinol are three¬
fold, but do not specifically address
the question of a biological link
between UA and mechanisms of
atherosclerosis.
Another approach to lowering se¬
rum UA concentrations is admin¬
istration of the enzyme urate oxidase
(UO), which catalyses the further
metabolism of UA. UO substantially
lowers circulating UA concen¬
trations, by up to 90%[6], and res¬
toration can take several days,
depending on the rate of purine
metabolism. UO provides an oppor¬
tunity to study the direct cardiovas¬
cular effects of UA lowering, in the
absence of effects on XO or H202
liberation. Therefore, UO is a more
effective and specific means of lower¬
ing serum UA concentrations than
allopurinol and may, therefore, pro¬
vide better insight into the relation¬
ship between UA and mechanisms of
atherosclerosis.
An alternative approach to UA low¬
ering is to study the cardiovascular
effects of raising circulating UA con¬
centrations, and the feasibility of sys¬
temic UA administration has recently
been established'7'. This is an equally
valid approach, because acute elev¬
ation of established major cardiovas¬
cular risk factors has been shown to
cause impaired endothelial function in
healthy individuals, for example after
ingestion of a meal rich in saturated
fats'8', or after raising circulating
homocysteine concentrations by oral
methionine administration'9'.
We accept that allopurinol may
confer significant cardiovascular ben¬
efits, and its therapeutic potential
should be explored. However, the
short-term approaches we have out¬
lined are more likely to allow a better
understanding of the possible mech¬
anisms that link raised serum UA
concentrations and increased cardio¬
vascular risk.
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Myocardiocyte loss due to apoptosis
The findings presented by Dispersyn
el al. (June 2002 issue)'1' on dediffer-
entiation and apoptosis of myocardio-
cytes late after AMI were extremely
interesting. The presence of both myo¬
cytes with metabolic rearrangement
('dedifferentiated' or 'hibernated') and
cells committed to programmed death
(apoptotic) in this experimental model
of post-infarction left ventricular
remodelling in sheep suggests that
both these mechanisms are possible
cellular responses to ischaemia.
However, a major issue is the effec¬
tive myocardiocyte loss due to apop¬
tosis. The data presented by the
authors'1' on myocardial apoptosis
substantially confirm results presented
earlier in a similar model of multiple
AMI in dogs'2' (012% of apoptosis in
the former and 0-53% in the latter),
while they appear strikingly different
from our recent data in post-mortem
human hearts'3'. We have recently
shown that the apoptotic rate is as
high as 25% in the infarcted area of the
hearts of human subjects who died 12
to 62 days after an AMI'3'. A compari¬
son of the two studies reveals a nearly
200-fold increase in our samples com¬
pared to the data by Dispersyn et a/.'1'.
Could these differences be due to selec¬
tion biases in both studies? Perhaps
yes.
We believe that estimates of apop¬
totic rates may show quite different
results in hearts of individuals dying
spontaneously compared to animals
surviving and being killed. In facts,
our results'3' may have been biased by
the selection of a population with a
significantly poor prognosis (median
time to death 23 days), who may have
been associated with extremely
elevated rates of apoptosis. On the
other hand, Dispersyn et a/.'1' may
have selected individuals who were
relatively protected from apoptosis
with a more favourable prognosis (the
sheep with a 50% reduction in left
ventricular ejection fraction were
allowed to survive at least 6 weeks
after the last embolization).
We think it would be of interest to
the readers of this Journal to know
whether any of the sheep in the proto¬
col by Dispersyn et al.m died before
reaching the time they were due to be
killed (as reported for the similar pro¬
tocol in dogs'4'). If this were the case,
it would be extremely interesting to
obtain data regarding the apoptotic
rates in this group of animals, who
were characterized by a certainly more
unfavourable prognosis.
Most experimental studies in
animals are affected by a similar selec¬
tion bias. Sabbah et a/.'4' reported that
approximately 30% of their dogs died
early after intervention and were
therefore excluded from the study. On
the other hand, when, in an exper¬
imental study conducted on mice'5', all
individuals were followed from time of
intervention (surgical constriction of
the aorta) until death, these animals,
apoptosis-prone due to genetic
manipulation, had an apoptotic rate
greater than 30% and almost all died
of dilated cardiopathy within a few
weeks. Furthermore, a human obser¬
vational study of post-mortem
samples showed an apoptotic rate of
11-6% up to 10 days after AMI'6'.
We were unable to understand,
moreover, whether coronary embol¬
ization in the protocol by Dispersyn
et a/.'1' resulted in total occlusion of a
major coronary artery. In particular,
we would like to know if coronary
artery angiograms were repeated
before they were killed. Patency of the
infarct-related artery at the time of
death may represent a major determi¬
nant for apoptosis late after AMI. We
have shown that individuals with an
open artery at the time of death have
significantly lower apoptotic rates at
sites of infarction'3'.
An accurate definition of the factors
promoting death or survival should
lead to a more complete understand¬
ing of the variability observed in
experimental animal models and
human observational studies. Indeed it
is possible that some individuals are
relatively protected from apoptosis,
surviving longer after AMI and show¬
ing only low grade apoptosis and a
very low rate of transition from meta¬
bolic rearrangements to commitment
to death, as in the cases presented by
Dispersyn et a/.'1'.
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Objective-. We have been developing lithium carbonate
solution as a vehicle for delivery of uric acid in a re¬
search setting. We wished to determine the pharmaco¬
kinetics of a single systemic administration of 500 mg
lithium carbonate (13.5 mmol free Li+) in healthy sub¬
jects.
Methods: Ten healthy subjects received 500 ml of a
0.1% lithium carbonate and 4% dextrose solution in¬
travenously over 1 h. Serum lithium concentrations were
determined at baseline, 15, 30, 45, 60, 75, and 90 min,
and 2, 3, 7, 24, and 48 h after the start of infusion for
kinetic analysis.
Results: Administration led to a time-dependent in¬
crease in plasma concentration, followed by a rapid
decay of serum lithium concentration. Kinetic analysis
showed that the pattern best fit a two-compartment
model, with rapid extravascular distribution, an elimi¬
nation phase half-life of 7.8 ±1.7 h, and clearance of
5.3 ±1.1 1/h.
Conclusions: In healthy subjects, lithium half-life is
shorter and clearance is higher than suggested by pre¬
vious reports in other groups. Administration of 500 ml
0.1% lithium carbonate and 4% dextrose over 1 h is
safe, well tolerated, and possibly a suitable vehicle for
other agents such as uric acid.
Keywords Lithium carbonate • Solubility •
Two-compartment decay • Uric acid
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Lithium carbonate was first introduced into medical
practice in the late nineteenth century for dissolution of
bladder stones and rheumatic nodules, in doses ranging
from 111 mg to 1,034 mg (3-26 mmol Li + ) per day [1],
More than 50 years ago, lithium carbonate was found to
be effective in psychiatric illness at doses of around
1,847 mg (50 mmol Li+) per day [2], and lithium salts
remain widely used in the treatment of bipolar affective
disorder. Based on the theory that uric acid dissolves
readily in lithium-based solutions, low-dose treatment
was advocated for the prophylaxis of gout by several
proponents, including James Parkinson [3], for many
years. We sought to develop a lithium carbonate-based
solution that would allow us to administer urate in a
research setting in order to explore its known antioxidant
properties. We determined that 1,000 mg uric acid could
be dissolved readily in 500 ml of a 0.1% lithium car¬
bonate and 4% dextrose vehicle, which could be admin¬
istered by systemic infusion over 1 h. Lithium has a
narrow therapeutic range (serum concentration
0.4-1.5 mmol/1), and toxicity becomes increasingly likely
beyond 2 mmol/1, typically manifesting as apathy, trem¬
or, restlessness, and in severe cases ataxia, renal dys¬
function, seizures, coma, and death [4], Lithium is not
subject to protein binding and is cleared exclusively by
renal excretion [5]. However, despite the use of lithium
over many years, there is a surprising lack of consistent
information about its clearance after administration of a
single dose. Reported plasma elimination half-life after
oral administration varies between 10 h and 50 h [6], and
this variability may partly reflect delayed absorption
from the gastrointestinal tract, which can occur over
3-6 h [5]. To determine its suitability as a vehicle for uric
acid delivery, we studied lithium kinetics and cardiovas¬
cular responses associated with intravenous administra¬
tion of 500 ml 0.1% lithium carbonate and 4% dextrose
over 1 h to ensure that unacceptably high plasma con¬




Subjects were selected from the healthy volunteer database at the
Clinical Research Centre of the University of Edinburgh and in¬
vited to participate. Included were males and females aged 18 to
40 years, and written, informed consent was required before study
participation. Exclusion criteria were clinical history of any major
cardiorespiratory or renal disease, baseline serum creatinine con¬
centration of >100 pmol/1, use of any medication, or pregnancy
determined by urinary human chorionic gonadotropin-based assay
[7]. The study protocol was approved by the local Research Ethics
Committee, and ten subjects were recruited.
Study protocol
The study was conducted in the Clinical Research Centre and, after
bladder voiding, subjects were asked to lie recumbent in a relaxed,
quiet, temperature-controlled room (22-24°C). Standard 22-gauge
cannulae were inserted into a large antecubital vein in each forearm
using aseptic technique and local anaesthesia. After resting for
20 min to establish baseline conditions, 500 mg lithium carbonate
(13.5 mmol free Li + ) in 500 ml 4% dextrose was infused over 1 h
via the cannula in the nondominant arm, and 5-ml venous blood
samples were drawn via the other cannula at baseline and 15, 30,
45, 60, 75, 90, 120, and 180 min for measurement of lithium con¬
centration using an automated colorimetric assay (Vitros dry slide)
(Johnson and Johnson, Calif., USA) [8], The venous cannulae were
removed and subjects allowed to leave, returning for three further
venous blood samples at 7, 24, and 48 h.
At 0, 15, 30, 45, 60, and 75 min, heart rate and blood pressure
were recorded in the dominant arm using a validated noninvasive
oscillometric device (HEM-705CP, Omron, Japan) [9], and cardiac
index was assessed using transthoracic bioimpedance (NCCOM3-
R7, BoMed, Calif., USA) [10]. Values were compared to baseline
using paired Student's /-tests.
Determination of elimination half-life
Standard linear and semilogarithmic graphs representing serum
lithium concentration vs time were plotted. Curve fitting by non¬
linear regression analysis was performed using Prism software,
version 3.0 for Windows (GraphPad, San Diego, Calif., USA) [11].
F tests were used to compare best-fit curves generated by one- and
two-exponent analyses for each subject, and statistical significance
was accepted at the 5% level.
Results
Ten subjects (four males) aged 24 ±2 years (mean ± -
SEM) with baseline serum creatinine 79 ± 7, body mass
index 23 ± 1, and systolic blood pressure (BP)
104 ±3 mmHg were studied. Lithium carbonate infusion
led to a time-dependent increase in serum lithium con¬
centration, with a peak concentration of 0.93 ±
0.05 mmol/1 (Fig. 1). This was followed by a rapid decay
that appeared consistent with a one- or two-compart¬
ment model (Fig. 2). The unweighted decay plot data
were subjected to exponential and biexponentiai ana¬
lyses and compared to determine the best fit. The F
value was >1.0 in favour of the two-compartment
model for data from each subject. As a measure of dis¬
tribution around the residuals, the sum of squares for
Fig. 1. Serum lithium concentration during intravenous adminis¬
tration of 500 mg lithium carbonate over 1 h in ten healthy subjects
Time (h)
Fig. 2. Mean ± SEM serum lithium concentration after intrave¬
nous administration of 500 mg lithium carbonate over 1 h. N= 10
(data at 48 h only available for six subjects)
the one- and two-compartment models were 1.313xl0 3
and 7.37XKT6, respectively (F = 96.06 and P= 0.0l for
the averaged data). Nonlinear biexponentiai regression
analysis of individual subject data found an elimination
half-life of 7.8 ± 1.7 h, distribution phase half-life of
37 ± 12 min, volume of distribution of 43.4±2.3 1, and
clearance of 5.3 ± 1.1 1/h.
There were no significant elfects on serum electrolyte
or creatinine concentrations, and there was a transient
increase in systolic BP, reduction in heart rate, and
cardiac index (Table 1).
433
Table 1. Serum chemistries
and systemic haemodynamics at
baseline and after administra¬
tion of 500 mg lithium carbon¬
ate over 1 h
Baseline 1 h 4 h 24 h
Sodium (mmol/1) 140 ±1 139 ± 1 140 ±1 141 ± 1
Potassium (mmol/1) 3.8±0.2 3.8±0.3 3.9 ±0.2 4.0 ±0.2
Urea (mmol/1) 4.2 ±1.1 4.3 ±1.0 4.0 ± 1.1 3.9 ± 1.2
Creatinine (pmol/1) 79±7 78 ±6 77 ± 6 77 ±7
Bicarbonate (mmol/1) 24±2 24 ± 1 24 ± 2 25 ±2
Uric acid (mmol/1) 0.23 ±0.05 0.23 ±0.05 0.22 ±0.05 0.23 ±0.05
Systolic BP (mmHg) 104 ±3 107 ±3* - -
Diastolic BP (mmHg) 64 ±2 66 ±2 - -
Heart rate (bpm) 59 ±3 55 ±2* - -
Cardiac index (l/min per m2) 4.2 ±0.2 3.8 ±0.2* - -
*/><0.05 compared to baseline
Discussion
We observed lithium plasma kinetics following admin¬
istration of a single intravenous dose in young healthy
men and women with normal renal function. The peak
serum lithium concentration of 0.93 mmol/1 was to¬
wards the upper part of the normal therapeutic reference
range (0.4—1.0 mmol/1) and followed by rapid extravas-
cular distribution and progressive plasma clearance. We
observed a decay of serum lithium concentration con¬
sistent with a two-compartment model, as previously
reported [12, 13], and plasma elimination half-life was
7.8 h. Clearance was more rapid than suggested by
previous observational studies of acute oral lithium in¬
toxication [14] that may have been confounded by con¬
comitant drug use, alcohol ingestion, or delayed
systemic absorption as a consequence of impaired gas¬
trointestinal motility following a high oral lithium load
[15]. During steady-state maintenance treatment [16, 17]
and acute toxicity superimposed on chronic treatment
[2, 18], plasma clearance has also been found to be
lower, possibly due to increased renal resorption in the
presence of fluid balance disturbance and impaired renal
tubular function due to drug toxicity [19].
The modest acute haemodynamic responses were
consistent with the effects of a 500-ml intravenous fluid
load [20] and unlikely to be of clinical significance.
A potential limitation of our present study is that all
subjects were of a similar age and fewer than ideally
required to develop a population kinetic model. Fur¬
thermore, elimination half-life calculations were based
on comparatively infrequent sampling in the terminal
phase. However, we were particularly interested in the
peak lithium concentrations attained during systemic
administration and the possible duration of exposure to
high concentrations. Our findings indicate that the
maximal concentrations attained by infusion of 500 mg
lithium carbonate over 1 h are short-lived. Together
with the rapid plasma clearance observed, we do not
anticipate any significant risk of adverse effects.
In summary, intravenous administration of 500 mg
lithium carbonate to healthy volunteers over 1 h results
in transient exposure to moderate plasma concentra¬
tions. There was rapid plasma clearance, and no adverse
effects were encountered. Therefore, 500 ml of a 0.1%
lithium carbonate and 4% dextrose solution may pro¬
vide a suitable vehicle for administration of compounds
with limited solubility in conventional aqueous media in
a research setting.
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Systemic Uric Acid Administration Increases Serum Antioxidant
Capacity in Healthy Volunteers
W. Stephen Waring, David J. Webb, and Simon R. J. Maxwell
Clinical Pharmacology Unit and Research Centre, Department ofMedical Sciences,
The University of Edinburgh, Edinburgh, U.K.
Summary: Oxidative stress plays an important role in the development of
atherosclerosis and contributes to tissue damage that occurs as a consequence,
particularly in myocardial infarction and acute stroke. Antioxidant properties
of uric acid have long been recognized and, as a result of its comparatively
high serum concentrations, it is the most abundant scavenger of free radicals
in humans. Elevation of serum uric acid concentration occurs as a physiologic
response to increased oxidative stress—for example, during acute exercise—
thus providing a counter-regulatory increase in antioxidant defenses. In view
of its antioxidant properties, uric acid may have potentially important and
beneficial effects within the cardiovascular system. We wished to investigate
whether administration of uric acid was feasible and if it could have an impact
on antioxidant function in vivo. We have, therefore, performed a randomized,
placebo-controlled double-blind study of the effects of systemic administra¬
tion of uric acid, 1,000 mg, in healthy volunteers, compared with vitamin C,
1,000 mg. We observed a significant increase in serum free-radical scaveng¬
ing capacity from baseline during uric acid and vitamin C infusion, using two
methodologically distinct antioxidant assays. The effect of uric acid was sub¬
stantially greater than that of vitamin C. Key Words: Urate—Antioxidant—
Cardiovascular—Vitamin C—Chemiluminescence—Free radicals.
Uric acid is the final product of purine metabolism in
humans, unlike the situation in virtually all other species,
in which uric acid is further metabolized by the enzyme
urate oxidase. The human urate oxidase gene has been
located on chromosome 1, but is not expressed because
of two nonsense mutations (1). Therefore, having lost the
ability to express urate oxidase, humans are exposed to
higher uric acid concentrations than other species, raising
the possibility that these could confer an evolutionary
advantage (2). Uric acid has important antioxidant prop¬
erties in vitro, by scavenging free radicals (3) and che¬
lating iron, the latter preventing iron-catalyzed oxidation
(4). There is a strong correlation between the concentra¬
tion of uric acid in biologic fluids and demonstrable an¬
tioxidant activity. Indeed, uric acid contributes as much
as 60% of free-radical scavenging in human serum (5),
and if persistently elevated uric acid concentrations offer
an evolutionary advantage in humans, this may be be¬
cause of its powerful antioxidant properties (3). Oxida¬
tive stress reflects an unfavorable imbalance between
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potentially harmful oxidants and protective antioxidants
and predisposes to local tissue damage, partly mediated
through excess free-radical activity (6-8). Oxidative
stress plays an important role in the development of
atherosclerosis (9), and acute oxidative stress occurs in
ischemic stroke (10), acute lower limb ischemia (11),
myocardial infarction (12), reperfusion injury (13), and
acute physical exercise (14) as a result of tissue ischemia
and altered cellular redox state. A consistent observation
in these states is the subsequent elevation of serum uric
acid concentration due to metabolism of adenosine gen¬
erated by ischemic tissues (15-17), loss of the inhibition
of xanthine oxidase caused by nitric oxide (18), and im¬
paired oxidative metabolism (19). The observed uric acid
elevation may be a protective response, capable of op¬
posing the harmful effects of free-radical activity and
oxidative stress. Smokers and patients with diabetes mel-
litus, hypertension, and hypercholesterolemia are ex¬
posed to chronic oxidative stress, which is thought to
play an important role in the development and progres¬
sion of atherosclerosis (20).
Each of these conditions is associated with an in¬
creased serum uric acid concentration, possibly confer¬
ring protection against persistent exposure to potentially
damaging vascular oxidants, characteristically found in
these conditions. There is further evidence that hydro-
philic antioxidants play a pivotal role within the cardio¬
vascular system; this evidence is underpinned by studies
of the effects of vitamin C in humans. In diabetic sub¬
jects, hypertensive subjects, and those who use tobacco
regularly, circulating vitamin C concentrations are lower
(5,21,22). Diabetes, hypertension, and tobacco use are
associated with characteristic impairment of nitric ox¬
ide-mediated endothelial function, which may be an im¬
portant intermediary step in the development of athero¬
sclerosis (23,24). Short-term administration of vitamin C
to these groups leads to restoration of normal vascular
function, offering further evidence that endothelial dys¬
function may be a consequence of oxidative stress (22,25,
26). Furthermore, short-term administration of vitamin C,
2,000 mg, improves flow-mediated coronary vasodilatation
in patients with coronary atherosclerosis, indicating
that aqueous antioxidants cause functional improvement,
even when vascular disease is already established (27).
Uric acid is a powerful free-radical scavenger, the se¬
rum concentration of which rises in the setting of acute
and chronic oxidative stress. Its potential value as a
therapeutic antioxidant has been recognized (28). We
wished to explore whether high doses of uric acid could
be administered systemically in humans, and to study its
effects on circulating antioxidant capacity in direct com¬
parison with vitamin C.
METHODS
Study volunteers
Eight healthy nonsmokers (three men and five
women) aged 24 ± 2 years (mean age ± SEM) partici¬
pated in these studies. Exclusion criteria included a his¬
tory of renal, joint, or cardiovascular disease, use of any
medication including antioxidant supplements, and preg¬
nancy, which was determined by a human chorionic go-
nadotrophin-based urinary test.
Study protocol
The study protocol was reviewed and approved by the
local research ethics committee and all participants pro¬
vided written informed consent before participation. The
study was randomized, placebo-controlled, and double-
blind and used a crossover design involving 3 study days,
each separated by at least 1 week. The study was con¬
ducted in a quiet, comfortable environment, maintained
at 24°-26°C, within the Clinical Research Centre. Par¬
ticipants attended at 09:00 a.m. on each study day and
were asked to avoid alcohol, caffeine, and purine-rich
foods for 24 h before. An 18-G cannula was inserted into
a large vein of each antecubital fossa using local anes¬
thesia and aseptic technique. The cannula in the non-
dominant forearm allowed infusion over 60 min of 1,000
mg uric acid (5,952 prnol) in 500 ml 4% dextrose/0.1%
lithium carbonate vehicle, vehicle alone, or 1,000 mg
vitamin C (5682 p-mol) in 500 ml 0.9% saline during
separate visits, in a randomized order. Five milliliters of
venous blood were drawn from the other cannula and
collected in serum gel tubes (Sarstedt Ltd., Leicester,
U.K.) at baseline and at 15-min intervals during infusion.
Uric acid concentration was determined by an automated
colorimetric assay (Vitros dry slide assay, Ortho-Clinical
Diagnostics, Amersham, U.K.). Blood collected in a
separate gel tube was allowed to clot, centrifuged at 6 g
for 10 min at 4°C, decanted immediately, and stored at
-40°C before determination of antioxidant capacity. Ad¬
ditional venous blood samples were drawn at 15, 30, 60,
120, 300, and 1,260 min after infusion for analysis of
uric acid kinetics.
Determination of antioxidant capacity
The total antioxidant status (TAS) assay (Randox
Laboratories, Antrim, U.K.) is based on the interaction
between a chromogen (2,2'-amino-di-[3-ethylbenz-
thiazole sulfonate], ABTS) and ferrylmyoglobin, a free
radical formed by the reaction of metmyoglobin and hy¬
drogen peroxide (29). The resultant radical cation
(ABTS ) is a blue-green chromophore with maximal ab-
sorbance at 417, 645, 734, and 815 nm (30). Antioxi¬
dants in added serum scavenge ABTS- and prevent ab-
J Cardiovasc Pharmacol™, Vol. 38, No. 3, 2001
URIC ACID INCREASES SERUM ANTIOXIDANT CAPACITY 367
sorbance to a degree related to overall serum antioxidant
capacity. Absorbance was determined at 600 nm using a
Cobas Fara (Roche Diagnostics, East Sussex, UK), cali¬
brated using 6-hydroxy-2,5,8-tetramethylchroman-2-
carboxylic acid, a water soluble tocopherol analogue
(Trolox; Sigma, Dorset, U.K.), and expressed as mM of
Trolox equivalent. The TAS assay gives an ex vivo quan¬
tification of global serum free-radical scavenging capac¬
ity and has been studied in a broad range of patients
(29-32).
Luminol emits light in response to oxidation by hy¬
drogen peroxide, catalyzed by horseradish peroxidase,
detectable using a photocurrent device (33). Added se¬
rum containing radical-scavenging antioxidants delays
photon emission due to consumption of intermediate
radicals, and the resultant lag period is proportional to
total serum antioxidant content (34). We used a lumi-
nometer (Model 1251; BioOrbit, Turku, Finland) to es¬
tablish the lag period after addition of serum, calibrated
to a standard curve generated by addition of 0.16, 0.32,
0.48, and 0.64 \lM Trolox, and serum antioxidant capac¬
ity was expressed as pM of Trolox (35).
Data analysis
Dose-response relationships during infusion of uric
acid and vitamin C were compared with those for vehicle
using ANOVA. Where appropriate, values at each time
point were compared using two-tailed Student's t tests,
and statistical significance was accepted at the 5% level
throughout.
RESULTS
Baseline serum uric acid and creatinine concentrations
were 227 ± 9 [lM (normal range, 120-420 |xM) and 74 ±
4 \lM (normal range, 70-10 \xM), respectively. Infusion
led to a significant time-dependent uric acid increment of
307 p,M (p < 0.001, compared with vehicle) (Fig. 1).
TAS increased by 23% from baseline during uric acid
infusion and by 7% during vitamin C infusion (p < 0.001
and p = 0.65, respectively, compared with vehicle) (Fig.
2). Antioxidant capacity determined by inhibition of che-
miluminescence increased by 139% during uric acid in¬
fusion and 20% during vitamin C infusion (p < 0.001 and
p = 0.56, respectively, compared with vehicle). Anti¬
oxidant capacity after uric acid infusion was significantly
greater than after vitamin C and vehicle by both TAS and
chemiluminescence-based assays (p < 0.001 in each
comparison). Serum uric acid concentration exhibited a
two-component decay, with mean elimination half-life of


















FIG. 1. Serum uric acid increment from baseline during infusion of 1,000 mg uric acid in 500 ml 4% dextrose/0.1% lithium carbonate
vehicle or vehicle solution alone (mean ± SEM). p < 0.001 by ANOVA. *p < 0.05, "p < 0.005 using Student's two-tailed ftest. Baseline
concentration 227 ± 9 \iM (normal range, 120-420 pM)-
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FIG. 2. Percentage change of serum antioxidant capacity (A0.C) from baseline during infusion of 1,000 mg uric acid in 500 ml 4%
dextrose/0.1% lithium carbonate, 500 ml vehicle alone, or 1,000 mg vitamin C in 500 ml 0.9% saline (mean ± SEM) determined by (A)
total antioxidant status assay (Randox Laboratories, UK) and (B) inhibition of chemiluminescence. *p < 0.01, "p < 0.005 between uric
acid and vehicle infusion, and #p < 0.01, ##p < 0.005 between uric acid and vitamin C infusion, using Student's two-tailed f tests.
DISCUSSION
We have previously described how a lithium-based
vehicle can be used as an aqueous medium for pharma¬
cologic delivery of uric acid (36). To the best of our
knowledge, this study is the first to demonstrate the ef¬
fects of uric acid administration on serum antioxidant
capacity in humans. Uric acid administration substan¬
tially increases ex vivo antioxidant capacity in healthy
volunteers with low baseline serum concentrations, con¬
sistent with normal antioxidant defenses and low oxidant
stress (37). We anticipate that the impact of these effects
may have been even greater in smokers or diabetic pa¬
tients, who have low background antioxidant capacity.
Serum uric acid is a potent free-radical scavenger and we
have demonstrated, using two methodologically distinct
assays, that systemic administration increases ex vivo
serum free-radical scavenging capacity to a significantly
J Cardiovasc Pharmacol™, Vol. 38, No. 3, 2001
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FIG. 3. Semi-logarithmic decay curve of serum uric acid increment (squares) after infusion of 1,000 mg of uric acid. Best-fit analysis of
elimination phase gives y = 209.7e~° 691x, and distribution phase (circles) by subtraction analysis gives y = 139.2s"1 saex. Calculated
elimination phase half-life = 10.8 h.
greater extent than vitamin C, another important aqueous
physiologic antioxidant. It is possible, therefore, that the
physiologic role of uric acid could be enhanced by short-
term administration to prevent oxidative and free-
radical-mediated tissue damage in, for example, sepsis
syndrome, in which early administration of combined
antioxidants led to significant improvement in cardiovas¬
cular hemodynamics (38). A further example of acute
oxidative stress is seen in acute myocardial infarction, in
which the subsequent rise of serum uric acid concentra¬
tion can take several minutes or hours to reach maximal
concentrations (39). However, systemic administration
would have an immediate effect. The observed elimina¬
tion half-life of administered uric acid suggests that the
increase in antioxidant capacity is likely to persist for at
least several hours after a single intravenous administra¬
tion, which coincides with the period of maximal early
free-radical activity, when potential for tissue protection
is greatest (39,40). Early initiation of antioxidant treat¬
ment in myocardial infarction using combined vitamins
A, C, and E and beta carotene led to a significant im¬
provement in left ventricular systolic function and a
trend toward overall mortality reduction (41). Repeated
administration of uric acid may be unfavorable in view
of the associations between persistent hyperuricemia and
joint and renal disease, although it is difficult to deter¬
mine an absolute serum concentration beyond which risk
is significantly increased. In relation to joint disease,
prolonged exposure to moderately elevated concentra¬
tions appears important because acute elevation, even to
concentrations beyond 1,200 \iM in tumor lysis syn¬
drome, does not necessarily cause gout (42).
However, serum concentrations of this magnitude are
associated with acute renal impairment due to precipi¬
tation of urate crystals in the collecting ducts and ureters,
causing obstructive nephropathy. Paradoxically, renal
impairment in the presence of chronic hyperuricemia
is more often attributable to other factors, such as hy¬
pertension or diabetes, rather than serum uric acid con¬
centration itself (43). We did not observe any adverse
effects after administration of uric acid, 1,000 mg, in
this study and we believe that the consequent short-
term elevation of serum uric acid concentration poses a
very low risk. The potential value of this novel thera¬
peutic strategy requires further evaluation in a clinical
setting.
J Cardiovasc Pharmacol™. Vol 38, No. 3, 2001
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Uric acid as a risk factor for cardiovascular disease
W.S. WARING, D.J. WEBB and S.R.J. MAXWELL
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Introduction
Over recent years there has been renewed debate
about the nature of the association between raised
serum uric acid concentration and cardiovascular
disease.1 Several large studies have identified the
value, in populations, of serum uric acid concentra¬
tion in predicting the risk of cardiovascular events,
such as myocardial infarction. This has directed
research towards the potential mechanisms by
which uric acid might have direct or indirect effects
on the cardiovascular system. It has been difficult to
identify the specific role of elevated serum uric acid
because of its association with established cardio¬
vascular risk factors such as hypertension, diabetes
mellitus, hyperlipidaemia and obesity.2,3 Indeed, it
is not even clear at this stage whether uric acid has
a damaging or protective effect in these circum¬
stances. Increased understanding of the mechanisms
underlying these associations may allow a clearer
interpretation of the importance of elevated serum
uric acid concentrations, and the potential value of
specific urate-lowering treatment on cardiovascular
disease.
Uric acid synthesis
Purines arise from metabolism of dietary and endo¬
genous nucleic acids, and are degraded ultimately
to uric acid in man, through the action of the
enzyme xanthine oxidase (Figure 1). Uric acid is
a weak acid (pKa 5.8), distributed throughout the
extracellular fluid compartment as sodium urate,
and cleared from the plasma by glomerular
filtration.4 Around 90% of filtered uric acid is
reabsorbed from the proximal renal tubule,
while active secretion into the distal tubule by an
ATPase-dependent mechanism contributes to
overall clearance.5 Serum uric acid concentration
within the population has a Gaussian distribution,
with a typical reference range (95% CI) of
120—420 pmol/l. For an individual, urate concen¬
tration is determined by a combination of the
rate of purine metabolism (both endogenous and
exogenous) and the efficiency of renal clearance.
Purine metabolism is influenced by dietary, as well
as genetic factors regulating cell turnover. Uric acid
is sparingly soluble in aqueous media, and persist¬
ent exposure to high serum levels predisposes to
urate crystal deposition within soft tissues.4 All
species apart from man and higher apes express
urate oxidase, an enzyme responsible for further
metabolism of uric acid to allantoin (a more sol¬
uble waste product) prior to excretion.6 In man, the
urate oxidase gene located on chromosome 1 is not
expressed due to two non-sense mutations.7 Loss of
uric oxidase activity appears to have developed
under evolutionary pressure,7 suggesting that higher
serum uric acid concentrations, or reduced urate
oxidase may confer important advantages in man.
Uric acid as a risk factor for
cardiovascular disease
An epidemiological link between elevated serum
uric acid and an increased cardiovascular risk has
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Figure 1. Adenosine release is increased during hypoxia, and its local vasodilatating action may preserve blood flow and
prevent tissue ischaemia. Uric acid is the end-product of purine metabolism in man, whereas other species express uric
oxidase, responsible for conversion of uric acid to more soluble excretory products.
been recognized for many years.8,9 Observational
studies show that serum uric acid concentrations
are higher in patients with established coronary
heart disease compared with healthy controls.10
Elevated serum uric acid concentrations are also
found in healthy offspring of parents with coronary
artery disease, indicating a possible causal relation¬
ship.2 However, hyperuricaemia is also associated
with possible confounding factors including elev¬
ated serum triglyceride and cholesterol concentra¬
tions, blood glucose, fasting and post-carbohydrate
plasma insulin concentrations, waist-hip ratio'
and body mass index.3,0,11,12 About one quarter
of hypertensive patients have co-existent hyper¬
uricaemia13 and, interestingly, asymptomatic
hyperuricaemia predicts future development of
hypertension, irrespective of renal function.14
Among patients with established hypertension,
elevated serum uric acid concentration has been
associated with a significantly increased cardio¬
vascular risk during a mean 6.6-year follow-up
period.15 The proportional hazard ratio for one SD
elevation of uric acid (29.2 pmol/l) was 1.22
(95%CI 1.11-1.35), which was higher than for
one S.D. elevation of blood glucose (1.10, 95%CI
1.02-1.19), cholesterol (1.18, 95%CI 1.09-1.29) or
systolic blood pressure (1.09, 95%CI 1.00-1.19).
Thiazide diuretics confer unequivocal benefits
in treatment of hypertensive patients, and cause
a significant reduction in cardiovascular and all-
cause mortality.16 Persistence of the relationship
between elevated serum uric acid concentration
and increased cardiovascular risk among thiazide-
treated patients has prompted speculation that uric
acid elevation may attenuate some of their potential
benefits.17 Indeed, the US National Health and
Nutrition Survey (NHANES) III showed that age-
adjusted rates of myocardial infarction and stroke
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are higher across increasing serum uric acid
quartiles among male and female hypertensive
patients.18
Some studies have suggested that the importance
of uric acid may be independent of confounding
risk factors. Multivariate analysis of data from the
MONICA cohort of 1044 males showed a signific¬
ant association between raised serum uric acid
and cardiovascular mortality, independent of body
mass index, serum cholesterol concentration, hyper¬
tension, diuretic use, alcohol intake and smoking
habits.19 Comparison of those individuals within the
highest serum uric acid quartile (>373 pmol/l)
versus those in the lowest quartile (<319 pmol/l)
gave an adjusted risk of myocardial infarction of
1.7 (95%CI 0.8-3.3) and cardiovascular death of
2.2 (95%CI 1.0-4.8). The Gothenburg prospective
study of 1462 women aged 38 to 60 years also
found a significant relationship between serum
uric acid concentration and total mortality during
12-year follow-up, which was independent of body
mass index, serum lipid concentrations, smoking
habit, blood pressure and age.20 Uric acid also
has a predictive role in high-risk patient groups.
For instance, diabetes mellitus is a very powerful
risk factor for cardiovascular disease, and a pro¬
spective study of 1017 non-insulin-dependent
patients showed that serum uric acid concentration
>295 pmol/l conferred a hazard ratio of 1.91
(95%CI 1.24-2.94) of fatal or non-fatal stroke
during 7-year follow-up.21
In contrast to these findings, several studies have
suggested that the relationship between elevated
serum uric acid and cardiovascular risk does not
persist after correcting for other risk factors. The
British Regional Heart Study of 7688 men aged
40 to 59 years showed a significant association
between elevated serum uric acid and fatal and
non-fatal coronary disease over a mean 16.8
years.22 However, this relationship disappeared
after correcting for other risk factors, particularly
serum cholesterol concentration. The Coronary
Drug Project Research Group studied 2789 men,
aged 30 to 64 years, and found that the association
between increased cardiovascular risk and elevated
serum uric acid concentration was not significant
after consideration of other risk factors, and when
thiazide diuretic use was considered.23 Similar find¬
ings have been reported from the Social Insurance
Institution of Finland Study24 and Framingharh
Heart Study.25
The Atherosclerosis Risk in Communities study
of 11 488 healthy men and women showed an
apparent association between serum uric acid
concentration and early carotid artery atheroscler¬
osis, which was dependent of other coronary risk
factors.26 Similarly, the Honolulu Heart Program
found that elevated serum uric acid was not an
independent risk factor for the presence at autopsy
of aortic or coronary atherosclerosis in Japanese
27
men.
In summary, although there is overwhelming
evidence that elevated serum uric acid concentra¬
tions are strongly associated with increased cardio¬
vascular risk and poor outcome, prospective
population studies are often confounded by
co-existent risk factors. It remains unclear whether
uric acid is an independent predictor of poor cardio¬
vascular outcome. To unravel this association, it is
important to understand the mechanisms by which
hyperuricaemia relates to other risk factors, vascular
dysfunction and cardiovascular disease. We shall
now consider these relationships in more detail.
Uric acid as a marker of
subclinical ischaemia
Adenosine is synthesized and released by cardiac
and vascular myocytes. Binding to specific adenos¬
ine receptors causes relaxation of vascular smooth
muscle and arteriolar vasodilatation.28 Adenosine
makes a small contribution to normal resting vas¬
cular tone, since competitive antagonism at the
adenosine receptor by methylxanthines, such as
theophylline, reduce blood flow response to
ischaemia in the forearm vascular bed.29 Under
conditions of hypoxia and tissue ischaemia, vascular
adenosine synthesis and release are upregulated,
causing significantly increased circulating concen¬
trations.30 Cardiac and visceral ischaemia promote
generation of adenosine, which may serve as an
important regulatory mechanism for restoring
blood flow and limiting the ischaemia31 (Figure 1).
Adenosine synthesized locally by vascular smooth
muscle in cardiac tissue is rapidly degraded by the
endothelium to uric acid, which undergoes rapid
efflux to the vascular lumen due to low intracellular
pH and negative membrane potential.32 Xanthine
oxidase activity33 and uric acid synthesis34 are
increased in vivo under ischaemic conditions, and
therefore elevated serum uric acid may act as
a marker of underlying tissue ischaemia. In the
human coronary circulation, hypoxia, caused by
transient coronary artery occlusion, leads to an
increase in the local circulating concentration of
uric acid.35 Study of tourniquet-induced lower limb
exsanguination in patients undergoing surgery
shows a five-fold increase in systemic vascular
xanthine oxidase activity during reperfusion, and
a significant elevation of serum uric acid, which
persists for at least 2 h.36 These findings are also
consistent with the inverse relation between base¬
line serum uric acid concentration and maximal
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lower limb blood flow in patients with cardiac
failure, where higher concentrations could predict
subclinical ischaemia.37 In conclusion therefore,
elevated serum uric acid may be a marker of local
or systemic tissue ischaemia and provides one
possible explanation for a non-causal associative
link between hyperuricaemia and cardiovascular
disease.
Uric acid as a marker of
insulin resistance
Insulin resistance syndromes result in attenuation
of insulin-mediated glucose utilization and confer
a substantial increase in cardiovascular risk,38
through activation of several pathways including
the sympathetic nervous system.39 Elevated serum
uric acid is a consistent feature of the insulin
resistance syndromes, which are also characterized
by elevated plasma insulin level (fasting and post-
carbohydrate), blood glucose concentration, and
serum triglyceride concentration, and raised body
mass index and waist-hip ratio.2,3 Insulin has
a physiological action on renal tubules, causing
reduced sodium and uric acid clearance.40 Despite
blunting of the action of insulin on glucose meta¬
bolism, sensitivity to the renal effects persists.40,41
Because plasma insulin concentration is character¬
istically elevated, hyperuricaemia may arise as
a consequence of enhanced renal insulin activity.
Elevated serum uric acid concentrations predict
subsequent development of diabetes mellitus42
and hypertension,14 even in the presence of
normal creatinine clearance and plasma glucose
concentrations, and therefore may be a subtle, early
marker of peripheral insulin resistance syndromes.
Thus a link between elevated serum uric acid
concentration and cardiovascular disease may arise
through its non-causal relationship with insulin
resistance syndromes, where cardiovascular risk is
mediated by other factors.
Direct impact of uric acid on
vascular function
The endothelium plays a central role in maintaining
vascular tone through synthesis and release of nitric'
oxide, a potent vasodilator.43 Reduction of nitric
oxide bioavailability is an important early step
in the development of atherosclerosis.44 So-called
endothelial dysfunction, associated with impaired
endothelium-dependent vasodilatation may arise
from excessive free radical activity, which disrupts
synthesis and accelerates degradation of nitric
oxide.45 Thus increased oxidative stress appears to
have an important role in development and pro¬
gression of atherosclerosis and is a characteristic
finding associated with its major risk factors, such
as diabetes mellitus, hypertension, hypercholes-
terolaemia and smoking 44,46 Serum uric acid pos¬
sesses antioxidant properties, and contributes about
60% of free radical scavenging activity in human
serum.47,48 Uric acid interacts with peroxynitrite to
form a stable nitric oxide donor, thus promoting
vasodilatation and reducing the potential for
peroxynitrite-induced oxidative damage.49 Thus,
uric acid could be expected to protect against
oxidative stresses.
However, uric acid has been found to promote
low-density lipoprotein (LDL) oxidation in vitro,
a key step in the progression of atherosclerosis,50'^1
and these effects are inhibited by vitamin C52
indicating an important interaction between aque¬
ous anti-oxidants. Uric acid can also stimulate
granulocyte adherence to the endothelium,53 and
peroxide and superoxide free radical liberation.53,54
Therefore uric acid may have a deleterious effect on
the endothelium through leukocyte activation and,
interestingly, a consistent relationship has been
noted between elevated serum uric acid concentra¬
tion and circulating inflammatory markers.55-57
Uric acid traverses dysfunctional endothelial cells
and accumulates as crystal within atherosclerotic
plaques.32,58 These crystals may contribute to local
inflammation and plaque progression, and we
speculate that crystal accumulation may be
greater in patients with elevated serum uric acid
concentration.
Thus, while uric acid appears to make a signi¬
ficant contribution to serum anti-oxidant capacity, it
could also lead directly or indirectly to vascular
injury. It is interesting to note that treatment of
chronic cardiac failure patients with allopurinol
(a xanthine oxidase inhibitor) restored endothelial
function.59 This effect may have been due to an
increase in recorded serum antioxidant capacity,59
although the effect of uric acid was not considered.
Study of the direct effects of uric acid on vascular
function has been hampered by its poor solubility,
although this has been overcome recently.60 Direct
study of the actions of uric acid on endothelial func¬
tion, platelet aggregation, vessel wall elasticity and
autonomic cardiovascular regulation is required
so that its effects on the cardiovascular system and
in cardiovascular disease can be determined.
Conclusions
Raised serum uric acid concentrations are a power¬
ful predictor of cardiovascular risk and poor
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